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Peripheral arterial disease (PAD) defines atherosclerotic disease of the arteries to the 
legs. PAD begins early in life and remains asymptomatic over long periods. The ankle 
brachial index (ABI) is an important diagnostic test which can identify asymptomatic 
individuals and serve as a good marker of the underlying peripheral and systemic 
atherosclerosis. Recent advances in vascular biology proposed a role of inflammatory 
and haemostatic mechanisms in atherosclerotic disease. Although inflammatory and 
haemostatic markers have been associated with coronary atherosclerosis in large scale 
epidemiological studies their role in PAD development is not well established and for 
many markers unknown. Also, their relationship with the progression of early 
asymptomatic disease has not been studied before.   
 
The aim of this thesis was to examine 12 markers of inflammation and haemostasis in 
relation to peripheral atherosclerotic progression and incident PAD. The Edinburgh 
Artery Study was used for this analysis. This is a population based cohort study of 1,592 
men and women recruited in 1987. ABI was measured at baseline and at two follow up 
examinations which were conducted after 5 and after 12 years. Also, subjects were 
followed up for cardiovascular events for 17 years. Conventional cardiovascular risk 
factors, C-reactive protein (CRP),  interleukin-6 (IL-6), intercellular adhesion 
molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1), E-selectin, fibrinogen, 
D-dimer, tissue plasminogen activator (t-PA), vonWillebrand factor (vWF), factor VII, 
 V 
fibrinopeptide A (FpA) and prothrombin fragments 1+2 (F1+2) were measured at 
baseline. 
 
Valid ABI measurements were available for 1,582 subjects at baseline, for 1,081 
subjects at the 5 year follow up and for 816 subjects at the 12 year follow up. The 
population showed a progression in atherosclerotic disease assessed by the mean ABI 
decline over time. The mean change in ABI was -0.04 (0.18) after 5 years and -0.06 
(0.19) after 12 years. From inflammatory markers, CRP (p <0.01), IL-6 (p <0.001) and 
ICAM-1 (p <0.01) were associated with atherosclerotic progression after 12 years, 
independently of baseline ABI and of conventional cardiovascular risk factors. Also, 
from haemostatic markers, fibrinogen (p =0.05) and D-dimer (p  0.05) were 
significantly associated with atherosclerotic progression independently of baseline ABI 
and cardiovascular risk factors. Moreover, subjects with higher levels of both D-dimer 
and IL-6 at baseline had the greatest ABI decline. Also, IL-6 showed the stronger 
independent effect on atherosclerotic progression and retained statistical significance 
after adjustments for all inflammatory markers and for fibrinogen and D-dimer.  
 
Approximately 26% of the baseline population developed at least one event of major 
CVD and 14% of the baseline population developed symptomatic PAD after 17 years of 
follow up. Inflammatory markers, CRP and IL-6 showed modest associations with PAD 
which lost statistical significance in the multivariable model. On the other hand, these 
markers were associated with incident major CVD with hazard ratios (95% CI) 1.6 (1.2, 
2.3) and 1.8 (1.3, 2.6) respectively (top vs. bottom tertile) in the multivariable model. 
 VI 
ICAM-1 showed weak associations with incident CVD, however, was significantly 
associated with PAD with hazard ratio (95% CI) 1.8 (1.2, 2.7) (top vs. bottom tertile) 
after adjustments for cardiovascular risk factors and CVD at baseline. Haemostatic 
markers, fibrinogen and D-dimer were associated with 2.2 (95% CI: 1.5, 3.2) and 1.7 
(1.2, 2.6) increase in the risk of PAD development and 1.8 (1.3, 2.3) and 1.6 (1.2, 2.1) 
increase in the risk of CVD independently of cardiovascular risk factors and history of 
CVD at baseline, respectively. 
 
This analysis showed a major role of inflammatory markers, CRP, IL-6 and ICAM-1 in 
atherosclerotic development and progression. In addition, fibrinogen and D-dimer, but 
not other haemostatic factors, were associated with progressive and incident peripheral 
atherosclerosis. Since D-dimer and fibrinogen are acute phase reactants, these data 
support the hypothesis that inflammation is more related to atherosclerosis than is 
hypercoagulation. Most importantly, the majority of the reported associations were not 
explained by increased levels of cardiovascular risk factors or pre-existing clinical or 
subclinical arterial disease. Thus these markers are more likely to have a causal than a 
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1 Peripheral arterial disease 
1.1 Introduction 
This chapter describes the epidemiology of peripheral arterial disease (PAD). The 
prevalence and incidence along with the natural history of the disease as evaluated in 
epidemiologic research are discussed. In addition, the established risk factors for the 
development and progression of the disease are summarized. Finally, the different 
diagnostic tests for the diagnosis of PAD are described with particular focus on the ankle 
brachial index (ABI); the most commonly used non-invasive test for PAD.  
 
1.2 Definition of PAD 
Atherosclerosis is a progressive disease of the large arteries characterized by the 
accumulation of lipids and fibrous elements in the arterial wall (Lusis 2000). At its 
earliest state consists of a ‘fatty streak’ which consists of subendothelial accumulations 
of cholesterol-engorged macrophages known as foam cells. The fatty streaks are not 
clinically important but are the precursors of more serious lesions and eventually of the 
atherosclerotic plaque. Plaques often become gradually more complex with calcification, 
ulceration and haemorrhage. Although, these lesion can grow large and eventually block 
blood flow, the most important and common complication is the rupture of the 
atherosclerotic plaque and the formation of the thrombus (Lusis 2000).  
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Atherosclerosis can affect several arterial beds. The term PAD refers to atherosclerotic 
disease that obstructs the blood supply to the lower limbs. Considerable confusion exists 
concerning this term because some investigators include carotid, mesenteric, renal and 
upper extremity disease in the definition of PAD. The term peripheral vascular disease 
(PVD) has less specificity since for many researchers this includes venous as well as 
arterial disease. Other terms have been used including peripheral arterial occlusive 
disease (PAOD), arteriosclerosis obliterans (ASO) and lower extremity arterial disease 
(LEAD). In this thesis, the term PAD is used solely to describe atherosclerotic disease in 
the arteries to the legs.    
 
PAD starts for many individuals early in life and remains asymptomatic for a long 
period of time. The disease often has clinical symptoms when it is relatively advanced. 
The most common symptom is intermittent claudication (IC), a cramping pain in the 
legs which is induced by exercise and relieved by rest. When PAD progresses to severe 
impairment of blood flow to the limb due to arterial stenosis and occlusion, an individual 
is considered to have critical limb ischemia (CLI). CLI is often characterized by 
persistent rest pain which becomes worse when the legs are elevated e.g. in bed at night.  
People diagnosed with CLI may also present with gangrene and ulceration in their legs. 
Finally, if the disease progresses further, patients might have to undergo surgical 
treatment and leg amputation.  
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1.3 Prevalence and incidence of PAD 
PAD is a relatively common condition which affects many adults worldwide (Hirsch et 
al 2006). The prevalence and incidence of PAD in populations has been measured in 
epidemiological studies that have used various definitions of PAD. Some use IC to 
define PAD whereas other use non invasive tests like an abnormal ABI to measure 
asymptomatic forms of the disease. Few reports focus on the later disease stages of CLI. 
In general, the prevalence of PAD varies with the age of the cohort studied, the risk 
factor profile of the cohort, and the diagnostic test used to measure the disease. An 
overview of population studies on the prevalence and incidence of lower extremity 
atherosclerosis is given here. 
 
1.3.1 Intermittent claudication  
IC as a symptomatic expression of PAD defines a subset of the total population with the 
disease. Epidemiological studies have assessed the prevalence of IC mainly by means of 
the Word Health Organization (WHO) IC questionnaire (Appendix I). Overall, the 
estimated prevalence of claudication assessed by an IC questionnaire ranges from 0.4 to 
14.4% (Dormandy et al 1989).  For example, in the Limburg study of 3,654 individuals 
aged 40-79 years the prevalence of IC using the Rose criteria was 1.4% (Stoffers et al 
1991). Similarly, the Whitehall study on over 18,000 individuals (40-69 years old) 
estimated the prevalence of IC at 1.8% (Smith et al 1990). The Edinburgh Artery Study 
reported a considerable higher prevalence of 4.5% for older people aged 55-74 years. 
Table 1 lists the aforementioned and other large scale studies that have estimated the 
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prevalence of IC with the WHO IC questionnaire in population samples. As Table 1 
shows, the prevalence of IC varied across studies and overall increased with age. Some 
evidence that IC is slightly more common in males than females is also presented. 
However, gender differences have not been observed in other studies. In the Edinburgh 
Artery Study (Fowkes et al 1991) of people aged 55-74 years the prevalence of IC was 
the same (4.6%) in men and women. In support of these findings, Reunanen (Reunanen 
et al 1982) reported 2.1% prevalence in men and 1.8% in women and the age adjusted 
prevalence was almost equal. These findings are keeping with an equilibration with 
frequency of cardiovascular disease (CVD) between men and women at older ages. 
 
There are fewer reports on the incidence of PAD in populations. In the Framingham 
Heart Study, incidence of PAD was based on IC symptoms in 2,336 men and 2,873 
women aged 29-62 years. The annual incidence was estimated to be 6 per 10,000 men 
and 3 per 10,000 women for those aged 30-44 and 61 per 10,000 men and 54 per 10,000 
women for those aged between 65-74 years (Kannel et al 1970). In the Edinburgh Artery 
Study of 1,529 subjects aged 55-74 years old the 5-year cumulative incidence was 
estimated at 9% when PAD was diagnosed by means of the WHO IC questionnaire 
(Leng et al 1996a). In another study in Israel of 8,343 men aged 40-65 years, after 21 
years, the cumulative incidence was 43.1 per 1,000 population (Bowlin et al 1997). On 
the other hand, the Quebec Cardiovascular study (Dagenais et al 1991) estimated the 
incidence of PAD at 41 per 10,000 population per year whereas the US Physicians 
Health Study (Camargo et al 1997) reported 433 PAD events among 22,071 healthy 
males during 11 years of follow up. These results demonstrate that like prevalence the 
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incidence in populations varies greatly depending on age structure and characteristics of 
the populations as well as the epidemiological methods used. However, most studies 
show that the incidence increased substantially with age. 
 
Table 1 Prevalence of intermittent claudication (IC) in different population studies assessed by 
means of the WHO/ IC questionnaire 
Reference N Population Location Age (years) IC (%) 










Hughson et al 1978 162 MW England 45-69 2.2 
Schroll & Munck 1981 666 MW Denmark >60 1.8 








Criqui et al 1985 613 MW USA 38-82 2.2 




Jerusalem 40-60 1.3 
1.8 
Smith et al 1990 18,388 MW Scotland 40-64 1.8 
45-54 0.6 
55-64 2.5 
Stoffers et al 1990 3,654 MF Holland 
65-74 8.8 
Fowkes et al 1991 1,592 MW Scotland 55–74 4.6 
Dewhurst et al 1991 259 MW England 65-95 5 




USA 65-85 2.0 
Skau et al 1993 2,748 MW Sweden 50-89 4.1 
Mittelmark et al 1993 5,201 M USA >65 3.0 










Bowlin et al 1994  10,059 M Israel 40-65 2.7 
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Bainton et al 1994 2,055 M Scotland 60-64 2.9 
Wilt et al 1996 4,159 MW USA - 8.5 





















Meijer et al 1998 7,715 MW Holland >55 1.6 














USA >40 3.9 
3.3 
Brevetti et al 2004  4,352 MW Italy 40-80 1.6 
Diehm et al 2004 6,821 MW Germany >65 2.8 
M: men, W: women 
† African-American, ‡ White 
 
Table 1 cont. 
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1.3.2  Asymptomatic disease 
The prevalence of asymptomatic disease can only be estimated by non-invasive 
diagnostic techniques. Therefore, the estimated prevalence is greatly dependent on the 
actual measurement technique used in each study. In general, the prevalence of 
asymptomatic disease is higher than that estimated on the basis of IC symptoms and 
ranges between 0.9% and 22% with the ratio of symptomatic to asymptomatic ranging 
between 1:0.9 and 1:6.0 (Dormandy et al 2000). Pioneer research by Hiatt et al. (Hiatt et 
al 1995) showed that for every individual with IC there are another 3 with asymptomatic 
disease causing a 50% or greater stenosis of the arteries supplying the legs. The 
predominance of asymptomatic patients was also demonstrated by Stoffers (Stoffers et al 
1996) who investigated the prevalence of asymptomatic PAD in a population of 18,884 
people between 45-74 years old and found that although the disease was diagnosed in 
6.9% by an ABI<0.95, only 22% of these people had symptoms of PAD. Table 2 shows 
similar data from the Rotterdam study highlighting that less than 50% of patients with 
PAD assessed by the ABI display symptoms of IC (Meijer et al 1998). 
 
The BASLE study (LeFevre et al 1959) was amongst the first studies to measure the 
prevalence of asymptomatic disease using pulse waveforms detected on oscillography. 
Among men, the prevalence of occlusion confirmed by arteriography was 7.5% at those 
aged between 60-64 years old. Later, Criqui (Criqui et al 1985) used 3 different 
diagnostic tests (ABI, pulse wave analysis and pulse examination) and the WHO 
questionnaire in 613 men and women in California to define PAD. The prevalence of 
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PAD was 12% which was considerably higher than that estimated by the claudication 
questionnaire alone (2.2%).  
 
The vast majority of epidemiological studies use the ABI<0.9 alone to define 
asymptomatic PAD (DeBacker et al 1979;Fowkes et al 1991;Gofin et al 1987;Hughson 
et al 1978;Meijer et al 1998;Schroll et al 1981). Although there is not a valid cut-off 
point to define PAD, this is though to correlate well with the severity of disease across 
different populations (Fowkes 1991b). In the Edinburgh artery study 8% of those 
between 55-74 years had asymptomatic disease defined by the ABI and reactive 
hyperaemia test and a further 9% had ABI<0.9 only (Fowkes et al 1991). Similarly, in 
the Golstrup study (Hughson et al 1978) 14% of a 60 years old population had ABI<0.9.  
Moreover, from 2,174 individuals older than 40 years old of the National Health and 
Nutrition Examination Survey (NHANES), 4.3% had an abnormal ABI (ABI<0.9) 
(Selvin et al 2004). 
 
Recently, the PAD Awareness, Risk and Treatment (PARTNERS) study measured the 
ABI in 6,979 primary care patients aged 70 years or older or aged 50-69 years but with a 
history of smoking or diabetes (Hirsch et al 2001). The PARTNERS program focused on 
subjects at increased risk rather than the general population or a healthy group and found 
that PAD defined as ABI<0.9 was present in 29% of the study population. This study 
provided further evidence that differences in prevalence of PAD between gender are 
very small, the prevalence of PAD in women was almost identical to than in men despite 
the fact that other CVD was almost twice as common in men than women.  
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The incidence of asymptomatic disease shows similar age and sex patterns as prevalence 
but has been studied less frequently. In the Basle study, for example, the 5 year 
cumulative incidence was 4% in men between 35 and 44 years old and 18% in men over 
65 years of age (Widmer et al 1991). In 2,327 Dutch subjects, after 7.2 years, the overall 
incidence rate for asymptomatic PAD, assessed with ABI<0.9, was 9.9% per 1,000 
person-years at risk (Hooi et al 2001). In this cohort, it was also noted that the incidence 
of asymptomatic PAD
 
was higher than the incidence of symptomatic PAD, with women
 
developing PAD more often than men.  
  
Table 2 Prevalence estimates of peripheral arterial disease (PAD) by different diagnostic methods in 
the Rotterdam Study (Meijer et al 1998) 
Age (years) PAD by ABI<0.9 (%) PAD by the WHO/IC 
questionnaire (%) 
55-59 9.0 1.0 
60-64 11.0 1.2 
65-69 15.0 1.7 
70-74 17.0 2.3 
75-79 23.0 3.2 
80-84 40.0 4.0 
85-89 57.0 5.0 
ABI: ankle brachial index, IC: intermittent claudication 
Data modified from Meijer et al 1998  
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1.3.3  Critical limb ischaemia 
There is little information on the incidence and prevalence of CLI. The Vascular 
Surgical Society of Great Britain and Ireland (The Vascular Surgery Society of Great 
Britain and Ireland 1995) estimated that there are approximately 20,000 people with CLI 
in the population with an annual incidence of 400 per million per year. Catalano 
(Catalano 1993) calculated the incidence of CLI using different approaches in an Italian 
population. After 7 years of follow up, of 200 people with IC and 180 controls, the 
incidence of CLI was 450 per million per year. Alternatively, looking at the 
hospitalizations for CLI for a sample of hospitals the incidence of CLI was 652 per 
million per year. Recently, the Oxford Vascular study followed up 19,106 subjects to 
record non-coronary event rates (Rothwell et al 2005). After 3 years, the rate for CLI 




On the assumption that all amputations are performed for CLI and that 25% of people 
with CLI require amputation the incidence of CLI can be estimated between 500-1,000 
per million per year (Dormandy et al 2000). Another approach would be to look at the 
prevalence of IC and assume that 5% of claudicants will progress to CLI after 5 years. 
Then the incidence of CLI is approximately 300 per million per year and approximately 
one patient per year will develop CLI for every 100 with IC (Dormandy et al 2000).  
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Recently, Jensen et al used a questionnaire to estimate the prevalence of CLI in 20,291 
Norwegian men and women aged 40-69 years (Jensen et al 2006). The authors defined 
CLI as ulcer in the toes, foot or ankle which failed to heal and/ or persistent pain in the 
forefoot while in supine position with relief of the pain when standing up. They found 
that the prevalence of CLI was 0.26% among men and 0.24% among women (Jensen et 
al 2006).  
 
1.4 Risk factors for developing PAD 
Specific risk factors have been associated with the development and progression of 
peripheral atherosclerosis. Epidemiological studies have shown that risk factors for PAD 
are almost identical to those associated with coronary heart disease (CHD). However, 
some such as smoking would appear to be particularly important in peripheral 
atherosclerosis. The importance of age and sex was already mentioned in the previous 
section which showed that prevalence and incidence of PAD increased with age and is 
slightly more common in males than females. Here, a brief review of epidemiologic data 
on well-established risk factors for the development of PAD is given. 
 
1.4.1 Smoking 
All epidemiological studies have confirmed that smoking is a strong risk factor for PAD 
(Criqui et al 1989;Fowkes et al 1992;Gofin et al 1987;Hughson et al 1978;Kannel et al 
1985;Murabito et al 1997;Reunanen et al 1982;Schroll et al 1981). In the Framingham 
study, 78% of patients with IC were smokers (Freund et al 1993) whereas in the 
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Edinburgh Artery Study the risk of developing the disease was 3 fold higher in smokers 
than in non-smokers (Price et al 1999). Data from these two studies also showed that 
diagnosis of PAD was made almost a decade earlier in smokers than in non-smokers 
(Fowkes et al 1992;Kannel et al 1985). Another study reported a 16 fold increase in risk 
of PAD in current smokers and a 7 fold increase in ex-smokers compared to never 
smokers (Cole et al 1993). Moreover, the Reykjavik Study (Ingolfsson et al 1994) of 
males older than 18 years found an 8 to 10 fold increase in the risk of IC among 
smokers. A recent meta-analysis of 4 prospective and 13 cross-sectional studies reported 
that overall the prevalence of symptomatic PAD was increased 2.6 fold in current 
smokers and 2.3 fold in ex smokers (Willigendael et al 2004).  
 
This importance of smoking in PAD has been shown to be stronger than in coronary 
artery disease (CAD). In the Framingham Study the increased risk in smokers compared 
to non smokers for PAD was double that for CAD (Kannel et al 1985). Similarly, in the 
Edinburgh Artery Study, smoking increased the risk of PAD (range of odds ratios, 
1.8-5.6) more than heart disease (range of odds ratios, 1.1-1.6) (Fowkes et al 1992).  
Cigarette smoking was also shown to have an independent effect on PAD in 
multivariable analysis and a relatively greater effect compared to other risk factors 
(Fowkes 1991a;Hughson et al 1978). A clear dose-response relationship, with a strong 
increase in risk for PAD in heavy smokers, has also been reported. In the Reykjavik 
Study (Ingolfsson et al 1994) among 8,045 individuals followed for 18 years the rate of 
developing PAD compared to non-smokers was 2.6 for those smoking 1-14 cigarettes 
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per day, 7.7 for those smoking 15-24 cigarettes per day and 10.2 for those smoking 25 or 
more cigarettes per day. 
 
1.4.2 Diabetes mellitus 
Overall, epidemiological evidence confirms an approximately 2-4 fold increase in 
prevalence of PAD in people with diabetes compared to those without (Fowkes et al 
1992;Gordon et al 1972;Kannel et al 1979;Kannel et al 1985;Murabito et al 1997). In 
studies using the ABI, the prevalence of PAD (defined as an ABI<0.90) in diabetic 
individuals ranges from 20% to 30% (Beks et al 1995;Hirsch et al 2001). Moreover, data 
from the Framingham and Rotterdam studies have shown increased rates of absent pedal 
pulses,
 
femoral bruits, and decreased ABI in people with diabetes (Abbott et al 
1990;Meijer et al 1998). 
 
Diabetic PAD often affects distal limb
 
vessels, such as the tibial and peroneal arteries, 
limiting
 
the potential for collateral vessel development (Luscher et al 2003;Meijer et al 
1998). As a result, patients with diabetes
 
are more likely to develop severe symptomatic 
forms of the disease such as rest pain, gangrene or ulceration as well as IC (Jude et al 
2001). In the Framingham study for both sexes, diabetes was associated with a 2 to 3 
fold excess risk of IC compared with its absence (Brand et al 1989). Also, in 467 men 
and 1,444 women older than 80 years, the odds ratio for PAD in patients with diabetes 
was 6.1 in men and 3.6 in women compared to those without diabetes (Ness et al 2000). 
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The duration and severity of
 
diabetes would appear to correlate with the incidence and 
extent of PAD (Jude et al 2001). A strongly positive association between the duration of 
diabetes and the risk of developing PAD especially among hypertensive men or current 
smokers was found (Al-Delaimy et al 2004). In addition, in the United Kingdom 
Prospective Diabetes Study (UKPDS) (Adler et al 2002) the frequency of PAD up to 18 
years after the diagnosis of diabetes in 4,987 subjects was higher the longer the duration 
of diabetes. 
 
1.4.3 Blood lipids 
The effect of blood lipids on PAD is less clear and it has been suggested that the 
association
 
between elevated cholesterol levels and PAD seems to be somewhat
 
weaker 
than that for CHD (Pasternak et al 2004). In the Framingham study, people with IC had 
a higher mean cholesterol level and people with total cholesterol >270 mg/dl had twice 
the incidence of developing IC (Kannel et al 1970;Murabito et al 1997). Similarly, in the 
NHANES 2,174 subjects older than 40 years with a total cholesterol of 240 mg/dl or 
greater had a risk ratio of 1.88 for PAD defined by ABI<0.9 (Murabito et al 1997;Selvin 
et al 2004b). In a Danish cohort, total cholesterol was associated with decreased ABI 10 
years later (Reunanen et al 1982).  Also, a modest risk ratio of 1.10 for PAD (ABI<0.9) 
was found in the Cardiovascular Health Study for a 10mg/dl increase in total cholesterol 
(Newman et al 1993). Interestingly, these results were not replicated by other studies 
(Criqui et al 1989;Dagenais et al 1991;Hughson et al 1978;Zimmerman et al 1981). 
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Similar evidence was found for decreased HDL levels. In the Rotterdam study total 
cholesterol but not HDL cholesterol was associated with an ABI<0.9 (Meijer et al 1998). 
However, in the Edinburgh Artery Study both increased total and decreased HDL 
cholesterol were independently associated with IC and with ABI<0.9 (Fowkes et al 
1992). Ness and colleagues, in a cohort of 467 men and 1,444 women, reported an odds 
ratio for PAD 0.95 in men and 0.97 in women for 1 mg/dl decrease in HDL levels (Ness 
et al 2000). The US physicians’ study compared the LDL, HDL, triglycerides and ratio 
of total/ HDL cholesterol as predictors of PAD and found the latter to have the greatest 
independent effect (Ridker et al 2001). Evidence that treatment of hyperlipidemia 
reduces both the progression and incidence of PAD has also been found (Duffield et al 
1983).  Finally, an association between increased triglycerides and PAD has been 
reported by many but the strength of this association was reduced on multivariable 
analysis and thus effect of triglycerides on PAD remains unclear (Criqui et al 
1989;Dormandy et al 1989;Fowkes et al 1992;Gofin et al 1987;Hughson et al 
1978;Kannel et al 1985;Schroll et al 1981). 
 
1.4.4 Hypertension 
Epidemiologic studies have confirmed an association between increased blood pressure 
levels and PAD and they estimated that approximately 50-92% of claudicants have 
hypertension (Hirsch et al 2001;Makin et al 2001;Olin 2005). In the Cardiovascular 
Health Study 52% of patients with asymptomatic PAD (ABI  0.9) had high blood 
pressure whereas hypertension was associated with the progression of PAD defined by 
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declining ABI after 6 years of follow up (Kennedy et al 2005;Newman et al 1993). 
Follow up data from the Framingham Study demonstrated a 2 to 4 fold increased risk of 
developing IC in men and women with hypertension (Kannel et al 1970). In the Golstrup 
study significant correlations were found between initial elevated systolic and diastolic 
blood pressure and ABI after 10 years (Reunanen et al 1982). This was also suggested in 
the Edinburgh (Fowkes et al 1992) and the Basle study (Widmer et al 1991) but not by 
the Whitehall study (Smith et al 1990) which found no association between hypertension 
and PAD. Overall high blood pressure is likely to be a risk factor for PAD but may not 
be as important as others such as smoking. 
 
1.4.5 Other risk factors 
Obesity and low physical activity have shown strong associations with CHD 
(Wannamethee et al 2001;Yusuf et al 2005) but their relationship with PAD is not well 
established. Few studies have examined the relationship between obesity, mainly 
measured by the body mass index (BMI), and incident PAD and the overall evidence for 
an association was weak (Criqui et al 1989;Hooi et al 1998;Jensen et al 2005;Planas et al 
2001). As in CHD, an alternative measure of body fat, such as waist circumference or 
waist to hip ratio, might show stronger associations with incident PAD; however, 
currently there are no data on this relationship. On the other hand, a physically active 
lifestyle has been associated with a reduced risk of developing PAD in two studies 
(Housley et al 1993;Planas et al 2001). However, physical activity may be particularly 
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difficult to study in PAD because symptomatic disease may result in reduced physical 
activity.   
 
Some evidence for ethnic differences in the prevalence of PAD has also been reported. 
In the San Diego population study, black ethnicity was an independent risk factor for 
PAD at a magnitude similar to that of other established risk factors (Criqui et al 2005). 
Likewise, the NHANES found an increase in the risk of PAD among non-Hispanic black 
individuals (Selvin et al 2004); a result that has been shown by others (Newman et al 
1993;Zheng et al 1997). The excess prevalence
 
of PAD in blacks could not be explained 
by the excess of diabetes,
 
hypertension, or other CVD risk factors or by any
 
greater 
susceptibility to CVD risk factors. 
 
A series of other potential risk factors have been associated with PAD along with 
coronary and cerebrovascular disease. These are often called non-traditional or 
non-conventional or novel risk factors because their importance in PAD and other 
manifestations of atherosclerosis awaits to be confirmed from epidemiological and 
clinical research. Currently there is burgeoning interest on the role of inflammation and 
haemostasis on atherosclerotic development and progression and the potential of 
inflammatory and haemostatic markers to serve as markers of atherosclerotic disease. 
The biology, epidemiology and pathophysiology of these markers in relation to 
atherosclerosis are described in the next chapter.  
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1.5 Progression of local disease in the legs 
Atherosclerotic disease of the lower extremities can progress locally (in the legs) and 
may also lead to systemic manifestations of the disease such as CHD or stroke. 
Interestingly, most people seem to experience other cardiovascular events and fewer 
have worsening PAD. The progression of the latter group is described here. 
 
1.5.1 Intermittent claudication and asymptomatic disease 
Intermittent claudication can progress in different ways including improvement or 
stabilization, or worsening of claudication which may then require surgical intervention 
and finally amputation (Dormandy et al 2000). Studies have shown that the majority of 
patients either improve or stabilize (Dormandy et al 2000). This can be clearly seen in a 
review of 10 trials of patients with IC where 75% of claudicants experienced 
stabilization of their symptoms over the next 5-18 years (Dormandy et al 1991).  In the 
Framingham
 
Study, only about 30% of patients with IC
 
had persistent symptoms for a 
minimum of 4 years (Peabody et al 1974). Also, symptoms progressed in only about 15-
30% of claudicants and, in total, 25% required surgery or experienced tissue loss and 
less
 
than 4% of claudicants required a major amputation (Dormandy et al 1991;Imparato 
et al 1975;McDaniel et al 1989;Peabody et al 1974). Of the 116 cases of claudication in 
the Edinburgh Artery Study, 28.8% still had symptoms of IC, 8.2% had had a surgical 




The progression of asymptomatic disease has been very little studied. The data available 
indicate a relatively benign course as far as the legs are concerned. In the Basle study, 
only 20% of people with asymptomatic PAD developed IC and 8% CLI over 10 years 
(Widmer et al 1991). In support of this study, a third of asymptomatic stenoses 
progressed over two years arteriographically (Walsh et al 1991). In the Edinburgh Artery 
Study, of the 345 asymptomatic PAD patients, 33 (9.6%) developed IC, and 3 (0.9%) 
underwent vascular surgery after 5 years of follow up. Progression of asymptomatic 
disease can also be measured via non-invasive modalities such as the ABI over time. 
However, the ABI is usually measured at one time point in epidemiological studies and 
information on its progression is limited.  
 
1.5.2 Critical limb ischaemia 
It is particularly difficult to describe the natural history of the critically ischaemic limb 
because most patients undergo some form of vascular intervention (Dormandy et al 
2000). Limb loss in patients with CLI is more common than in claudicants and 10-40% 
of people with CLI need amputation (Dormandy et al 1989). The remaining patients 
often require supportive or medical treatment (Dormandy et al 2000). Results from two 
multicenter studies showed that, in one, 61% of patients with CLI had attempted 
revascularization and 7% a primary amputation after 1 year of follow up (Wolfe 1986). 
In the other study, 44.4% of patients with CLI had attempted revascularization and 9.4% 
amputation after 2 years of follow up (The ICAI group 1997). A more recent study 
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reported that after 6 months, 12% of 1,569 patients with CLI needed amputation and 
17.9% had persistent CLI (Bertele et al 1999).   
 
1.5.3 Risk factors for worsening PAD 
Limited data are available concerning prognostic factors that play a role in the transition 
of asymptomatic PAD to symptomatic PAD. For the progression of symptomatic 
disease, the most important risk factors for the development of PAD, smoking and 
diabetes, have also been shown to have an effect on disease progression (Dormandy et al 
2000). Patients with IC who continued to smoke have been shown to develop CLI more 
often than those patients with IC that quit smoking (Jonason et al 1987). Likewise, 
patients with IC who had a high load of lifetime smoking have required reconstructive 
vascular surgery 3 times more than those who smoked less (Cronenwett et al 1984). 
Finally, patients with IC who continued to smoke had higher amputation rates than those 
who quitted in two other studies (Cronenwett et al 1984;Faulkner et al 1983;Lassila et al 
1988).   
 
Overall, patients with diabetes have more aggressive progression of PAD. Patients with 
IC and diabetes have shown to have a 35% risk of sudden ischemia and 2% risk of major 
amputation compared to claudicants without diabetes who had 19% risk of sudden 
ischemia and 3% risk of major amputation (Cronenwett et al 1984;McDaniel et al 1989). 
In addition, amputation or gangrene was 10 times more frequent is subjects with diabetic 
PAD than in PAD patients without diabetes (Dormandy et al 1999). 
 32 
 
The ABI has also been shown to be predictive of progressive PAD. In a prospective 
study of 1,969 claudicants, an ABI<0.5 was the most significant predictor of 
deterioration of PAD assessed by arterial surgery or intervention (Dormandy et al 1991). 
Also a low ABI was associated with 2.4 fold higher risk of local atherosclerotic 
progression after 6.5 years of follow up (Jelnes et al 1986).  There is also some evidence 
that the nature and symptoms of claudication might be related to disease progression. In 
Bloor’s classic follow up study, a patient with sudden onset of claudication was twice as 
likely to improve as a patient with gradual onset (Bloor 1961). Also, there is some 
evidence that claudication has a less severe course in women. Studies have reported that 
although the ratio between males and females is 2:1 in claudicants it increases between 
3:1 and 13:1 in later stages of the disease (Fowkes 1991).  
 
1.6 PAD and other cardiovascular diseases 
1.6.1 PAD and co-existing CVD 
The prognosis of patients with lower extremity PAD is characterized by an increased 
risk of cardiovascular ischaemic events at least partly due to concomitant CAD and 
cerebrovascular disease in these patients. This has been confirmed by epidemiological 
research measuring the co-prevalence of PAD with other manifestations of 
atherosclerosis. The reported co-prevalence is highly dependent on the sensitivity of 
diagnostic tools used to define atherosclerotic disease either PAD, CHD or stroke.  
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Overall, between 40-60% of claudicants suffer from co-existing CAD diagnosed by 
history of disease, clinical examination or electrocardiogram (ECG) and 26-50% of 
claudicants suffer from co-existing carotid disease diagnosed with duplex examination 
(Dormandy et al 2000). Aronow and colleagues studied the co-prevalence of PAD with 
other atherosclerotic manifestations in a long term care facility (Aronow et al 1994). 
This study showed that of 468 patients with PAD, 58% had CAD and 34% had suffered 
from ischaemic stroke (diagnosed with clinical history or ECG). Likewise, in a study of 
1,802 men and women, 161 of 236 subjects (68%) with PAD had co-existent CAD and 
100 of 236 subjects (42%) with PAD had co-existent cerebrovascular disease (Ness et al 
2000). Similar findings were reported in the Whitehall Study which found the 
prevalence of CVD in patients with IC to be 54% (Smith et al 1990). In a Danish cohort, 
44.3% of men and 31.2% of women with IC also suffered from CVD (Reunanen et al 
1982). Finally, when angiography was used to define CVD the co-prevalence with IC 
was reported as high as 90% by two studies (Hertzer et al 1984;Valentine et al 1994. 
 
The Edinburgh Artery Study and the PARTNERS showed that when PAD was defined 
by ABI<0.9 then 71% and 56% of subjects had co-existing CVD, respectively (Fowkes 
et al 1991;Hirsch et al 2001). In the NHANES study, the prevalence of CHD was 24% 
and of stroke 11% among those with ABI<0.9 whereas of those with normal ABI, 7% 
had CHD and 3% had stroke (Selvin et al 2004). Further evidence was found in the 
Cardiovascular Health Study, where ABI was inversely correlated with the number of 
patients suffering from myocardial infarction (MI), angina and congestive heart failure. 
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In addition, the ABI was reported to correlate well with other measures of arterial 
disease in other vascular beds. The Edinburgh Artery Study and the Rotterdam study 
have found, for example, that low ABI was associated with higher carotid intima media 
thickness (IMT) (Allan et al 1997;Bots et al 1994). In support of these results, the 
Multi-Ethnic Study of Atherosclerosis, showed that ABI was inversely associated with 
coronary artery calcium levels and carotid IMT (McDermott et al 2005b). 
 
1.6.2 Intermittent claudication 
Patients with IC have been shown to have an increased risk of angina, heart failure, fatal 
and non-fatal MI, fatal and non-fatal stroke and cardiovascular and all cause mortality as 
reported by large scale epidemiological studies (Ouriel 2001). Table 3 presents results 
from prospective studies on CVD and all cause mortality in patients with IC assessed by 
the WHO IC questionnaire and it shows that most of the total mortality could be 
attributed to cardiovascular death. For example, the Helsinki study (Reunanen et al 
1982) found a 3 fold increase in the risk of cardiovascular mortality in male claudicants 
compared to males without claudication whereas in the Framingham study the annual 
mortality rate was 4% greater in claudicants (Kannel et al 1971).  
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Table 3 All cause and cardiovascular mortality in subjects with intermittent claudication (IC) 
assessed by the WHO questionnaire 
Study Population 





























Quebec Vascular Study 
(Dagenais et al 1991) 
 
188 M 35–64  12 11.2 8.5 
Edinburgh Artery Study 
(Leng et al 1996) 
73 MW 55-74  5 19.2 13.4 
NR: not reported 
M: men, W: women 




1.6.3 Asymptomatic disease 
People with asymptomatic (subclinical) atherosclerosis measured by the ABI or other 
non-invasive modalities also have an increased risk of cardiovascular morbidity and 
mortality (Abbott et al 2000;Criqui et al 1992;Leng et al 1996;Newman et al 1993). 
Table 4 summarizes results from prospective studies and shows that individuals with an 
ABI<0.9 are at increased risk of experiencing either coronary or cerebrovascular events. 
Moreover, a recent meta-analysis of 9 studies which followed up subjects prospectively 
showed that the specificity and sensitivity of a low ABI (ABI<0.9) to predict CHD were 
16.5% and 92.5%, for incident stroke were 16.0% and 92.2% and for cardiovascular 
mortality were 41.0% and 87.9 %, respectively (Doobay et al 2005).  
 
In the Edinburgh Artery Study, after 5 years of follow up, people with an ABI<0.9 at 
baseline had an increased risk of non-fatal MI (relative risk 1.38), stroke (1.98) and 
cardiovascular death (1.85) after adjustment for age, sex, coronary disease, and diabetes 
(Leng et al 1996). A later report from this study, with 12 years follow up, demonstrated 
that an ABI<0.9 had improved prediction of fatal MI over and above that of 
conventional risk factors (Lee et al 2004). In the Honolulu Heart Program, men older 
than 70 years with ABI<0.8 had a significantly higher risk of CHD (Abbott et al 2000). 
The Framingham study of 251 men and 423 women aged 80 and older showed that 
ABI<0.9 was associated with a 2 fold increase in the risk of stroke but not with the risk 
of CHD (Murabito et al 2003).  
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The Cardiovascular Health Study measured the ABI in adults older than 65 years of age 
and found that an ABI<0.9 was significantly associated with incident CVD and recurrent 
CVD (Newman et al 1999). Moreover, the Atherosclerosis Risk in Communities (ARIC) 
study examined the relation between ABI and incident stroke after 7 years and reported 
a more than 5 fold increase in the risk of stroke in people with ABI<0.8 (Tsai et al 
2001). In another analysis of the ARIC study, ABI was weakly associated with recurrent 
CVD in the univariable analysis only (Wattanakit et al 2005). However, results from the 
ARIC study need to be interpreted with caution since only one leg was used for the 
calculation of the ABI and therefore the prevalence of disease is likely to be 
underestimated. 
 
In addition, the Cardiovascular Health Study along with the Strong Heart Study has 
recently examined the prognostic significance of high ABI (O'Hare et al 2006;Resnick et 
al 2004). As previously described, in subjects with diabetes, the ABI is artificially high 
due to arterial calcification. With that perception, high ABI could be a measure of 
increased arterial stiffness and therefore predictive of adverse cardiovascular results. 
Most epidemiologic studies have excluded subjects with increased ABI above 1.4 or 1.5 
from their analyses. The Cardiovascular Health Study and the Strong Heart Study did 
not make these exclusions and have recently found a U shaped relationship between ABI 
and the risk of mortality; however, these results need replication from other studies 
(O'Hare et al 2006;Resnick et al 2004). 
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Finally, a low ABI has been shown to be a strong predictor of mortality. An ABI <0.85 
was associated with a more than 2 fold increase in all cause mortality, whereas a strong 
trend between increasing risk of death and decreasing ABI has also been reported (Leng 
et al 1996;Mckenna et al 1991). 
 
Table 4 List of prospective studies that have evaluated the risk ratio (95% CI) of people with 
ABI<0.9 for the development of non-fatal coronary heart disease or stroke in the general population 
Risk ratio of  
ABI  0.9 vs. >0.9 (95% CI) 














10 5.0 (p= 0.006) NR 
Edinburgh Artery 
Study 














65 6 2.0 (1.4, 3.0) 1.6 (1.1, 2.3) 
Honolulu Heart 
Program 
(Abbott et al 2000) 
 
2,863 men 71-93 3-6 3.3 (2.2, 4.9) 























4 1.2 (0.7, 2.1) 2.0 (1.1, 3.7)‡ 
NR: not reported 
† adjusted for age, sex, coronary disease, and diabetes at baseline 
‡ adjusted for age, sex, and prevalent cardiovascular disease 
§PAD defined by ABI<0.8. First risk ratio adjusted for age and second for 
cardiovascular risk factors    
 age and sex adjusted 
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1.6.4 Critical limb ischemia 
In general, cardiovascular and all cause mortality among those with CLI is high. In 
addition, patients with CLI have an elevated risk of future MI, stroke and vascular death, 
3 fold higher than patients with IC (Novo et al 2004). There are few studies which have 
followed up subjects with CLI. In one study, 20% of patients with CLI died within a 
year (Wolfe 1986). While in another, 40-70% died after 5 years of follow up (Dormandy 
et al 1999). Similar results were presented from a follow up study in Italy; of 574 
patients diagnosed with CLI, 21.9% have died within one year (The ICAI group 1997). 
As expected, the overall incidence of vascular deaths was significantly higher than that 
of non-vascular deaths (34.5 vs. 8.5%).  
 
1.7 Diagnosis of PAD 
In general, clinical examination and measurement of PAD is a complex task due to the 
variable clinical and subclinical manifestations of the disease. Various diagnostic tests 
appropriate for the assessment of PAD in large scale community programs and 
epidemiological studies (non-invasive, easy to use, cheap, and reproducible) have been 
described. An overview of the most commonly used is presented here. 
 
1.7.1 Questionnaires for intermittent claudication 
Claudication is the symptom that is often associated with PAD. However, the diagnosis 
of claudication is not straightforward. IC must be differentiated from lower extremity 
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pain due to non-vascular causes. True claudication begins after a reproducible length of 
ambulation and disappears after the patient stops walking even if she or he remains 
standing.  
 
For the diagnosis of IC in epidemiological research several questionnaires have been 
developed over the years. The WHO/ Rose claudication questionnaire is the most 
commonly used (Rose 1962). It defines claudication as the calf pain that occurs in one or 
both calves during exercise, which does not begin at rest, does not disappear while 
walking, is provoked by hurrying or walking uphill and makes the individual stop or 
decrease walking speed. However, the pain should cease within 10 minutes of rest. The 
severity of IC can be graded using this questionnaire to Grade I (symptoms occur while 
walking at an ordinary pace on the level) and Grade II (symptoms occur while walking 
uphill or in a hurry).  
 
The Edinburgh Claudication Questionnaire (Leng et al 1992) is a modified version of the 
WHO questionnaire which does not include questions asking whether the individual 
experiences calf or calves pain while walking, whether the pain disappears while 
walking and what is done if pain is experienced while walking. This questionnaire 
includes a diagram of the lower extremities and defines claudication as pain in the calf 
even if pain is also identified in other areas. It also includes a definition of atypical 
claudication as pain in the thigh or buttock without calf pain. 
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Finally the San Diego Claudication Questionnaire (Criqui et al 1996) allowed for the 
individual to report pain specific to the right or left leg and to specify whether the pain is 
in the calves, thighs and/ or buttocks. This questionnaire defines the following 
categories: no pain, pain at rest, non-calf pain, non –Rose exercise calf pain and Rose 
claudication.  
 
Although these questionnaires are useful especially in large epidemiological studies for 
the diagnosis of PAD, they seem to have high specificity but moderate sensitivity. For 
example, the Edinburgh Claudication questionnaire showed 85% sensitivity compared to 
65% for the WHO questionnaire although the specificity was over 95% for both (Leng et 
al 1992). Most importantly, IC itself might be an insensitive marker of PAD according 
to recent evidence which shows a broader range of symptoms in patients with PAD 
(McDermott et al 1999;McDermott et al 2001).  
 
1.7.2 The ankle brachial index 
Travis Winsor was the first to notice in 1950 that the ankle pressure is usually decreased 
if the arteries in the lower limb are obstructed (Winsor 1950). Later studies showed that 
with increasing degrees of arterial narrowing there is a progressive fall in systolic blood 
pressure distal to the sites of involvement (Yao 1970). These observations have led to 
the development of methods that detect the pressure drop and associate it with 
atherosclerotic disease of the limbs.  
 42 
 
Systolic blood pressure is expected to augment as it travels down the limb due to the 
muscular peripheral arteries as well as the summation of reflected pressure waves (Weitz 
et al 1996). Therefore, systolic pressures of the tibial arteries of each ankle should be 
greater or at least equal to those of the arm. The ratio of the ankle to the brachial systolic 
pressure, called the ABI or the ankle brachial pressure index (ABPI) or the ankle arm 
index (AAI), is the cornerstone of non-invasive assessment of the patients with 
symptomatic or asymptomatic PAD. The normal ABI should be greater or equal to 1. An 
ABI less than unity (or less than 0.9 in practice) at rest, indicates haemodynamically 
significant arterial obstruction in the legs (Halperin 2002).  
 
The ABI has been validated against classic angiography to determine its sensitivity, 
specificity, and accuracy as a lower extremity PAD diagnostic tool but only in selected 
populations. For example, Fiegelson (Feigelson et al 1994) measured a sensitivity of 
89% and a specificity of 99% compared with angiography, using only posterior tibial 
measurements with a threshold of 0.8. That study demonstrated that the ABI had a 
positive predictive value of 90%, a negative predictive value of 99%, and an overall 
accuracy of 98%. In accordance, Lijmer (Lijmer et al 1996) demonstrated that the 
sensitivity of the ABI<0.91 to detect stenoses of 50% or more reduction in lumen 
diameter was 79% and the specificity was 96%. Nassoura et al. (Nassoura et al 1996) 
compared the ABI with angiography after vascular occlusive injury due to trauma and 
demonstrated that the ABI had a sensitivity of 72%, a specificity of 100%, a positive 
predictive value of 100% and a negative predictive value of 96%. However, all these 
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reported specificity and sensitivity for cut-off points of ABI have been calculated using 
selected hospital populations and is unknown how ABI would correlate with 
angiographically measured peripheral atheroma in the general population (Fowkes 
1991b).  Thus, there is not a universally valid cut-off point below which people may be 
considered to have defined severity of atherosclerotic disease. Alternatively, abnormal 
ABI values represent a continuous variable less than a dichotomous value (above or 
below 0.90). Therefore, in patients with IC, the ABI is expected to decrease between 
0.6-0.9, while in those with rest pain and tissue loss usually the ABI is <0.4 and <0.25, 
respectively (Ouriel 2001).  
 
A limitation of the ABI is that it may not be accurate in individuals with non-
compressible pedal arteries due to diabetes or very old age. Variations of the ABI have 
been designed for those individuals and they are described in the next section. 
 
Methodology of ABI 
The ankle systolic pressure can be measured by a cuff inflated proximally to the ankle 
and the detection of blood flow by means of a Doppler probe. A stethoscope is 
insufficiently sensitive in detecting pulses at the ankle. Either the posterior tibial and/ or 
the dorsalis pedis artery’s pulse are detected or the peroneal artery if no audible signal is 
forthcoming from these two vessels.    
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In epidemiological surveys the calculation of the ABI varies while several methods for 
its measurement have been described. In most cases, the ankle systolic pressure is 
measured in both legs and similarly the brachial systolic pressure is measured in both 
arms which lead to at least 4 ratios of ABI. However, only one ratio is used to diagnose 
PAD. In some reports, the highest arterial pressure of either the dorsalis pedis or the 
posterior tibial artery in each leg is used to calculate the ABI (Mckenna et al 
1991;McLafferty et al 1997), while in others the lowest arterial pressure in each leg is 
used (McDermott et al 1998). Alternatively, the dorsalis pedis and posterior tibial 
arterial pressures within the leg are averaged (Vogt et al 1993), or the posterior tibial 
arterial pressures in the right and left legs are averaged (Newman et al 1993;Vogt et al 
1993). In other studies including the Framingham study, the Rotterdam study and the 
Edinburgh Artery Study, the ankle systolic pressure was measured in the posteriol tibial 
artery and if that wasn’t found in the dorsalis pedis in each leg (Fowkes et al 
1991;Meijer et al 1998;Murabito et al 2003;Vogt et al 1993). Also, the ARIC study 
randomly selected one leg to measure the ankle systolic pressure. One brachial pressure 
is also measured in some studies; usually the right (Newman et al 1993;Zheng et al 
1997). 
 
After measuring the ankle and the brachial systolic pressures, in most studies, the ABI is 
calculated for each leg by dividing the left ankle to left arm pressures and right ankle to 
right arm pressures. The lowest of these ratios is used as it denotes disease severity. If 
only the right arm was used then the two ratios have the right brachial index as the 
denominator (Zheng et al 1997).    
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Currently there are no recommendations for the most appropriate measurement of the 
ABI. Some studies have used only the right brachial systolic pressure for the calculation 
of the ABI. However, patients at risk for arterial disease in the lower extremities often 
have concomitant occlusive arterial disease in the upper extremities and it is possible 
that the right and left brachial pressures may be discrepant (Federman et al 2006). It has 
been estimated that the pressure difference between the right and left brachial arteries is 
at least 20 mmHg is present in 3.5% of the normal healthy population and in over 20% 
of patients with PAD (Caruana et al 2005). If for example the left brachial pressure is 
higher than the right for a sizable proportion of subjects, the calculation of the ABI using 
only the right systolic pressure might be biased so its is probably vital to measure both 
brachial pressures.  
 
In addition, recent studies comparing different methods of calculating the ABI agreed 
that lower ABI taken by averaging the dorsalis pedis and posterior tibial arterial 
pressures in each leg was most predictive of walking endurance and walking velocity in 
PAD and had lower intra- and inter-observer variability (Aboyans et al 2003). However, 
in epidemiologic research where thousands of people are undergoing a specific test, 
taking measurement from both arteries of the ankle might be particularly difficult and 
time consuming. In this case, the measurement of posterior tibial and if not present the 
dorsalis pedis should be a good marker of the underlying atherosclerosis.  
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Finally, the method used to measure the systolic pressure may differ across different 
studies. The traditionally used mercury sphygmomanometers are less used due to safety 
reasons and automatic devices are taking their place (Caruana et al 2005). Few studies 
have evaluated the use of these automatic devices but the results show that is still 
probably inadequate. Lee (Lee et al 1996) and Mundt (Mundt et al 1992) concluded that 
results taken with automatic device are the same with these taken with a cuff and a 
Doppler probe. On the contrary, in another study there was no correlation between 
values obtained with a Doppler technique and those obtained by an automatic device and 
the latter overestimated the ankle pressure (Jonsson et al 2001).  
 
Variability of ABI 
Few studies have examined the variability of ABI and concluded that it is such that ABI 
is a suitable measurement for epidemiological studies (Caruana et al 2005). Overall, the 
ABI is considered to have a reproducibility of approximately 0.10 (Hirsch et al 2006). 
Early research by Carter (Carter 1968) showed that 95% of repeat measures of ankle 
blood pressures were within 9% of the average; a result which is similar to that obtained 
when measuring brachial systolic pressure. The intra-observer variability of the
 
test was 
estimated by Fowkes (Fowkes et al 1988) as 7.2% in diseased subjects and 10.4% in 
normal subjects. Kaiser (Kaiser et al 1999) reported 11.8% variability when 
measurement was taken by a single observer. The latter study also pointed out that 
trained observers might have significantly decreased intra-observer variability as low 
as 7%. Yao (Yao 1970) found the measurement of ABI as 0.08 assessed in 179 patients 
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on different days using 4 technicians. When 69 patients were assessed on 6 different 
days using the same technician, the measurement variance decreased to 0.05. These 
results suggest that most of the variance is attributed to the measurement method and 
less due to inter-observer differences.  
 
1.7.3 Other diagnostic tests 
In addition to the ABI, a number of other diagnostic tests have been developed for the 
diagnosis of PAD. For example, the sensitivity of the ABI can be increased with a stress 
test. A similar test which might be more appropriate for epidemiological surveys is the 
reactive hyperaemia test. This is conducted at rest and uses simpler equipment. The 
blood flow is occluded at the upper thigh or above the knee and the systolic blood 
pressure is measured after releasing the obstruction (Johnson 1975). Moreover, along 
with the ABI, multiple pressure measurements can be calculated along the lower 
extremity which may help localize the site of arterial obstruction. Finally, in elderly 
subjects and in subjects with diabetes, the arteries are often calcified and thus 
incompressible and the ABI can be artificially elevated. In these situations, toe pressures 
can also be informative.  
 
The anatomical level of the disease can also be identified by the palpation of pulses in 
the femoral, popliteal and ankle regions. However, pulse palpation is of limited use in 
epidemiologic research due to its low sensitivity, high variability and its discrete 
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(qualitative not quantitative) measure of perfusion (Brearley et al 1992;Myers et al 
1987). 
 
Another diagnostic test is flow velocity determination. This diagnostic test does not 
provide visualization of the arterial anatomy but can be useful in assessing PAD 
anatomy, severity and progression (Hirsch et al 2006). It should be noted that it has 
greater specificity for superficial femoral arteries than for aortoiliac occlusive disease 
(Hirsch et al 2006). Other disadvantages include limited accuracy in tortuous, 
overlapping or calcified arteries and high dependence on the operator (Strandness et al 
1967). Alternatively, duplex ultrasound which combines B-mode and Doppler 
ultrasound measurements and can provide information concerning artery wall thickness, 
degree of flow turbulence, changes in blood flow and vessel morphologic characteristics 
(Kohler et al 1990;Strandness et al 1967).  
 
Finally, angiography or arteriography remains the gold standard for the diagnosis of 
PAD with which the specificity and sensitivity of all other tests are compared. This is an 
invasive test and it is only used in those people that surgical intervention is planned 
because angiography is associated with both local and systemic complications, 
morbidity and mortality. Alternatively, magnetic resonance angiography and 
computerized tomography arteriography can be used which contrary to traditional 
angiography, are not associated with increased risk of stroke or of arterial injury. 
However, their correlation with angiography needs to be established (Halperin 2002). 
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1.8 Summary 
PAD is a manifestation of atherosclerotic disease in the arteries to the legs. The clinical 
presentation of PAD includes a spectrum which spans individuals with asymptomatic 
disease, those who experience IC and those with more severe symptoms of CLI.  
 
Epidemiologic research has confirmed that PAD is a common condition which affects a 
large proportion of the adult population worldwide. The estimated prevalence of 
claudication ranges from 0.4 to 14.4%. The prevalence of asymptomatic disease 
diagnosed with non-invasive tests is much higher and ranges between 0.9% and 22% 
with the ratio of symptomatic to asymptomatic ranging between 1:0.9 and 1:6.0. Risk 
factors for atherosclerosis such as age, cigarette smoking, diabetes, dyslipidemia, and 
hypertension increase the likelihood of developing PAD. Smoking and diabetes have 
also been associated with the progression of symptomatic disease. Risk factors for the 
progression of asymptomatic disease have been very little studied.   
 
The majority of patients with IC experience stabilization of their symptoms in the next 5 
years and only 10-15% ever develop CLI. The progression in the legs of those with 
asymptomatic disease is very little studied. However, both claudicants and those with 
asymptomatic disease are at increased risk of systemic cardiovascular events.  
 The diagnosis of PAD in epidemiologic studies is usually performed by non-invasive 
diagnostic tests. The ABI is the most commonly used non-invasive test and can be 
considered as an accurate and reliable marker of subclinical peripheral and generalized 
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atherosclerosis in populations. Indeed, a decreased ABI (usually below 0.9) has been 
associated with increased risk of MI, stroke and other manifestations of atherosclerosis 
and with other non-invasive test of subclinical disease in other vascular beds.  
 
Thus PAD is a common condition especially if asymptomatic individuals are accounted 
for. However, the natural history of asymptomatic disease is not well established. 
Specific risk factors for the progression of asymptomatic disease need to be established 
to help the identification of seemingly healthy individuals who are at increased risk of 





2 Inflammation and haemostasis 
2.1 Introduction 
The previous chapter focused on the epidemiology of PAD- an atherosclerotic disease of 
the lower extremities. Several mechanisms have been proposed for the initiation and 
accumulation of atherosclerosis in the peripheral and other vascular beds. Historically, 
the aging hypothesis proposed that atherosclerosis is a process of the aging of the 
arteries. This was replaced by the lipid hypothesis which stated that the accumulation of 
lipids due to diet and genetic factors result in atherosclerotic lesions in the arteries.  
 
Latterly, with advances of molecular and vascular biology, the role of haemostasis and 
inflammation in atherosclerotic development and progression was recognized. 
Fundamental research since then has shown that these two universal responses to injury 
seem to interact and may play a key role in the initiation and propagation of 
atherosclerosis.  
 
This chapter presents a brief overview of the inflammatory and haemostatic mechanisms 
and their interactions. It also describes the hypothesized role of these mechanisms in the 
atherosclerotic process and focuses on specific biological factors that may serve as 
markers of the ongoing inflammation and haemostatic process and therefore of the 
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atherosclerotic process. The biological structure and function of each marker and a 
summary of their measurement methods is described here.   
 
Many studies have examined the role of these biomarkers in CVD. A literature review 
on epidemiological studies of these markers and different CVD endpoints is also 
included in this chapter. The literature review included only studies in the English 
language and with prospective design which were sought by MEDLINE searches. 
Computer searches used combinations of key words relating
 
to the blood factors (e.g., 
fibrinogen, C-reactive protein, CRP,
 
interleukin-6, IL-6, D-dimer, acute phase
 
reactants) 
and to the disease of interest (e.g., coronary heart
 
disease, myocardial infarction, 
atherosclerosis, peripheral arterial disease).
 
References cited in the articles identified 
through the literature review were also examined. Some examples of cross-sectional or 
case control studies were also mentioned. Also, since the Edinburgh Artery Study is a 
population based cohort study, the literature review included studies on healthy or 
apparently healthy individuals. However, studies on selected population groups (people 
with pre-existing CVD) were summarized.  Because a meta-analysis has already been 
published for the majority of the markers mentioned here, a systematic review was not 
performed. Moreover, because this thesis is on epidemiology, animal studies and basic 
biological studies are not reported. Finally, studies on genetic epidemiology of these 




2.2 Overview of haemostasis 
Haemostasis is the physiological response to blood loss following vascular injury and 
thus an important defence mechanism against bleeding. The process produces a fibrin 
platelet clot which effectively seals the damaged blood vessel. Generation of the clot and 
subsequent clot lysis involves complex interactions between vascular endothelium, 
blood platelets, coagulation factors and components of the fibrinolytic system which are 
finely regulated to localise the clot to the area of damage.  
 
2.2.1 Coagulation 
The main role of the coagulation system is to produce thrombin from its precursor 
prothrombin. The precise and balanced generation of thrombin at sites of vascular injury 
is the result of an ordered series of reactions collectively referred to as blood coagulation 
(Mann 1999). Thrombin is a protein with many biologically important functions such as 
the activation of platelets, conversion of fibrinogen to a fibrin network and feedback 
amplification of coagulation (Dahlback 2005). 
 
More than 35 years ago, Mc Farlane (Macfarlane 1964) and Davie and Ratnoff (Davie & 
Ratnoff 1964) proposed a cascade/ waterfall model of coagulation. This was the first 
step towards the understanding of individual coagulation proteins and their interactions 
(Becker 2005). According to the cascade model, two distinct systems of fibrin formation 
exist, the extrinsic (tissue factor) and the intrinsic (contact) pathway. These pathways are 
outlined in a Y-shaped scheme, with the distinct “intrinsic” and “extrinsic” pathways 
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initiated by factor XII (FXII) and FVIIa/ tissue factor, respectively (Figure 1). The 
pathways eventually converge on a “common” pathway where factor Xa converts 
prothrombin to thrombin
 
which then acts on fibrinogen. The coagulation complexes are 
generally noted to require phospholipid and calcium for their activity. 
 
Research over the past decade showed that these two pathways cannot operate 
independently as was initially proposed in the cascade model (Hoffman et al 2001). In 
fact, these two systems seem to interact extensively so that coagulation in vivo results 
from a complex and multidimensional system (Becker 2005). Hoffman (Hoffman et al 
2001) proposed a cell based approach to coagulation. He suggested that rather than 
conceiving coagulation as only a "cascade" of proteolytic reactions, the coagulation 
reactions occur as overlapping steps: initiation, amplification, and propagation. Under 
this model, the extrinsic and intrinsic pathways play distinct and complementary roles 
(Hoffman et al 2001). 
 
A number of mechanisms prevent initiation of coagulation under normal circumstances. 
Among them, the three dominant anti-coagulant mechanisms include the heparin –
antithrombotic system, protein C-anticoagulant pathway and tissue factor pathway 
inhibitor (Esmon 2004).  
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Once haemostasis is restored and the tissue is repaired the clot must be removed from 
the injured tissue. This is achieved by the fibrinolytic pathway which is illustrated on 
Figure 2. Plasmin is the major fibrinolytic protease. Plasminogen, a circulating plasma 
zymogen, can be converted to plasmin by both tissue plasminogen activator (t-PA) as 
well as by urokinase (u-PA). The t-PA pathway is primarily involved in fibrin 
haemostasis whereas the u-PA is primarily involved in tissue remodelling (Collen 1999).  
 
Once it is formed, plasmin degrades fibrin and can activate metalloproteinases which in 
turn degrade the extracellular matrix (Collen et al 1991). Fibrin, the major plasmin 
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substrate, regulates its own degradation by binding both plasminogen and t-PA on its 
surface, promoting plasmin generation (Cesarman-Maus et al 2005).  
 
Inhibition of the fibrinolytic system can occur by several mechanisms. Three of these 
include the plasminogen activator inhibitor-1 and plasminogen activator inhibitor-2 
(PAI-1 and PAI-2) which inhibit plasminogen activators, alpha 2-antiplasmin and alpha 
2-macroglobulin which inactivate plasmin and the tissue inhibitors of metalloproteinases 
(Collen 1999). 
 
Figure 2 The fibrinolytic system 













2.3 Overview of inflammation 
Inflammation is the body’s first line of defence against injury or invasion. The purpose 
of inflammation is to limit damage to the body after injury such as abrasions and 
lacerations or invasion by foreign organisms, such as bacteria or viruses. The principal 
signs of inflammation—redness, heat, pain, and swelling—are easily perceptible. On a 
microscopic level, the inflammatory response involves numerous different chemicals, 
each performing a specific action. 
 
2.3.1 Acute inflammation 
The inflammatory process can be divided into three major and interrelated components: 
vascular dilation, endothelial activation and neutrophil activation (Stevens et al 2002a). 
The earliest event of an inflammatory response is vasodilation. Relaxation of the 
vascular smooth muscle leads to increased permeability and blood flow (hyperaemia) 
that causes redness (erythema) and the entry of fluid into the tissues (oedema).   
 
Due to increased permeability, plasma proteins pass into the tissues that cause the 
expression of adhesion molecules. Adhesion molecules mediate leukocyte adherence. 
The leukocytes, in particular neutrophils, attach themselves to the endothelial cells 
within the blood vessels and then migrate into the surrounding tissue. The complement 
cascade is then initiated forming several key plasma mediators of inflammation. If the 
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vessel wall is damaged fibrinogen is cleaved to form fibrin at the site of injury, platelets 
aggregate and become activated, and the red cells aggregate to help stop bleeding and 
lead eventually to clot formation. 
 
Possible outcomes of acute inflammation include resolution (meaning that the normal 
tissue architecture is restored) or scarring (fibrosis) when tissue is unable to regenerate 
and excessive fibrin deposition occurs at the site of injury (Stevens et al 2002a).  Also, 
abscess formation can occur with some infections or progression to chronic 
inflammation may follow.  
 
2.3.2 Chronic inflammation 
Chronic inflammation is characterized by inflammatory processes which continue for a 
relatively long duration. Essentially, chronic inflammation is caused by one of two 
means, either by a persistent inflammatory stimulus or ineffective inflammatory 
mechanisms.  
 
Chronic inflammation involves monocytes, macrophages, lymphocytes and plasma cells 
(Stevens et al 2002b). The sequence of chronic inflammation centres around the activity 
of macrophages derived from blood monocytes. Once at the site of inflammation, the 
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macrophage is incapable of completing its role. As a consequence, more monocytes are 
recruited from the blood, more macrophages proliferate locally, and both groups are 
effectively stranded at the site. Increased macrophage activity and local destruction 
liberates a number of cytokines including interleukins and growth factors. These attract a 
range of supplementary cells including lymphocytes, fibroblasts, plasma cells, 
eosinophils and mast cells. The interaction between various cells is essential: 
lymphocytes and macrophages act in a complementary manner, each inducing the other's 
proliferation and differentiation via mediators such as interferon and interleukins. 
Growth factors cause random matrix-deposition, angiogenesis and epithelialization. 
 
2.3.3 The acute phase response 
Inflammation, either chronic or acute, is accompanied by systemic and metabolic 
changes collective known as the acute phase response (Kushner 1982, Baumann 1994). 
The purpose of this response is to restore haemostasis and to remove the cause of 
disturbance.   
 
The acute phase response is characterized by the activation of the complement and the 
blood coagulation system, hormonal changes and changes in the lipid metabolism and 
induction of acute phase proteins (Whicher et al 1992). The acute phase proteins are 
defined as those 30 or so plasma proteins which increase in concentration by 25% or 
more in the first 7 days following tissue damage. They are widely measured to indicate 
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the presence of inflammation and its extent or severity (Kushner 1982). Most acute 
phase proteins are produced in the liver but some are produced by other cell types, 
including monocytes, endothelial cells, fibroblasts and adipocytes (Gabay et al 1999). 
The most common acute phase proteins are listed in Table 5. Major acute phase proteins 
can increase concentration to 1,000 fold over normal levels. This group includes serum 
amyloid A (SAA), C-reactive protein (CRP) and serum amyloid P component (SAP). 
So-called negative acute phase proteins are decreased in plasma concentration during the 
acute phase response. 
 
The function of most acute phase proteins has not been totally elucidated. They seem to 
have a wide range of activities that contribute to host defence: they can directly 
neutralize inflammatory mediators, limit the extent of local tissue damage, as well as 
participate in tissue repair and regeneration (Baumann et al 1994). Some proteins also 
have anti-inflammatory properties, whereas, coagulation components, such as 
fibrinogen, play an essential role in promoting wound healing (Gabay et al 1999). The 
interleukin-6 (IL-6) family of cytokines are the major inducers of acute phase protein 
synthesis in experimental studies, with IL-1 and tumor necrosis factor (TNF) playing a 
minor role. 
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Table 5 Positive and negative acute phase proteins (Gabay et al 1999) 
Proteins whose levels increase 
 
Complement proteins C3, C4, C9, factor B, C1 inhibitor, C4b 
binding protein, mannose binding lectin 
 
Proteins of the haemostatic system fibrinogen, plasminogen, tissue 
plasminogen activator, urokinase, protein 
S, vitronectin,  
plasminogen-activator inhibitor-1 
 
Proteins of the inflammation system phospholipase A2, liposacharide 
 
Antiproteases a1 protease inhibitor, a1 antichymotripsin 
 
Transport proteins cerulopasmin, haptoglobin, hemopexin 
 
Others C-reactive protein, serum amyloid A, 
fibronectin, ferritin, angiotensinogen 
 
Proteins whose levels decrease 
 
 albumin, transferrin, factor XII, 
transthyretin, a- fetoprotein 
 
2.4 Inflammation and haemostasis in atherosclerosis 
There is compelling evidence from both clinical and basic biological studies that the 
aforementioned physiological mechanisms originally involved in defence against the 
hostile world, play an important role in the initiation and progression of atherosclerotic 
disease. However, the exact underlying cellular and molecular pathways that predispose 
to atherosclerosis are not fully known yet and several models have been proposed to 
explain the initiation and progression of this complex disease. Here, the current evidence 
on the pathophysiology of atherosclerosis is summarized, with emphasis on the 
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inflammatory or haemostatic mechanisms that have been proposed as participates in 
several stages of disease development and progression.  
 
2.4.1 Formation of atherosclerotic plaque 
Inflammation and haemostasis are believed to participate in atherosclerosis from its 
inception. Endothelial dysfunction is one of the earliest events that contribute to 
atherosclerotic development. Normally, leukocytes are unable to attach to the arterial 
wall. However, the expression of adhesion molecules by the endothelial cells permits the 
attachment of leukocytes to the arterial wall. This first step includes the rolling of 
leucocytes along the endothelial surface and is mediated by selectins. Fibrinogen also 
binds to adhesion molecules and causes the release of vasoactive mediators and 
modulates the endothelial cell’s permeability (Koenig 2003).  
 
Once adhered to the arterial endothelium, leukocytes- mainly monocytes- transmigrate 
through the endothelial lining to the intima. This process is induced by chemokines. 
Once the monocytes reach the intima they mature into macrophages and participate in 
and perpetuate a local inflammation response (Libby 2002). The macrophages express 
scavenger receptors, engulf modified lipoproteins and become foam cells. Additional 
injurious stimuli continue the attraction of macrophages, mast cells and activated T cells 
into the developing lesion (Pearson et al 2003). Further release of cytokines, chemokines 
and growth factors induce further damage and eventually lead to focal necrosis. 
Inflammatory cytokines initiate coagulation through the induction of tissue factor 
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expression, primarily on monocytes (Edgington et al 1991). Also, primary cytokines 
induce the expression of IL-6 which further induces the expression of hepatic genes that 
encode acute phase reactants including CRP and fibrinogen (Tousoulis et al 2003).  New 
cycles of accumulation of mononuclear cells, migration and proliferation of smooth 
muscle cells and formation of fibrous tissue lead to the forming of a fibrous cap which 
overlies a core of lipid and necrotic tissue (Ross 1999).  
 
2.4.2 Plaque rupture 
During the atherosclerotic development the disease is often asymptomatic. However, 
there is an increased chance of plaque rupture and activation of the coagulation system. 
Atherosclerotic plaques that are at increased risk of rupture are called vulnerable or 
high-risk plaques (Fuster et al 2005). In general, if the thrombi are small they contribute 
to the growth of the atherosclerotic plaque; however, if they are large the may lead to 
acute syndromes. Notably, in some patients with acute syndromes, there is no plaque 
rupture but only superficial erosions. 
 
The fibrous cap, which is located on top of the atherosclerotic plaque, protects the blood 
from contacting the lipid core of the plaque. Therefore, disruption of the atherosclerotic 
plaque is usually a result of fibrous cap rupture. The fibrous cap is stabilized through 
collagen. However, activated macrophages secrete connective tissue enzymes, tissue 
factor and metalloproteinases which may break down collagen, weaken the fibrous cap 
and contribute significantly to its rupture (Libby 1996). Rupture of the fibrous cap 
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exposes thrombogenic and procoagulant material initiating the coagulation cascade 
(Virmany et al 2000). Platelet activation and aggregation, thrombin generation and the 
development of a large potentially occlusive thrombus follow (Tracy 2003).  
 
2.4.3 Markers of inflammation and haemostasis 
As described in the previous sections, numerous activated molecules are involved in 
inflammatory and haemostatic responses. Levels of such molecules may serve as 
attractive measurements of the ongoing inflammation or haemostatic processes and 
therefore potentially of the atherosclerotic process. Indeed, a series of inflammatory and 
haemostatic markers have been thoroughly examined in epidemiological research over 
the past 20 years to test this hypothesis. The observed associations are of particular 
interest since they may provide further insights into the pathophysiological mechanisms 
of atherosclerosis and also yield predictive and prognostic information of clinical utility.   
 
This thesis examines the epidemiology of inflammatory and haemostatic molecules in 
the atherosclerotic process focusing on peripheral atherosclerosis. Five markers of 
inflammation and seven markers of haemostasis were included in the analysis. However, 
as described previously, the boundaries between inflammation and haemostasis often 
overlap and some markers might reflect both mechanisms. The following section briefly 
describes the function of each marker under investigation and summarizes the 




2.5 C-reactive protein 
2.5.1 Structure and function 
CRP was first detected in 1930 in the sera of patients acutely infected with 
pneumococcal pneumonia and named by its reactivity with polysaccharide C of 
Streptococcus pneumonia (Tillett et al 1930). It is a calcium-binding pentameric protein 
consisting of five identical non-glycosilated polypeptide 23-kd subunits. It is present in 
trace amount in humans and has been highly conserved over hundreds of millions of 
years.  
 
CRP is an acute phase reactant. It is produced by hepatocytes predominately within 
hours of an injury or the presence of inflammation under the control of IL-6 but also of 
IL-1 and TNF (Li et al 2004). Its concentration in acute inflammation is raised by 1,000 
fold or more. CRP may also be produced away from the liver by vascular sources 
including cells residing in atherosclerotic plaques (Lind 2003). Its levels remain elevated 
throughout the acute phase response until normal tissue function and structure are 
restored. Normal CRP levels are generally defined <10 mg/L and healthy individuals 
generally have <1mg/L (Armani et al 2005). 
 
Its role its not fully understood but two functional properties of CRP including the 
ability to activate complement through the classic complement pathway, and the ability 
to modulate the function of phagocytic cells have been demonstrated (Li et al 2004). It is 
also known to bind in a wide variety of substances such as microbial polysaccharides, 
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damaged cell membranes (Volanakis et al 1979), LDL in vitro (Pepys et al 1985) and 
apoptotic cells (Gershov et al 2000). Moreover, it is has been shown that CRP helps the 
induction of inflammatory cytokines and tissue factor in monocytes (Cermak et al 1993) 
and that it activates endothelial cells to produce VCAM-1, ICAM-1 and E-selectin 
(Pasceri et al 2000). 
 
2.5.2 Measurement  
Low levels of CRP are easily and inexpensively measured. Standardized high-sensitivity 
assays are commercially available for this purpose and provide similar results in stored, 
fresh or frozen plasma (Koenig 2005). The high sensitivity CRP assay detects levels of 
CRP from 0-2 mg/L and their coefficient of variation is generally <10% (Pearson et al 
2003). Several high sensitivity CRP assays have been described including 
immunonephelometric, immunoturbidimetric and immunoluminometric methodology. 
Fasting samples are not required. Also, samples have been shown to be stable at room 
temperature and there are no variations with time of the day (Ockene 2001; Wilson 
2003). Moreover, the variability and classification accuracy of CRP is similar to that of 
total cholesterol (Ockene et al 2001).  
 
CRP levels are known to be higher among patients with traditional cardiovascular risk 
factors. Obesity, increased blood pressure, dyslipidemia, diabetes and the metabolic 
syndrome are associated with elevated CRP (Pearson et al 1997). Similarly, moderate 
alcohol use (Sierksma et al 2002), increased physical activity (Kasapis et al 2005), high 
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fiber diet (Ma et al 2006) and medications, such as statins, are associated with decreased 
CRP levels (Strandberg et al 1999). CRP is also elevated in the first trimester of 
pregnancy and in women taking oral contraceptives or hormone replacement therapy 
(Gol et al 2006;Ridker et al 1999).  
 
2.5.3 C-reactive protein and CVD 
CRP is the most thoroughly investigated inflammatory marker. One of the earliest 
studies on CRP, in 1982, showed that peak CRP concentrations correlated with 
myocardial ischemia and necrosis (de Beer FC et al 1982). From that time, levels of 
CRP have been found to predict future risk among selected populations including 
patients with unstable angina, acute coronary syndromes, stable coronary disease, 
metabolic syndrome and among patients undergoing revascularization procedures (Blake 
et al 2002;de Ferranti et al 2002;Haverkate et al 1997;Liuzzo et al 1994;Ridker et al 
2003;Ridker et al 2001;Rifai et al 2001).  
 
There is now a wealth of evidence from large-scale prospective studies of apparently 
healthy individuals that baseline levels of CRP are associated with future cardiovascular 
events (Koenig 2005). Up to date, at least 33 prospective epidemiological studies have 
tested the association between CRP and incident CVD in healthy populations (Table 6). 
As Table 6 shows, the vast majority of these studies have focused on coronary events 
either MI or CHD, and much fewer on stroke events.  
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Interestingly, the earlier studies have found significant associations between CRP and 
incident CVD, CHD or MI which were independent of traditional cardiovascular risk 
factors (Table 6). However, several later studies failed to replicate these results. For 
example, data from the ARIC (Folsom et al 2002), the health ABC (Cesari et al 2003) 
and the British Women’s Heart and Health study (Lawlor et al 2005) did not show 
significant associations between CRP and future CHD in the multivariable analyses. In 
support, meta-analysis of most published studies up to year 2000 (Danesh et al 2000) 
showed a relative risk (95% CI) of 2.0 (1.6, 2.5) in subjects with single CRP baseline 
measurement in the upper tertile compared with the lower tertile.  However, an updated 
meta-analysis (Danesh et al 2004) showed a much smaller relative risk (95% CI) of 
about 1.5 (1.37, 1.62). In fact, despite the fact the CRP is often cited as having 
consisting results and strong and independent associations with incident CVD in many 
epidemiological studies, careful investigation of Table 6 reveals that the effect of CRP 
might be modest and that, in at least 13 studies, did not retain statistical significance in 
the multivariable model.  
 
Nevertheless, CRP has been found to confer additional prognostic value to that of other 
biomarkers such as lipid levels, lipoprotein (a) and other inflammatory markers in one 
study (Ridker et al 2000a). In addition, CRP was also found superior even to LDL 
cholesterol levels (Ridker et al 2002) and proved to enhance global coronary risk as 
assessed by the Framingham Risk Score (Koenig et al 2004;Wilson et al 2003). 
However, in several other studies, CRP failed to improve significantly the c-statistics of 
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the Framingham risk function alone (Danesh et al 2004;Rutter et al 2004;van der Meer 
et al 2003). 
 
Two cross-sectional studies have indicated that a history of stroke was associated with 
raised plasma concentrations of CRP (Ford et al 2000, Exel et al 2002). Also, 6 other 
prospective studies have tested this relationship and their results seem comparable to 
those on coronary disease (Table 6). The Physicians' Health Study (Ridker et al 1997) 
and the Honolulu Heart Program (Curb et al 2003) showed that baseline concentration of 
CRP in apparently healthy men could predict the risk of first ischaemic stroke 
independently of CVD risk factors. The Cardiovascular Health Study (Cao et al 2003) 
replicated these results in a population of both men and women. However, in the 
Framingham Study (Rost et al 2001), raised plasma CRP concentrations independently 
predicted the risk of future ischaemic stroke in women but not in men. The health ABC 
study did not find an association between CRP and incident stroke but their follow up 
period was only 3.6 years (Cesari et al 2003). In a Danish cohort CRP was associated 
with carotid IMT levels but not with the number of carotid plaques (De Maat et al 2003). 
Finally, a meta-analysis of studies on stroke with long follow up (>8 years) showed that 
the relative risk for stroke in healthy individuals with the highest quartile of CRP was 
1.68 (95% CI 1.40, 2.01) compared to those with the lowest quartile (Kuo et al 2005).  
 
Notably, despite the wealth of epidemiologic data on CHD, there is only one prospective 
study on CRP and incident symptomatic PAD which was contacted in a male only 
population (Ridker et al 1998c). In fact, even cross-sectional data are very limited. 
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Cassar et al showed that CRP levels are higher in patients with symptomatic PAD (IC or 
CLI) compared to healthy controls (Cassar et al 2005). Most other published studies 
have used the ABI<0.9 to define PAD. Among them, the InCHIANTI study (McDermott 
et al 2005a) and the recent NHANES (Wildman et al 2005) found significant 
associations between CRP and prevalence of ABI<0.9. However, in a study by 
McDermott (McDermott et al 2003), CRP was not associated independently with ABI in 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.6.1 Structure and function 
IL-6 is a 26 kDa acute inflammatory cytokine which is produced by several cell types 
including activated monocytes and macrophages, endothelial cells and adipose cells 
(Aarden et al 1987;Jirik et al 1989). Its expression is regulated in response to a number 
of stimuli including endotoxins, IL-1, tumour necrosis factor- (TNF-), IL-4 and 
interferon- (Kerr et al 2001).  
 
The biological activities of IL-6 are initiated by binding to a receptor complex. This 
receptor is made of an 80kDa protein subunit (IL-6R), which binds to the cytokine, and 
of a 130kDa glycoprotein subunit (gp130), which mediates the signal transduction 
(Rattazzi et al 2003). Binding of the IL-6/IL−6R complex to gp130 leads to the 
activation of several transcription factors (Kishimoto et al 1995).  
 
IL-6 has both inflammatory and haemostatic properties. During the acute phase 
response, by acting on hepatocytes, it up-regulates the production of acute phase 
proteins. It also has other important inflammatory roles leading to increased endothelial 
cell adhesiveness
 
by up-regulating E-selectin, ICAM-1, and VCAM-1 and releasing
 
inflammatory mediators, including IL-6 itself (Von der Thusen et al 2003). IL-6 
promotes the coagulation cascade through a number of pathways (Kerr et al 2001). It 
increases the production of platelets and enhances their activation. Also, IL-6 
up-regulates several haemostatic variables,
 




and factor VIII (Kerr et al 2001;Neumann et al 
1997;Stirling et al 1998).  
 
2.6.2 Measurement 
IL-6 levels can be measured by bioassays or by enzyme-linked immunosorbant assays 
(ELISAs). Bioassays usually have low specificity and therefore IL-6 levels are mainly 
measured in sera and in cell culture supernatants by ELISA, using antibodies against a 
specific cytokine (Krakauer 1998). ELISA kits are commercially available and they are 
standardized, generally sensitive, specific and easy to use but can be expensive 
(Krakauer 1998). In-house ELISAs are commonly used, which makes it difficult to 
compare them in different laboratories. Their coefficient of variation is generally <15 % 
(Pearson et al 2003). IL-6 levels are stable in frozen plasma only and IL-6 plasma 
variability is such that it could be considered acceptable over long periods of time (Rao 
et al 1994). Dibbs (Dibbs et al 1999) examined the variability of IL-6 in patients with 
heart failure compared to healthy controls. The authors found that considerable natural, 
daily, weekly and monthly variability existed both in cases and controls. A circadian 
variability with increased plasma levels of IL-6 at night in men has also been shown 
(Sothern et al 1995).  
 
Increased IL-6 levels have been associated with increased blood pressure, smoking, and 
diabetes (Rattazzi et al 2003). Also IL-6 levels are increased in obese subjects whereas 
studies have shown that IL-6 is expressed in adipose tissue (Yudkin et al 2000). 
 76 
Psychological stress can also elevate circulating levels of IL-6 (Yudkin et al 2000). On 
the other hand, physical activity is associated with lower plasma levels of IL-6 (Pischon 
et al 2003). An increase in IL-6 has been described after the menopause and with use of 
hormone replacement therapy (Davison et al 2003). Finally, its levels have been shown 
to be influenced by statins (Undas et al 2004). 
 
2.6.3 Interleukin-6 and CVD 
IL-6 is much less studied as a cardiovascular risk factor compared to CRP. Table 7 
summarizes the prospective epidemiological studies on IL-6 in relation to CVD among 
healthy individuals. Only 9 prospective studies have been conducted to date with the 
vast majority of those focusing on coronary events (Cesari et al 2003;Harris et al 
1999;Lowe et al 2004b;Luc et al 2003b;Pai et al 2004;Pradhan et al 2002b;Ridker et al 
2000a;Ridker et al 2000b). In general, studies showed consistent results suggesting that 
IL-6 is significantly associated with incident CVD and that after adjustment for 
cardiovascular risk factors this association retains statistical significance. However, three 
studies (Pai et al 2004;Ridker et al 2000a;Tuomisto et al 2006) reported non-significant 
associations between IL-6 and CHD in the multivariable analysis.  
 
IL-6 has also been shown to have significant associations with future CVD in patients 
with unstable angina, unstable coronary arterial disease, atrial fibrillation and diabetes 
(Conway et al 2004;Doo et al 2004;Koukkunen et al 2001;Lindmark et al 2001;Pai et al 
2004) and it has also been associated with total mortality among patients with CVD 
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(Volpato et al 2001). Moreover, IL-6 levels are increased in patients with acute MI and 
also in patients with unstable, but not with stable, angina whereas increased levels of 
IL-6 and IL-1 receptor
 
antagonist at 48 hours after admission are associated with a
 
complicated in-hospital course (Blake et al 2002;Ikeda et al 2001). 
 
Only the health ABC study has tested the relationship between IL-6 and stroke (Cesari et 
al 2003). The authors have found significant and independent associations between IL-6 
levels and incident stroke. Ridker and colleagues (Ridker et al 2000a) have also included 
stroke events in their definition of CVD but they did not report specific risk ratio for 
stroke events only. Results from these 2 studies are in accordance with evidence from 
several studies that have demonstrated IL-6 increase in serum/plasma of acute stroke 
patients (Dziedzic et al 2003). On the other hand, in a subsample of
 
the Rotterdam Study 
(van der Meer et al 2002a), IL-6 levels were found not to be associated with either 
carotid IMT or carotid plaques. This result was replicated by Chapman (Chapman et al 
2004) in a healthy population of 1,111 men and women. 
 
Data on IL-6 and PAD is very limited. In fact, there are no prospective epidemiological 
data on IL-6 and incident PAD in the general population. Several cross-sectional data 
exist showing that IL-6 is elevated in patients with PAD compared to healthy controls 
(Brevetti et al 2003;DePalma et al 2003;Erren et al 1999;McDermott et al 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.7 Adhesion molecules 
Adhesion molecules are transmembrane glycoproteins that mediate cell-cell and 
cell-extracellular matrix interactions. They can be divided into a number of families 
based on their function and structure including the selectins, the immunoglobin 
superfamily and the intergrins (Hope et al 2003). 
 
2.7.1 Structure and function 
E-selectin 
E-selectin is a member of the selectin family and is expressed by activated endothelial 
cells. Selectins are glycoproteins with a conserved structure containing an N-terminal 
C-type lectin domain, an epidermal growth factor like domain and a variable number of 
short consensus repeat domains, a short transmembrane domain and finally a small 
cytoplasmic domain (Blankenberg et al 2003). E-selectin mediates the first step in 
leukocyte adhesion at sites of inflammation or injury and it is involved in the initiation 
of rolling and tethering of leukocytes to the endothelial surface, to platelets, or to other 
leukocytes (McEver et al 1995). Also, it interacts with ligands and creates weak bonds 
between activated endothelial cells or leukocytes. Finally, it favours interactions 
between platelets and leukocytes (Kansas 1998). 
 
ICAM-1 and VCAM-1 
The immunoglobin superfamily includes glycoprotein receptors with immunoglobin like 
domains that are active in various tissues. The intracellular adhesion molecule-1 
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(ICAM-1) and the vascular adhesion molecule-1 (VCAM-1) are the most common 
members of this family. ICAM-1 is widely expressed at a basal level and is up-regulated 
by pro-inflammatory cytokines in leukocytes and endothelial cells. It mediates adhesion 
of leukocytes to activate endothelium and participates in leukocyte extravasation 
(Blankenberg et al 2003). VCAM-1 is expressed on endothelial cells and participates in 
the leukocyte’s firm adhesion to the endothelial wall. It also triggers endothelial cells to 
change their shape allowing the emigration of leukocytes in the arterial wall.  
Expression of E-selectin, ICAM-1 and VCAM-1 is induced by inflammatory cytokines 
mainly by TNF- and IL-1 and maximum cell surface expression observed after 4-6 
hours (Blankenberg et al 2003).  
 
The aforementioned adhesion molecules may be discarded from the endothelial cell 
surface and found in soluble forms in the peripheral blood by a mechanism which is 
little understood (Ridker 2001). Circulating forms of adhesion molecules are thought to 
be the result of a shedding/ proteolytic mechanism which rapidly removes adhesion 
molecules form the cell surface following endothelial cell activation (Leeuwenberg et al 
1992). Consequently, these soluble forms measured in the plasma are considered to be 
direct measures of the expression of membrane molecules.  
 
2.7.2 Measurement 
Levels of soluble adhesion molecules in the plasma may be measured by ELISA 
techniques. However, the availability
 
of commercial kits is generally limited, 
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standardization does not exist yet and little is known about their pre-analytical 
conditions
 
(Roberts 2004). Their levels are unstable unless frozen. Their coefficient of 
variation is estimated <15% (Pearson et al 2003).  
 
Circulating levels of adhesion molecules have been associated with hormone 
replacement therapy (Blankenberg et al 2003). Also their levels have been shown to be 
increased in people with diabetes, hypertension or increased cholesterol levels and in 
smokers (Blankenberg et al 2003). Some studies have also shown associations with 
statin therapy but others did not confirm those results (Hope et al 2003). Finally, studies 
have found associations between ICAM-1 and E-selectin with BMI or the presence of 
clinical obesity (Hope et al 2003). 
 
2.7.3 Adhesion molecules and CVD 
Adhesion molecules have received considerable attention in epidemiologic research as 
risk factors for CVD. Increased levels have been associated with future events in 
patients with pre-existing disease. Blankenberg et al. (Blankenberg et al 2001) reported 
that baseline soluble VCAM-1, ICAM-1, and E-selectin were all significantly related to 
future death from cardiovascular causes among 1,246
 
patients with documented CAD. In 
support, Wallen et al. (Wallen et al 1999) showed that patients with stable angina 
pectoris who developed an MI or died from cardiovascular causes had elevated serum 
levels of soluble cell adhesion molecules, ICAM-1, VCAM-1 and E-selectin. Yin et al. 
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(Yin et al 2003) showed that levels of ICAM-1 and VCAM-1 were related to clinical 
outcomes among subjects with coronary heart failure.  
 
Several prospective studies that have been conducted in healthy populations are listed on 
Table 8. A combined analysis of the 5 studies on ICAM-1 yielded an odds ratio of 1.39 
(1.11, 1.73) for CHD in those in the top third compared with those in the bottom third of 
baseline measurements (Malik et al 2001). For VCAM-1 and E-selectin, the combined 
analysis yielded an odds ratio of 1.02 (0.81, 1.29) and 1.16 (0.87, 1.55), respectively 
(Malik et al 2001). The Physicians' Health Study, the ARIC study, the Prospective 
Epidemiological Study of Myocardial Infarction (PRIME) study and a British cohort 
study, found significant associations between ICAM-1 and incident CHD which were 
independent of cardiovascular risk factors (Hwang et al 1997;Luc et al 2003a;Malik et al 
2001;Ridker et al 1998a). Only, in the Cardiovascular Health Study, ICAM-1 failed to 
show significant associations in the multivariable analysis (Jenny et al 2006). Finally, 
Malik (Malik et al 2001), showed that ICAM-1 was no longer significantly associated 
with incident CHD when the analysis was further adjusted for markers of socioeconomic 
status.  
 
Compared to ICAM-1, VCAM-1 and E-selectin have shown consistently negative 
results in relation to CHD. Five prospective studies on VCAM-1 failed to show 
significant associations between VCAM-1 and incident CHD even in unadjusted 
analysis (Table 8). E-selectin was only investigated by two prospective studies but 
showed no evidence for associations in the multivariable analysis (Table 8).  
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As with IL-6, the relationship between adhesion molecules and stroke events is 
under-studied compared to CHD events. Ridker (Ridker et al 2000a) also included 
stroke events in their definition of CVD but they did not report the odds ratio explicitly 
for stroke events. The PRIME study reported the unadjusted odds ratio (95% CI) for 
stroke per 1SD increase of ICAM-1 levels as 1.07 (0.92, 1.27) (Jenny et al 2006). In 
contrast, the ARIC study reported increased risk for carotid artery disease among those 
with increased ICAM-1 (OR (95% CI) for 1 SD increase 1.38 (1.12, 2.72)) and E-
selectin (1.71 (1.13, 1.75)) but not for those with increased VCAM-1 levels 
independently of CVD risk factors (Hwang et al 1997). Finally, among people with 
CHD, elevated concentrations of ICAM-1were associated with increased risk of 
ischaemic stroke, independent of other traditional cerebrovascular risk factors and of 
plasma fibrinogen (Tanne et al 2002). 
 
Further evidence for associations between stroke and adhesion molecules exist from 
cross-sectional data and post stroke studies. In fact, acute ischaemic stroke was 
associated with elevated plasma levels of ICAM-1, VCAM-1 and E-selectin, 
independent of age, sex and other recognized risk factors for stroke (Simundic et al 
2004). Also, the serum level of ICAM-1 on admission was associated with neurological 
deterioration of ischaemic stroke (Wang et al 2006). In support, Rohde (Rohde et al 
1998) reported a strong correlation between carotid
 
artery IMT and plasma ICAM-1 and 
VCAM-1. Also, ICAM-1 was independently associated with the risk of having at least 
one carotid plaque and with the risk of having at least one femoral plaque but not with 
IMT in another study (Bongard et al 2002). In contrast to these studies, it was found that 
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symptomatic carotid disease was not associated with increased expression of adhesion 
molecules in the endothelium of advanced carotid plaques or in the circulation (Nuotio 
et al 2003). Finally among subjects who had experienced stroke or who had 
asymptomatic carotid stenosis, ICAM-1 levels were not associated with ischaemic 
events after more than 3 years of follow up (Ehrensperger et al 2005).  
 
In relation to PAD even fewer data exist and studies are usually small, use different 
diagnostic criteria for PAD and are conducted in different population groups (Hope et al 
2003). One prospective study, examined the association between ICAM-1 and VCAM-1 
with symptomatic PAD. ICAM-1, and not VCAM-1, was associated with a more than a 
3-fold increase in the risk of developing symptomatic PAD in analysis adjusted for 
cardiovascular risk factors (Pradhan et al 2002a). Both increased ICAM-1 and VCAM-1 
were found in patients with PAD compared to healthy controls (Blann et al 1998). Peter 
and colleagues (Peter et al 1997) found that VCAM-1 was associated with the presence 
and the extent of PAD assessed by extensive angiography. To date, there are no 
prospective data on E-selectin. In a case-control study, Signorelli (Signorelli et al 2003) 
showed that increased E-selectin levels were found among those with IC. However, two 
other studies failed to show differences in circulating levels of E-selectin between 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.8.1 Structure and function 
Fibrinogen is a plasma glycoprotein with molecular weight of 40 KDa (Doolittle et al 
1998). It consists of three pairs of polypeptide chains, two A, two B, and two  which 
are bond together by disulphide bonds. The composition of fibrinogen varies according 
to differences in amino acids residues in the three polypeptide chains.  The most 
common variants are due to A chain heterogeneity. Among them three forms have been 
identified, a high molecular weight fibrinogen and two low molecular weight 
fibrinogen’s variants (Mosesson 1983). 
 
Fibrinogen is synthesized in the liver by hepatocytes and has a biological half life of 
approximately 100 hours (Kamath et al 2003). It circulates in the plasma at 
concentrations between 1.5g/L and 4.5g/L whereas concentrations above 0.5g/L are 
required for normal haemostasis. Fibrinogen is the main coagulation protein in plasma. 
In the final step of the coagulation cascade, it is transformed into fibrin under the action 
of thrombin. In addition, as CRP, fibrinogen is an acute phase reactant. Hepatic 
synthesis of fibrinogen is regulated by inflammatory cytokines, mainly by IL-6. There is 







unstable and plasma should be frozen
 
as soon as possible if not 
analyzed immediately (Roberts 2004). There are two main methods for determining 
fibrinogen levels, the ‘functional’ and the ‘direct’ method. The first is, in essence, 
measuring the coagulation time which is proportional to the fibrinogen concentration. 
The Clauss method which is the most commonly used functional method records the 
time taken to reach the formation of a clot (Kamath et al 2003). The disadvantage of this 
method is that it is associated with a degree of variability due to heterogeneity of 
fibrinogen structure and also due to other haemostatic factors (such as fibrin degradation 
products) that can become attached to the clot and alter the clotting time. In addition, the 
Clauss method can underestimate
 
the fibrinogen concentrations in the presence of 
hirudin peptide
 
54-65 and fibrinogen fragment E (De Cristofaro et al 1998;Roberts 
2004). 
 
The direct methods quantify fibrinogen either gravimetrically, immunologically or by 
precipitation (Kamath et al 2003). In the first method thrombin is added to a sample of 
plasma and allowed to set until the clot is formed. Fibrinogen is then measured by 
gravimetry. This assay is, in general, time consuming and laborious. On the contrary, 
immunological assays are easy to use and do not take much time. They involve ELISA 
methods that use monoclonal antibodies that recognize the A chain but do not 
recognize other fibrinogen derivatives. Finally, in precipitation assays fibrinogen is 
precipitated (by heat or salting out) and then measured usually by nephelometry. In this 
method, total fibrinogen is measured and therefore the estimated fibrinogen is generally 
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higher than that estimated by the functional assays. However, other molecules such as 
fibrin degradation products can be precipitated and then measured leading to 
overestimated fibrinogen levels.  
 
The imprecision of most fibrinogen assays ranges between 4% and 8% (Roberts 2004). 
The Clauss method has a larger methodological variability than other fibrinogen assays 
(Rosenson et al 2001). The precipitation- nephelometric assay has shown a 
methodological coefficient of variation between 2.4 and 3.0% whereas the gravimetric 
method has a reported a coefficient of variation of 1% (De Maat et al 1996;Krobot et al 
1992). The methodological coefficient of variation for fibrinogen with the Clauss 
method was 3.3 to 4.5% when an automated procedure was used that averaged the 
results from three samples each assayed in duplicate (Rosenson et al 2001).  
 
Due to the large number of assays proposed for the determination of fibrinogen, the 




standard (WHO 2nd 
International
 
Standard [IS] Fibrinogen, Plasma 98/612) is available for fibrinogen which 
uses the Clauss method (Whitton et al 2000).  This standard has been established at 
2.19 g/L of clottable fibrinogen. 
 
In epidemiologic research different fibrinogen assays have been used. A systematic 
review did not show heterogeneity between studies that used different fibrinogen assays 
(Danesh et al 1998). The Caerphilly and Speedwell studies directly compared a 
precipitation-nephelometric assay and a Clauss method assay for the prediction of 
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ischaemic heart disease (IHD) (Sweetnam et al 1998). They concluded that the direct 
method was a significantly stronger predictor of IHD than the clotting method 
(Sweetnam et al 1998). Moreover, the correlation coefficient between the two 
measurements was only 0.62 (Yarnell et al 1985).  
 
Finally, several factors that influence fibrinogen levels have been described. In 
summary, raised fibrinogen is associated with older age, female sex, smoking, obesity, 
reduced physical activity, diabetes, hypertension and increased cholesterol levels 
(Kamath et al 2003). Moreover, menopause, oral contraception and stress have been also 
associated with high fibrinogen levels (Koenig 2003;Lee et al 1993;Meade et al 1983). 
On the other hand, decreased fibrinogen has been associated with moderate alcohol 
consumption and with hormone replacement therapy (Koenig 2003;Lee et al 1993). 
Fibrinogen levels also show seasonal variation with higher levels in winter than in 
summer (Stout et al 1991). 
 
2.8.3 Fibrinogen and CVD 
Since the first report by Meade (Meade et al 1983), the role of fibrinogen in CVD 
prediction has been extensively studied in epidemiological studies. All now agree that 
fibrinogen is an independent predictor of CHD in healthy subjects and in subjects with 
pre-existing CVD. Less evidence is available on stroke and PAD. Table 9 summarizes 
the prospective epidemiological studies that have examined the relationship between 
fibrinogen and CVD in healthy populations. The results on CHD are remarkably 
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consistent and with very few exceptions provide support for fibrinogen as a strong and 
independent predictor of CHD (Table 9). Meta-analysis of published studies of plasma 
fibrinogen on CHD showed a risk ratio of 1.8 (1.6, 2.0) between the top vs. the bottom 
tertile of plasma fibrinogen. A recent individual patient meta-analysis of 7,213 cases 
confirmed this result (Fibrinogen Studies Collaboration 2005). The age and sex adjusted 
hazard ratio (95% CI) per 1g/L increase in fibrinogen level for CHD was 2.42 (2.24, 
2.60); stroke, 2.06 (1.83, 2.33); other vascular
 
mortality, 2.76 (2.28, 3.35); and non-
vascular mortality,
 
2.03 (1.90, 2.18). The hazard ratios for CHD and stroke
 
were reduced 
to about 1.8 after adjustments for established cardiovascular risk factors which was 
further reduced after adjustment for intra-individual variability in confounders 
(Fibrinogen Studies Collaboration 2005).  
 
Lind (Lind et al 2001) investigated the interaction between fibrinogen and other 
inflammatory proteins. Among 6,075 men, they observed that any other marker of 
inflammation (orosomucoid,
 1-antitrypsin, haptoglobin, and ceruloplasmin) in addition 
to increased fibrinogen was associated with a further increase in incident CHD and CVD 
mortality compared to fibrinogen alone. Another study proposed that the effect of 
fibrinogen varied according to the atherogenic lipid profile (Assmann et al 1996).  When 
fibrinogen and LDL levels were considered together, there was a graded and dramatic 
8-fold increase in 8 year risk from 17 per 1,000 of population among men with both 
fibrinogen and LDL cholesterol in the lower tertiles to 130 per 1,000 in men with both of 
these parameters in the upper tertile (Assmann et al 1996). In support, results from 
Cantin (Cantin et al 2002) showed an interaction between fibrinogen and Lp(a) in CVD 
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risk prediction. Finally, fibrinogen has been associated with future CHD among high 
risk populations with diagnosed diabetes, IC, angina or CHD (Koenig 2003).  
 
As with other biomarkers studied here, the relationship between fibrinogen and stroke is 
much less studied compared to that of CHD (Table 9). However, few studies are 
consistent in showing an independent association between increased fibrinogen and 
stroke events which is comparable to that observed in CHD (Smith et al 2005;Smith et al 
1997;Wilhelmsen et al 1984). Further evidence supports these results showing that 
fibrinogen levels remaining elevated after stroke and were associated with an increased 
risk
 
of a recurrent vascular event (Beamer et al 1998). Also, in patients with a previous 
transient ischaemic attack or ischaemic
 
stroke, risks of recurrent ischaemic stroke and 
acute coronary
 
events increased linearly with fibrinogen levels (Rothwell et al 2004). In 
addition, in 473 first-ever ischaemic stroke patients fibrinogen in the top tertile within 
the first 24 hours after stroke onset was associated with a 63% excess risk of new a 
cardiovascular event compared to patients in the bottom tertile (Di Napoli et al 2002). 
 
Moreover, fibrinogen was associated with carotid plaque formation independently of 
cardiovascular risk factors (Chapman et al 2004;De Maat et al 2003). In support of these 
findings, in a population sample of adults without clinically overt atherosclerotic 
disease, elevated fibrinogen was related to carotid IMT independent of a wide range 
confounding variables (Martinez-Vila et al 2003). Fibrinogen was also associated with 
IMT in the ARIC study but not in the Glostrup study (De Maat et al 2003;Folsom et al 
1993).  
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The association between fibrinogen and PAD has been confirmed by many cross-
sectional studies (Fabsitz et al 1999;McDermott et al 2003;McDermott et al 
2005a;Meijer et al 2000;Selvin et al 2004;Smith et al 1993;Wildman et al 2005;Zheng et 
al 2005). However, evidence from prospective studies is very limited. The prognostic
 
value of fibrinogen was illustrated in the Edinburgh Artery Study,
 
in which median 
fibrinogen levels were higher in patients who later went on to develop PAD (Smith et al 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.9  Coagulation factors 
Several markers that reflect the ongoing coagulation process can be measured in plasma 
samples. Here, 3 major markers of coagulation, factor VII, vWF and prothrombin 
fragments 1+2 (F1+2), which have been analysed in epidemiological research, are 
described. 
 
2.9.1  Structure and function 
Factor VII 
Factor VII is a vitamin K dependent serine protease with a pivotal role in coagulation 
since it initiates the extrinsic coagulation cascade. In this form, it is a 406 amino acid 
residue glycoprotein with a molecular mass of about 50kDa and a plasma half-life of 
5±6 hours. Factor VII is converted to its active form factor VIIa in the presence of tissue 
factor. By binding to tissue factor it converts factor IX and X into their active forms and 
leads to thrombin formation (Feinbloom et al 2005). The majority of factor VII in blood 
is in the form of inactivated factor VII zymogen, while trace amounts of factor VIIa are 
present. The activation of zymogen factor VII to enzyme factor VIIa is largely 
dependent on tissue factor and arises at the site of vascular injury after formation of a 
TF/FVII complex (Eigenbrot 2002). The key event in the activation of factor VII is a 






Previously named factor VIII related antigen, vWF, is a multimeric glycoprotein 
secreted by the endothelium. It comprises of 50-100 monomers and is subject to 
post-transcriptional modification before becoming functional (Blann 2006). Different 
molecular weight multimers of vWF exist (Wagner 1990). Also, there are two release 
pathways of vWF, constitutive and regulated. Constitutively secreted vWF is 
predominately composed of small multimers (Lip et al 1997). However, regulated 
release occurs from preformed intracellular storage granules (Weiber-Palade bodies) and 
they consist of high molecular weight polymers that are most effective in mediating 
platelet binding (Blann 2006). The main function of vWF is to carry factor VIII in the 
circulation. Through this role it also regulates the formation of fibrin thrombus at the site 
of the injury. Under normal circumstances, plasma vWF is derived from endothelial 
cells rather than from platelets making vWF a good marker of endothelial dysfunction.  
 
F1+2 
Another marker of the coagulation process, F1+2, is released during the conversion of 
prothrombin to thrombin in the presence of factor Xa. Its plasma life is approximately 90 
minutes. Therefore levels of F1+2 are a marker of thrombin formation and can be used 
as a marker of this in vivo (Saigo et al 2004). The formation of thrombin from 
prothrombin requires cleavage of two peptide bonds in the prothrombin molecule. 
Prothrombin consists of a single polypeptide chain of nearly 608 amino acids and can be 
described as having two halves—a “pro” half and a “thrombin-forming” half (Becker et 
al 1998). The amino terminal end (pro half), which has been designated prothrombin 
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Factor VII can be measured in several ways including measuring zymogen mass, factor 
VII activity or factor VII antigen. The classic assay which measures factor VII 
coagulation activity (factor VIIc) is based on the ability of a test plasma to correct the 
clotting time of FVII deficient plasma (Marckmann et al 1998). This is an one-stage 
clotting assay in which the clotting time is recorded and factor VIIc is expressed based 
on a reference plasma calibration curve. The factor VIIc measurement is dependent on 
the quality of the factor VII deficient plasma (Poggio et al 1991). The active factor VIIa 
can be measured by an ELISA assay based on factor VIIa antibodies or by a clotting 
assay which uses a truncated, soluble, recombinant TF that possesses cofactor function 
for FVIIa (Marckmann et al 1998). Finally, the total factor VII protein concentration in 
plasma may be assessed by two methods with comparable results, either by an ELISA 
assay or by a functional two-stage assay.  
 
Similarly, plasma vWF can be measured in various ways. The vWF antigen assay is 
probably the best tool for measuring the level of total vWF. However, it detects all vWF 
multimer forms without discrimination and it does not assess vWF function (Favaloro et 
al 2002). Functional assays such as the VWF:RCo provide a marker of vWF function 




 international standard for vWF antigen and VWF:RCo has recently been 
established (Hubbard et al 2004). Alternatively, vWF:Multimer testing identifies the 
structural integrity of vWF, the retention or loss of various molecular weight forms of 
vWF, and qualitative vWF defects. Nevertheless, it does not give quantitative 
information on detected vWF and is expensive and time consuming (Favaloro et al 
2002).  
 
F1+2 is measured by standard immunoassays (ELISA). In general, the pre-analytical and 
analytic properties of F1+2 are very little studied. The assay has low sensitivity and it 
has a relatively low susceptibility to in vitro artefacts.  
 
Both F1+2 and vWF are elevated in pregnancy (Fareed et al 1998). Moreover, factor VII 
concentrations have also increased with serum glucose, blood pressure, BMI, and post 
menopausal status in women (Pearson 1997). Similarly, vWF is associated with 
smoking, BMI, physical activity, blood pressure, alcohol and cholesterol levels (Yarnell 
et al 2000). No circadian variation on vWF levels has been found. Plasma levels of vWF 
antigen have also been found to be lower in persons of blood group O compared to those 
in non-O groups (Meade et al 1994). Finally, F1+2 has been associated with smoking, 
high levels of triglyceride, and low levels of glucose (Cushman et al 1996); however, the 
ARIC study did not report any associations between F1+2 levels and cardiovascular risk 
factors (Folsom et al 2001). 
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2.9.3 Coagulation factors and CVD 
There is substantial epidemiologic research on coagulation markers and CVD. Table 10 
lists prospective epidemiologic studies in the general population on vWF, factor VII and 
F1+2 and incident CVD. vWF has received considerable attention whereas F1+2 has 
been little studied. Also, as with previous markers, the vast majority of studies focus on 
coronary atherosclerosis. The only meta-analysis available is for vWF: 5 prospective 
studies with 1,524 CHD cases yielded a combined risk ratio (95% CI) of 1.5 (1.1, 2.0) in 
individuals with vWF in the top third compared with those in the bottom third (Whincup 
et al 2002). However, most individual studies up to date, demonstrated that vWF often 
loses statistical significance in the multivariable analysis and that the magnitude of the 
reported risk ratios is generally modest.  
 
On the other hand, most prospective studies in patients with baseline evidence of arterial 
disease show independent associations of vWF with future vascular events (Cortellaro et 
al 1993;Jansson et al 1991;Thompson et al 1995). For example, in the ECAT study 
among 3,043 patients with angina pectoris, those with levels of vWF in the top quintile 
compared to independently had a subsequent 20% increase in the risk of acute coronary 
syndrome after 2 years of follow up (Thompson et al 1995). 
 
A meta-analysis has not been reported on either factor VII or on F1+2 and CHD. Table 
10 lists the prospective epidemiological studies on these markers and incident CVD in 
the general population. The first Northwick Park Heart Study demonstrated an 
association between factor VII activity and incident CVD but only in univariable 
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analysis (Meade et al 1993). Surprisingly, two studies, the Second Northwick Park Study 
and the Caerphilly Prospective Study found an inverse significant association in 
multivariable analysis between factor VII and CVD (Cooper et al 2000; Smith at el 
2005). Although the authors suggest that this might be due to chance, the fact that both 
studies had the same conclusions merits further investigation. Almost all the other 
studies provided no evidence for an association between factor VII and CVD (Table 10).  
The same is true for F1+2 because cohort studies, including the ARIC, the Second 
Northwick Park Study and the Caerphilly Prospective Study, did not show statistically 
significant associations between this marker and incidence of CVD. However, 
conflicting results have been reported from studies on subjects with pre-existing CVD 
and from cross-sectional analyses. F1+2 was elevated in those with angiographically 
verified coronary atherosclerosis as compared to patients with normal coronary arteries 
(Giannitsis et al 1999). Similarly, factor VII was higher in those who had experienced an 
MI compared to healthy controls and in people with angiographically defined coronary 
stenoses (Pearson et al 1997). 
 
None of the three markers has been associated with incident stroke. However, F1+2 
levels (median 1.28 vs. 1.06 nmol/L) and vWF levels (216 vs. 198 IU/dL) levels were 
higher in patients with progressive stroke than in stable/improving patients (Barber et al 
2004). In addition, levels of vWF were elevated initially (1.86 IU/ml) and after 3 months 
(1.51 IU/ml) in stroke patients compared with a healthy reference population (1.26 
IU/ml) (Catto et al 1997). In the same study, analysis of 6 month case fatality, vWF 
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levels were associated with risk of death in stroke patients (odds ratio 1.73 (1.12, 2.66) 
for an increase of I U/ml), even after allowing for stroke type (Catto et al 1997). 
 
There are very few data on these markers and PAD in the literature. After 5 years of 
follow up in the Edinburgh Artery Study, factor VII and vWF showed no significant 
associations with incident PAD (Smith et al 2000b). Supporting these results, a 
case-control study showed that vWF and factor VII were not significantly increased in 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.10 Fibrinolytic factors 
In addition to coagulation factors, a number of molecules that participate in fibrinolysis 
may serve as measurements of thrombin and plasmin formation. This section is focused 
on three pivotal molecules of the fibrinolytic process, t-PA, D-dimer and fibrinopeptide 
A (FpA). 
 
2.10.1 Structure and function 
t-PA 
t-PA regulates fibrinolysis by activating the conversion of plasminogen to plasmin. It is 
synthesized and secreted by endothelial cells and is a single chain enzyme with 
molecular weight of 68kD (Dobrovolsky 2002). Only a small amount of t-PA is active 
whereas the remaining is bound to its inhibitor PAI-1. The complex t-PA/PAI-1 retains 
affinity to fibrin and therefore competes with free t-PA in the binding of fibrin. Thus, 
free plasma levels of t-PA should be a marker of fibrinolytic activity (Saigo 2004).  
 
D-dimer 
The digestion of fibrinogen yields fragments X, Y, D and E which are known as fibrin 
degradation products (Fareed 1998). The digestion of fibrin yields distinct fragments 
products including D-dimer which consists of two fibrin monomers, cross linked 
through  chain. Thus plasma levels of D-dimer reflect the extent of cross-linked fibrin 
turnover without significant interference with fibrinogen or non-cross linked fibrin 
degradation products (Saigo 2004, Lowe 1995).   
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FpA 
Finally, when thrombin cleaves fibrinogen in the A and B chain, fibrinopeptides A 
(FpA) and B (FpB) are released, respectively. FpA is initially released more rapidly than 
FpB, but soon the rate of FpB release accelerates (Binnie et al 1993). FpA is a 16 amino 
acid peptide with a molecular weight of 1540 D and a very short plasma half-life (3-5 
min) (Stegnar et al 2006). Since the fibrinogen molecule has a dimeric structure, two 
identical FpA molecules can be cleaved from each fibrinogen molecule (Stegnar et al 
2006). Thrombin, in turn, cleaves fibrinopeptides leading to fibrin monomers that 
spontaneously polymerize to form a fibrin clot. Therefore levels of FpA are specific for 
thrombin activity and the formation of fibrin (Fareed et al 1998). 
 
2.10.2 Measurement 
The mean plasma levels of t-PA are 5-10 ng/ ml and its half life is 2-3 min (Dobrovolsky 
2002). The assessment of t-PA is complicated by a number of factors. PAI-1 rapidly 
binds to t-PA to inhibit its functional activity. Thus, it is difficult to perform functional 
assays for t-PA unless steps (such as acidification of the plasma) are taken to inhibit the 
interaction between t-PA and PAI-1. Alternatively, the plasma concentration of t-PA can 
be determined by immunologic assays, such as enzyme-linked immunosorbent assays, 
for which there are commercially available reagents. Thus the measured active t-PA 
reflects three processes, the secretion of t-PA from endothelial cells, the inhibition of 
t-PA by PAI-1 and other molecules, and the clearance of t-PA by the liver (Chandler et 
al 2000). 
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 A variety of different methods are available for the measurement of D-dimer. These 
include manual latex agglutination assays, ELISAs, latex-enhanced photometric 
immunoassays (LPIA), and membrane-based immunofiltration assay (IFA) systems 
(Dempfle 2001). However, the numerical results of these assays vary noticeably. Two 
attempts have been made to standardize D-dimer assays, but the researchers concluded 
that the standardization of D-dimer is impossible and so reference preparations and/or 
guidelines have not been distributed (Gaffney 1995, Nieuwenhuizen 1997).  
 
Dempfle (Dempfle 2001) evaluated 23 quantitative D-dimer assays and concluded that 
they differ concerning specificity for cross-linked fibrin, and preference for detecting 
either high molecular weight fibrin complexes, or low molecular weight fibrin 
degradation products. There results were also confirmed by an external quality 
assessment program (De Maat 2000). However, Meijer (Meijer et al 2006) recently 
developed a model for harmonization between different quantitative D-dimer methods.  
This harmonization resulted in a reduction of the variability between method-specific 
consensus values from 75% to approximately 25% (Meijer et al 2006).   
 
Normal FpA plasma levels are around or below 2 ng/mL. Sensitive methods for FpA 
measurement are radioimmunoassay or enzyme-linked immunoassay (ELISA), however, 
these have very long turn-around times (Stegnar et al 2006). In addition, sample 
handling of FpA requires careful acquisition, collection, and processing in order to avoid 
thrombin elaboration and ex vivo increases in FpA concentration (Stegnar et al 2006). 
Alternatively, urine measurement of FpA can be more sensitive.  
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t-PA has shown diurnal variation with elevated levels in the morning (Andreotti et al 
1991;Jafri et al 1992). Also, D-dimer and t-PA have been associated with cardiovascular 
risk factors such as BMI, smoking, diabetes, alcohol, blood pressure, total and HDL 
cholesterol (Stegnar et al 2006). Associations between cardiovascular risk factors and 
FpA are less consistent (Cushman et al 1996). There is also some evidence for 
associations between these fibrinolytic factors with hormone replacement therapy (Koh 
2002;Pinto et al 1997;Sowers et al 2005).  
 
2.10.3 Fibrinolytic factors and CVD 
Fibrinolytic factors have been investigated in several epidemiologic studies in relation to 
CVD. A recent meta-analysis on D-dimer of 7 population studies with 1,535 CHD cases 
found a significant odds ratio (95% CI) of 1.7 (1.3, 2.2) for individuals in the top vs. 
those in the bottom tertile at baseline (Danesh et al 2001). This association is
 
of similar 
strength to that between plasma fibrinogen and CHD. Similarly, when 7 available 
prospective cohort studies on t-PA and CHD in general populations (2,119 cases) were 
synthesized, the combined odds ratio was 2.2 (1.8, 2.7) after adjustment for age and sex 
only, which decreased to 1.5 (1.2, 1.8) after further adjustments for cardiovascular risk 
factors (Lowe et al 2004a).  
To date, at least 15 prospective studies among apparently healthy individuals of either 
D-dimer or t-PA have been conducted, as listed in Table 11. Most studies suggest that 
D-dimer levels are associated with incident CHD independently of cardiovascular risk 
factors although the estimated relative risks were modest. Interestingly, in an elderly 
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cohort, D-dimer was a better predictor of events early in the follow up than later in the 
follow up (Cushman et al 1999). In the same study, D-dimer had stronger associations 
among those with subclinical disease. Moreover, in the West of Scotland Coronary 
Prevention Study, D-dimer showed a significant independent relationship with coronary 
risk even when it was adjusted for other inflammatory molecules including fibrinogen, 
CRP and IL-6 (Lowe et al 2004b).   
 
There is less evidence for an association of t-PA with CVD. In fact, in most studies, 
adjustment for potential confounders seems to reduce considerably the strength of the 
associations usually below statistical significance (Lowe et al 1998;Thogersen et al 
1998). Pradhan (Pradhan et al 2004) evaluated both t-PA and D-dimer and found that 
elevated t-PA antigen and, to a lesser extent,
 
D-dimer were independently associated 
with incident coronary events among postmenopausal women. In the same cohort, the 
odds ratio for women with baseline elevations in both t-PA antigen and D-dimer was 
greater than for those with low levels of both biomarkers
 
or with elevations of either 
marker alone (Pradhan et al 2004). Only one epidemiological study has examined the 
associations between FpA and incident cardiovascular events in a male cohort (Cooper 
et al 2000). The authors found no evidence for an association with CHD events (Table 
11). 
D-dimer and t-PA have  also been associated with recurrent events in people with 
existing coronary disease (Moss et al 1999;Niessner et al 2003). They have also been 
shown to predict cardiovascular events in people with pre-existing PAD (Smith et al 
1998). Elevated D-dimer levels have also been shown to be an independent risk factor 
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for cardiovascular mortality in patients with heart failure (Alehagen et al 2004). t-PA has 
shown strong associations with future CHD in people with angina in two other studies 
(Juhan-Vague et al 1996;Thompson et al 1995). Increased levels of FpA have also been 
documented in patients with unstable angina who developed acute MI or who were at 
increased risk of cardiovascular mortality (Ardissino et al 1996;Li et al 1999). D-dimer 
and FpA are also elevated in people with atrial fibrillation (Kumagai et al 1990).  
 
Data on fibrinolytic markers and stroke is very limited. Two prospective studies have 
shown strong and independent associations between D-dimer and stroke events with 
more than a 2 fold increase in the risk of stroke for people in the highest tertile of 
D-dimer (Smith et al 2005;Smith et al 1997). Similarly, 4 prospective studies have 
shown comparable results for t-PA (Johansson et al 2000;Ridker et al 1994b;Smith et al 
2005;Smith et al 1997). The Caerphilly Prospective Study failed to show independent 
associations between t-PA and incident stroke (Smith et al 2005). Nevertheless, the 
Physicians' Health Study, the Edinburgh Artery Study and the MONICA study reported 
strong independent associations between t-PA and future stroke events (Ridker et al 
1997b; Smith et al 1997; Johansson et al 2000). 
 
D-dimer has also shown prognostic information after ischaemic stroke (Barber et al 
2006) and along with FpA has been independently associated with survival after stroke 
(Feinberg et al 1996). Elevated levels of D-dimer and FpA were also reported following 
brain infarction (Kataoka et al 2000). However, both D-dimer and t-PA failed to show 
associations with recurrent stroke in two other studies (Barber et al 2006;Squizzato et al 
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2006). In addition, there is evidence that D-dimer levels might be associated with stroke 
subtype. After acute stroke, D-dimer levels were significantly higher in the 
cardioembolic group than in the atherothrombotic and lacunar groups (Ageno et al 
2002). 
 
D-dimer and t-PA have not shown evidence for associations with IMT (De Maat et al 
2003;Lee et al 1998). However, in the ARIC study both markers were higher in subjects 
with IMT in the top compared to the bottom tertile (Salomaa et al 1995). In a Finnish 
male cohort, FpA correlated with common carotid and carotid bifurcation IMT but only 
in the univariable and not in the multivariable analysis (Rankinen et al 1994). These 
associations were abolished after adjusting for confounders (Rankinen et al 1994). 
 
The relationship between these fibrinolytic markers and PAD is not well-established. In 
the Edinburgh Artery Study, t-PA and D-dimer were not associated with incident PAD 
after 5 years of follow up (Smith et al 2000b). However, both plasma markers have 
shown higher levels with the presence and increasing severity of PAD in cross-sectional 
analyses (Cassar et al 2005;Killewich et al 1998;Smith et al 1995;Unlu et al 2006). Data 
on FpA is even more limited. In cross-sectional analysis of the Edinburgh Artery Study, 
FpA was not significantly elevated in subjects with PAD but prospective data was not 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Inflammation and haemostasis are two interrelated and universal responses to injury.  
Recent advances in molecular biology have suggested that these two mechanisms also 
play an important role in atherosclerotic development and progression. Molecular 
markers representing activated inflammation and haemostasis might therefore serve as 
attractive measurements of the ongoing atherosclerotic process. 
 
Epidemiological research has focused on several markers and tested their associations 
with CVD. This thesis focuses on 12 markers of inflammation and haemostasis in 
relation to atherosclerotic disease and in particular to peripheral atherosclerosis. Markers 
of systemic inflammation under study include CRP, the proinflammatory cytokine IL-6, 
and soluble adhesion molecules such as ICAM-1, VCAM-1 and E-selectin. CRP has 
received the most attention and, along with IL-6, appears to be a consistent predictor of 
future cardiovascular events in large prospective studies. Epidemiological data on 
adhesion molecules predicting risk of CVD in less consistent. ICAM-1 has shown 
independent associations with CHD in prospective studies but VCAM-1 and E-selectin 
have shown consistently negative results. 
 
For the haemostatic markers, fibrinogen has been studied extensively and overwhelming 
evidence that it is an independent predictor of CHD in healthy subjects and in subjects 
with pre-existing CVD exists. D-dimer, t-PA and vWF have shown less consistent 
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evidence whereas factor VII, FpA and F1+2 have shown very little or no evidence for 
associations with CVD.  
 
Overall, the epidemiological research on these molecules in relation to stroke or 
especially PAD is sparse. Some evidence for associations between CRP and fibrinogen 






3 Aim and Objectives 
Chapter 1 highlighted the fact that PAD is a relatively common disease especially when 
asymptomatic individuals are accounted for. However, very little data is available on 
incident asymptomatic PAD and the risk factors associated with its progression. In 
addition, the literature review in Chapter 2 demonstrated that several markers of 
inflammation and haemostasis have been hypothesized as potential risk factors for CHD 
in numerous studies but their relation with PAD is not well-established and for many of 
them unknown.  
 
3.1 Aim 
The aim of this thesis is to determine whether plasma levels of several inflammatory and 
haemostatic markers are related to the progression of PAD and to the incidence of PAD 
events in order to identify possible mechanisms involved in the aetiology, development 
and progression of disease. For this reason, the Edinburgh Artery Study, a population 
cohort study which is described in detail in the following chapter, was used. The 
inflammatory markers, CRP, IL-6, ICAM-1, VCAM-1 and E-selectin, and the 




The main endpoints examined here were: progression of peripheral atherosclerosis and 
incidence of clinical PAD. Similar analyses were performed for both endpoints. More 
specifically, the objectives of the analyses were: 
 
3.2.1 Progression of peripheral atherosclerosis 
1. To examine the change in a non-invasive marker of subclinical peripheral 
atherosclerosis, the ABI, over 5 and 12 years of follow up in the general 
population. 
2. To determine univariable and multivariable associations between traditional 
cardiovascular risk factors (age, sex, BMI, diabetes, total/ HDL cholesterol ratio, 
smoking, physical activity) and progressive peripheral atherosclerosis measured 
by the change in ABI after 5 and 12 years of follow up. 
3. To determine univariable associations between inflammatory markers (CRP, 
IL-6, ICAM-1, VCAM-1, E-selectin) and progressive peripheral atherosclerosis 
measured by the change in ABI after 5 and 12 years of follow up. 
4. To determine univariable associations between haemostatic markers (fibrinogen, 
D-dimer, t-PA, vWF, factor VII, F1+2, FpA) and progressive peripheral 
atherosclerosis measured by the change in ABI after 5 and 12 years of follow up. 
5. To determine multivariable associations between each of the aforementioned 
inflammatory or haemostatic marker with progressive peripheral atherosclerosis 
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measured by the change in ABI after 5 and 12 years of follow up accounting for 
traditional cardiovascular risk factors. 
6. To determine multivariable associations between the aforementioned 
inflammatory and haemostatic marker with peripheral progressive atherosclerosis 
measured by the change in ABI after 5 and 12 years of follow up after 
accounting for each other. 
7. To compare the relative associations of the aforementioned inflammatory and 
haemostatic marker and examine whether they have an additive effect on the 
progression of peripheral atherosclerosis measured by the change in ABI after 5 
and 12 years of follow up. 
8. To examine the associations of the aforementioned inflammatory or haemostatic 
markers with progression of peripheral atherosclerosis measured by the change 
in ABI after 5 and 12 years of follow up according to cardiovascular risk factor 
status. 
  
3.2.2 Incident PAD 
1. To examine the incidence of clinical PAD, not only of IC but also of the more 
severe form of CLI (rest pain, gangrene, ulceration and surgical intervention). 
2. To determine univariable associations between inflammatory markers (CRP, 
IL-6, ICAM-1, VCAM-1, E-selectin) and incident PAD over 12 years of follow 
up. 
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3. To determine univariable associations between haemostatic markers (fibrinogen, 
D-dimer, t-PA, vWF, factor VII, F1+2, FpA) and incident PAD over 12 years of 
follow up. 
4. To determine multivariable associations between each of the aforementioned 
inflammatory or haemostatic marker with incident PAD over 12 years of follow 
up after accounting for traditional cardiovascular risk factors. 
5. To determine multivariable associations between each of the aforementioned 
inflammatory and haemostatic marker after accounting for each other with 
incident PAD over 17 years of follow up. 
6. To compare the relative associations of the aforementioned inflammatory and 
haemostatic marker and examine whether they have an additive effect on 
incident PAD over 17 years of follow up. 
7. To examine the associations of the aforementioned inflammatory or haemostatic 
markers with incident PAD over 17 years of follow up according to 
cardiovascular risk factor status. 
 
3.2.3 Incident CVD, MI and stroke 
Apart from progression of peripheral atherosclerosis and incident PAD another endpoint 
of combined cardiovascular events (MI and stroke) was also included in the following 
analysis. This analysis had the following objectives: 
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1. To determine if the previously described associations between inflammatory and 
haemostatic markers and PAD occurred with other manifestations of 
atherosclerosis including MI and stroke. 
2. To examine if any of the inflammatory and haemostatic markers were more 
important for specific cardiovascular endpoints (peripheral, coronary or 
cerebrovascular). 
3. To determine univariable associations between inflammatory markers or 
haemostatic markers and incident stroke after 17 years of follow up. 
4. To determine multivariable associations between inflammatory markers or 
haemostatic markers and incident stroke after accounting for traditional risk 
factors. 
5. To determine multivariable associations between inflammatory markers or 
haemostatic markers and incident CVD, MI or stroke after accounting for a 








Here, the methodology of this thesis is described. As it was already mentioned, the 
analysis is based on the Edinburgh Artery Study: a population based cohort which was 
designed to study risk factors for CVD. The study began in 1987 and took place in the 
Department of Community Health Sciences, University of Edinburgh and was headed by 
Professor Gerry Fowkes. It was funded by the British Heart Foundation. At the end of 
this chapter the statistical methodology is outlined.   
 
4.2 Study design 
The Edinburgh Artery Study commenced as a cross-sectional survey in 1987 and 
continued as a longitudinal study. The target population for the Edinburgh Artery Study 
comprised inhabitants of Edinburgh aged 55-74 years old. A random sample stratified by 
5 years age band was selected from 10 general practises serving a wide range of 
socioeconomic and geographical areas throughout the city. The sample size of 1,500 
participants was estimated on the basis of the number required to conduct a subsequent 
follow up study with adequate power to detect differences in incidence of vascular 
events according to baseline characteristics. The overall recruitment summary is shown 
in Figure 1. In order to produce at least 1,500 participants, 272 subjects were selected 
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from each practice: 34 males and females from each 5 years age band. General 
practitioners reviewed lists of their patients selected for the study and excluded those 
unfit to participate (e.g. due to mental illness), those who had moved from the practice, 
or those who had died. These exclusions were replaced by other randomly selected 
patients. 
 
Following publicity in the local media, letters of invitation signed jointly by the study 
director and a partner in each general practice were sent to the subjects inviting them to 
attend a university clinic for a medical examination. Transport or an examination at 
home was available for those having difficulty in attending the clinic. Travelling 
expenses were offered. Letters returned by the Post Office were replaced with invitations 
to other patients selected at random. On receipt of an affirmative reply, an appointment 
was booked and a map, along with details of the examination was send. Responders who 
did not attend were offered a second appointment usually by telephone. Non-responders 
were sent a second letter of invitation. 
 
Some 20% (222 subjects) of non-responders in each practice were randomly selected 
and followed up. Each was sent a letter and enclosing a short questionnaire. Subjects not 
returning the questionnaire were telephoned or visited at home on up to three occasions 
at different times of the day and evening. Thirty-seven had moved address on their 
general practitioner register, 6 had died or were in the hospital and 9 could not been 
contacted, 17 refused to take part and 152 completed the questionnaire by post, phone or 
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home visit.   The follow up of the non-responders did not show any particular bias 
(Figure 4). The study was approved by the Lothian Health Board Ethics Committee and 
informed consent was obtained from each participant. 
 
Figure 3 Recruitment summary of the Edinburgh Artery Study
Replace: 503 
Exclusions: 504 Inclusions 
1
st
 invitation letter: 2,709 
Accept: 1,666 
No reply: 1,228 
2
nd
 invitation letter 















20% follow up 
Sample list screened by GPs: 2,720 
1,592 subjects of the Edinburgh Artery Study 
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Figure 4 Follow up of the non-responders/ non attenders 
1,043 Non-responders/ Refuse to take part 
74 Respond but did not attend 
1,117 
subjects 
Random sample of 20 





27 replies by post 
126 replies by 
phone or at home 
17 refused 
(7.7 %) 
9 could not be 







4.3 Five and 12 years follow up 
Follow up examinations were held after 5 and after 12 years from the baseline 
examination. During both follow up examinations, participants still residing in the 
Edinburgh area were sent a letter of invitation asking if they wished to attend the 
second/ third examination, and if so, whether they would travel to the clinic 
(expenses offered) or if they would like to be examined at home. Participants who 
lived outside the area were offered overnight accommodation and travel expenses but 
not a visit at home. Those who did not wish to attend, missed appointments or did 
not respond after three invitations were sent a self-administrative questionnaire. 
Participants whose questionnaire was not returned were first telephoned and then 
visited at home and asked to complete the questionnaire. Finally, participants whose 
letters were returned by the Post Office were traced through Lothian Health Board 
and if a new address was found the invitation procedure was repeated. 
 
4.4 Clinical examinations 
At baseline, clinical examinations were held each weekday morning from August 
1987 to September 1988. The 5 year follow up examination was held between 
November 1992 and March 1999; whereas, the 12 year follow up examination was 
held between February 1999 and October 2001.  
 
Before conducting the main study at baseline, a pilot study was carried out on 50 
volunteers from one general practice. The quality of measurement were checked 
before and during the study by repeat measurements taken intermittently by the study 
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co-ordinator. Individual observer measurements were assessed for drift. Variability 
of some measurements especially ABI measurement was previously assessed 
(Fowkes et al 1998). 
 
Standing height (without shoes) was measured to the nearest 5mm using a free 
standing metal ruler on a heavy base. Weight (without shoes and outer clothing) was 
measured to the nearest 100g on digital scales (Soehnle). BMI was calculated as the 
weight in kilograms divided by square of the height in meters. A 12-lead ECG was 
taken and coded independently by two observers using the Minnesota code (Prineas 
et al 1982). If a discrepancy occurred, a final decision was made by a consultant 
cardiologist. Systolic and diastolic (phase V) blood pressures were recorded in the 
right arm only, after 10 minutes rest in the supine position, using a Hawksley random 
zero sphygmomanometer. The femoral, posterior tibial, and dorsalis pedis pulses 
were palpated in both legs. Ankle systolic pressures were measured first in the right 
leg and then in the left leg at the posterior tibial artery, using a Sonicaid Doppler 
ultrasound probe and a random zero sphygmomanometer with the cuff placed 
proximal to the malleoli. The pulse was located with the Doppler probe, and the cuff 
was inflated until the pulse was no longer audible. The cuff was then deflated, and 
the pressure was noted when the pulse re-appeared. If the posterior tibial pulse was 
not detectable, the dorsalis pedis pulse was used wherever possible. The ABI was 
calculated by dividing the ankle systolic pressure by the brachial systolic pressure. 
The lower of the two leg indices was used in the analysis as indicative of worse 
disease.  
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4.5 Blood processing and laboratory assays 
At baseline, 20 ml of venous blood and a urine sample was taken initially for 
subsequent estimation of biochemical, haemostatic and inflammatory factors. All 
samples were taken between 09:00am and 12:30pm to minimise diurnal variation. 
Subjects were asked to refrain from smoking for two hours prior to the visit and to 
fast from 11:00pm the previous evening if not diabetic. 
 
4.5.1 Glucose 
A fasting blood sample was taken for measurement of blood glucose and then each 
subject not known to be diabetic consumed 75g of glucose in the form of 335ml 
Solripe Gluctoza Health Drink (Strathmore Mineral Water Company, Forfar, 
Scotland).  A second blood glucose specimen was taken 2 hours after the oral 
glucose load.  Both fasting and post-glucose samples were analysed by the 
hexokinase U.V. method using a standard kit (Boehringer).    
 
4.5.2 Serum Lipids 
Tests for serum total cholesterol and high density lipoprotein (HDL) cholesterol were 
performed on a Cobas Bio analyzer (Roche Products) using standard kits. Total 
cholesterol was measured using an analysis kit from Boehringer which is an 
enzymatic colometric test. Magnesium chloride and dextran sulphate were used to 
precipitate the VLDL and LDL protein fractions. The HDL cholesterol was estimated 
in the supernatant using the Boehringer cholesterol kit.  
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4.5.3 Inflammatory and haemostatic markers 
The assays for the inflammatory and haemostatic markers except for fibrinogen were 
carried out in the Haemostasis, Thrombosis and Vascular Medicine Unit at the 
Glasgow Royal Infirmary. Fibrinogen was measured at the University of Edinburgh. 
For these assays, all blood samples were centrifuged within 2 hours of collection and 
were stored the same day at -40°C. Storing time varied between variables from 5 
years (haemostatic markers) to 10 years (inflammatory markers). Each variable was 
assayed for the whole population at the same time. In addition, internal quality 
control plasma was run for each marker and measurements of markers that fell 
outside the 95% normal range were repeated. 
 
CRP was measured immunologically using a high-sensitivity assay in a BN ProSpec 
nephelometer (Dade Behring, Milton Keynes, UK). Plasma levels of IL-6, ICAM-1, 
VCAM-1, E-selectin, were measured using high sensitivity ELISA kits (R&D 
Systems, Oxford, UK). The coefficients of variation were as follows, respectively: 
for CRP, 4.7%; for IL-6, 7.4%, for ICAM-1, 4.8%; for VCAM-1 4.3% and for 
E-selectin, 4.8. 
 
vWF, D-dimer and t-PA were measured using high sensitivity ELISA kits (DAKO 
(Copenhagen, Denmark); AGEN (Parsippanny, NJ, USA) and Biopool (Umea, 
Sweden); respectively). Fibrinogen was measured in citrated plasma by a thrombin-
clotting turbidometric method in a centrifugal analyser. Urinary FpA was measured 
by radioimmunoassay (IMCO, Stockholm); factor VII was measured using
 
a 
chromogenic assay (Kabi Diagnostica); and plasma F1 + 2 was measured by ELISA 
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(Dade Behring, Marburg, Germany). The coefficients of variation were as follows, 
respectively: for fibrinogen, 5.2%; for D-dimer, 12.7%, for t-PA, 9.3%; for vWF, 
7.2%; for factor VII, 8.1; and for F1+2, 9.2. 
 
Data on some markers was missing due to attrition or decreasing availability of 
plasma sample. This was mostly due to the volume of the original sample and is not 
expected to be associated with any of the demographic and cardiovascular risk 
profile of the study subjects. Thus, it was considered as missing ‘at random’. To 
demonstrate this, Table 12 shows the cardiovascular risk factors of the cohort in 
subjects without and with missing CRP. As expected, the numbers fluctuated slightly 
between the two groups but no major differences were observed. Same was true for 
the other markers included in the analysis.  
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Table 12 Baseline characteristics in people with and without C-reactive protein (CRP) 
measurement at baseline 
 Subjects with CRP 
measurements 
Subjects with missing 
CRP measurement 
 N Mean (SD)/ 
Percent 
N Mean (SD)/ 
Percent 
Age (years) 1,154 64.8 (5.67) 438 64.8 (5.72) 
Males  570 51 % 239 54 % 
BMI (kg/m
2
) 1,154 25.6 (3.91) 437 25.2 (3.70) 
Total cholesterol (mmol/L) 1,154 7.03 (1.33) 419 6.97 (1.29) 
HDL cholesterol (mmol/L) 1,151 1.44 (0.41) 416 1.41 (0.42) 
Total/ HDL cholesterol ratio 1,151 5.24 (1.96) 416 5.45 (2.81) 
Pack years smoking
†
 1,129 23.9 (4.12) 431 24.3 (4.41) 
Diabetes  69 6 % 22 5 % 
Hypertension 629 55 % 241 55% 
Cardiovascular disease     
   Myocardial infarction 
   Stroke 
   Angina 
   Intermittent claudication 





















Physical activity  
   Light 
   Moderate 

















Ankle brachial index 1,145 1.03 (0.17) 434 1.02 (0.18) 
† among smokers 
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4.6 Self-administrative questionnaire 
At baseline, 5 and 12 years follow up, subjects completed a self administrative 
questionnaire which contained mostly validated questions about personal 
characteristics, social class (Office of Population Censuses and Surveys 1980), 
medical history, smoking, exercise, personality, alcohol consumption and diet. 
Medical history items addressed subject’s recall of a diagnosis by the doctor of 
stroke or MI. Chest pain, angina and leg pain symptoms were assessed by the WHO 
angina and WHO IC questionnaires, respectively (Appendix I) (Rose 1962). 
Smoking habits were self-reported and information was converted into pack years for 
each person obtained by calculating the number of 20-cigarette packs per day 
smoked, multiplied by number of years being a smoker. This measure was judged to 
be sufficiently accurate because the self-reported levels correlated with thiocyanate 
levels. Information on diabetes status, use of insulin injections and tablets for 
diabetes was also recorded 
 
4.7 Follow up of cardiovascular events 
Information about the following cardiovascular events was obtained during the 
follow up period (approximately 17 years): MI, angina, stroke, transient ischaemic 
attacks, IC, CLI, thrombo-embolism, vascular surgery, angioplasty and coronary 
artery bypass grafting (CABG). Data was collected from 5 main sources: 
a) Scottish National Health Service Central Registry 
b) Information and Statistics Division of the Common Services Agency 
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c) Annual questionnaires 
d) General Practitioners 
e) Hospital Records 
 
4.7.1 Scottish National Health Service Central Registry 
To identify the cardiovascular events each study participant was flagged at the 
United Kingdom National Health Service Central Registry, thus ensuring any deaths 
certificates would be automatically forwarded for all subjects dying within the UK.  
The name, address, date of birth, sex and study number of each patient was typed 
onto an index card and forwarded to the Central Registry. When notification of death 
was received by the Central Registry, the death certification was sent (after a period 
of at least 2 months) to the University of Edinburgh Medical School. The primary 
and secondary causes of death were recorded on the database in a file restricted to 
deceased patients. When a post-mortem was conducted information was used to 
verify the underlying cause of death.  All causes of death had been allocated a 
diagnostic code according to the ISD-9 or ISD-10. In addition, the cause of death 
was allocated a code indicating whether the patient had died of MI (code 1), stroke 
(code 2), other CVD (code 3), or non-cardiovascular causes (code 4).  
 
4.7.2 Information and Statistics Division 
To obtain information on the non-fatal events, information was sought from the 
Information and Statistics Division (ISD) of the Scottish Office Home and Health 
Department. The ISD office holds patient data derived from summaries created when 
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patients are discharged from hospitals. An application was send to the ISD at the 
beginning of the study to obtain access to the Scottish Morbidity Records on all 
patients participating in the study. The procedure entailed record linkage to 
computerised ISD data with our own patient data. The merged file was then released 
in the form of a computerised print-out with the cases in a specific order. The ISD 
subsequently provided a computer printout at several time points during the follow 
up identifying all subjects who had attended a hospital for a vascular event according 
to specifies ICD codes, in addition to the relevant hospital and date of submission 
and discharge.      
 
4.7.3 General Practitioners 
At the start of the study, information on general practices and doctors was obtained 
from each participant. A letter was then sent to each listed doctor explaining the 
purpose of the study along with a card with participant’s details. The doctor was then 
asked to attach the card to the front of the subject’s records and to return it after a 
cardiovascular event or if patient had died. A pre-paid envelop was also sent for the 
reply. Also, the card had to be returned if the subject had changed address or general 
practice in which case they were traced by contacting the Practitioner Services. If a 
new general practice was found, it was contacted and a pink card along with a cover 
letter was sent to them. When a card was returned to notify a cardiovascular event, a 
new card was sent to the general practice.  
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4.7.4 Annual Questionnaire 
Each participant also received an annual questionnaire enquiring about the 
development a heart attack, stroke, chest pain, leg pain, angina or hardening of the 
arteries during the last year. A cover letter reminding them about participation in the 
study and a prepaid envelop for returning the questionnaire was sent. Details of 
hospital attendances and aspirin medication were also requested. An example of the 
cover letter and questionnaire is shown on Appendix II. If a positive response on leg 
pain or chest pain was received from the annual questionnaire, a WHO IC or angina 
questionnaire was sent to the participant. The WHO IC and angina questionnaires are 
shown on Appendix I. If a positive response for other events was received, the 
general practice was contacted and the hospital records were searched to determine 
whether the event criteria were fulfilled.  
 
4.7.5 Retrieval of hospital records 
Participants who had a cardiovascular event during follow up identified from at least 
one of the following sources: the ISD computer print-out, the general practitioner or 
the annual questionnaires were further investigated by searching the hospital records. 
The records were first searched in hospitals cited in the ISD handouts, the general 
practitioner responses or the patient questionnaire. Permission to visit each hospital 
was requested by a letter signed by the study director. After September 2003, an 
event was confirmed if it appeared in the ISD handout and no other visits to the 
hospitals were performed. 
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4.8 Criteria for diagnosis of cardiovascular events 
Criteria to define these events were adapted from the American Heart Association as 
described below (Gillum et al 1984;Hooi et al 2001). An event was recorded if these 
criteria were fulfilled. 
 
4.8.1 Myocardial Infarction 
1) Non-fatal MI 
a) Definite MI was coded if two of the following criteria were present: 
i) Prolonged cardiac pain, anywhere in the anterior chest, left arm or jaw 
(possibly also involving back, shoulder, right arm or abdomen and lasting 
at least 20 min) 
ii) Diagnostic ECG codes, including Minnesota Codes: 1.1.1-1.2.5; 1.2.7; or 
9.2 plus 5.1 or 5.2. 
iii) Elevated enzyme levels: creatine phosphokinase greater than twice the 
upper limits of normal, and one of the following also greater than twice 
the upper limits of normal: lactate dehydrogenase, glutamic oxalo-acetic 
transaminase, or MB isoenzyme of creatine phosphokinase. The enzymes 
must have been measured within 72 hours of an acute event. 
b) Possible MI was coded if: 
i) One of the above defines criteria was present plus either 
- equivocal ECG codes: 1.2.8-1.3.6; 4.1-4.3; 5.1-5.3; or 9.2. 
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- equivocal enzyme levels: above normal but not twice normal or one was 
above twice normal but could be attributed to other cause. 
ii) Equivocal ECG codes and equivocal enzyme levels 
c) Silent MI was coded if:   
i) ECG codes were diagnostic but elevated enzyme levels or cardiac pain 
was absent 
2) Fatal MI 
a) Definite MI was reported if one of the following criteria was present: 
i) Post mortem evidence of acute MI 
ii) Definite criteria for MI were present during the last 4 weeks prior to death 
iii) International Classification of Diseases-9 (ICD) codes for cause of death 
were 410-414 or ICD-10 codes I21, I22, I24-I25.8 plus participant had a 
history of definite or possible MI; or plus definite or possible criteria for 
MI immediately preceding death; or plus post mortem evidence of severe 
coronary atherosclerosis or MI 
b) Possible MI was coded if: 
i) Death certificate codes were ICD-9 codes: 410-414 or ICD-10 codes: I21, 
I22, I24-I25.8 but no other evidence was found 
4.8.2 Angina Pectoris 
A diagnosis of angina during the follow up period required that there was no WHO 
evidence of angina at baseline plus either: 
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i) Evidence of angina on the WHO questionnaire and recall of a doctor’s 
diagnosis of angina 
ii)  WHO angina plus ECG ischaemia 
iii) Clinical diagnosis of angina investigated by the general practitioner or in 
hospital 
4.8.3 Stroke 
1) Non-fatal stroke 
a) Definite stroke was coded if one of the following criteria was present: 
i) A history of onset of symptoms of less than 48 hours, plus clinical 
confirmation of a focal or global disturbance of cerebral function lasting 
more than 24 hours 
ii) Computerised tomography scan showed evidence of cerebral infarction of 
haemorrhage 
b) Possible stroke was coded if: 
i) Primary or secondary discharge diagnosis included ICD-9 codes 431- 437 
or ICD-10 codes I61-I67.9 
2) Fatal stroke 
a) Definite stroke was coded if one of the following was present: 
i) Post mortem evidence of cerebral infarction or haemorrhage 
ii) Criteria for definite stroke were met within 6 weeks prior to death 
b) Possible stroke was coded if: 
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i) Death certificate codes for underlying cause of death were ICD-9 431- 
437 or ICD-10 codes I61-I67.9 
4.8.4 Transient Ischaemic Attack 
A possible transient ischaemic attack was defined as a recorded history of rapid onset 
of clinical signs of focal or global disturbance of cerebral function lasting less than 
24 hours. 
4.8.5 Intermittent Claudication 
Intermittent claudication was diagnosed using the WHO IC questionnaire.  
4.8.6 Thrombo-embolism 
Thrombo-embolism was coded if the diagnosis was confirmed by laboratory, 
radiological or surgical evidence. 
4.8.7 Amputation/Surgery/ Angioplasty 
A code of amputation referred to the amputation of any part of the lower limb, due to 
diabetes or vascular causes only. Vascular surgery, angioplasty, rest pain/ ulcer/ 
gangrene and CABG could be coded if these events were noted in participants’ 
records. 
 
4.9 Data analysis 
This part describes the statistical analysis. Statistical tests and data handling are 
described for each section of the results separately. Analysis of the Edinburgh Artery 
Study data has been performed using SPSS v12-14. The information from 
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Total/ HDL cholesterol 
Smoking status                                                 





History of CVD at baseline 
 
questionnaires and records forms was entered in a DBASE IV database from which 
the SPSS files were exported.  
 
4.9.1 List of variables 






























4.9.2 Calculation and coding of variables 
The following variables were calculated using the formulas shown below:  





Pack years of smoking: number of years smoked * average number of packs per      
day (zero was entered for lifelong non-smokers) 
Total/ HDL cholesterol ratio: Total cholesterol/ HDL cholesterol 
ABI: minimum [(left ankle systolic pressure/ left brachial systolic pressure), (right 
ankle systolic pressure/ right brachial systolic pressure)] 
ABI change 5 years= ABI at 5 years- ABI at baseline  
ABI change 12 years= ABI at 12 years- ABI at baseline  
Also, the following categorical variables were coded as described below: 
Smoking status was coded as a 2 level categorical variable. Subjects were classified 
as never smokers if they have answered to the questionnaire that they were never 
smokers and as ever smokers if the have answered that they were current or ex-
smokers.   
Physical activity was measured by a leisure activity questionnaire. A 4-group 
categorical variable was then calculated (no activity, light activity, moderate activity, 
and strenuous activity). 
Outcomes: 
Progression of peripheral atherosclerosis assessed by ABI change 
after 5 years and after 12 years 
Incident PAD 




Diabetes status of subjects was defined by a number of ways. Subjects were 
classified as diabetic if they had answered the self-administrative questionnaire that 
they had been told by a doctor that they suffered from diabetes and were receiving 
either insulin or oral therapy. Also, a participant was recorded as suffering from 
diabetes if because of a doctor’s diagnosis of diabetes they did not undergo the oral 
glucose intolerance test at baseline. Finally, if plasma glucose concentration was  
7.8mmol/L or the 2h blood sample was  11.1mmol/L the subject was classified as 
diabetic. 
Hypertension was defined as systolic blood pressure 140mmHg or diastolic blood 
pressure 90mmHg or when subject was self reported as taking drugs to lower his/ 
her blood pressure.  
History of CVD at baseline was defined as MI (2 out of the 3 of recall of doctor’s 
diagnosis, WHO questionnaire and ECG ischemia), stroke (recall of doctor’s 
diagnosis), angina (WHO questionnaire and either ECG ischemia or recall of 
doctor’s diagnosis) or IC (WHO questionnaire). 
Survival time was calculated in years by using the follow up of each participant 
from the baseline examination until death, most recent follow up assessment or until 
the event under examination (PAD, major CVD, MI, and stroke). Details for the 
calculation of each survival time are presented in the following sections. 
Incident PAD was defined as an event of IC, rest pain, ulceration, amputation or 
vascular surgery during the follow up period. Criteria for IC were as defined in the 
previous section. 
Incident major CVD was defined as fatal or non fatal MI, fatal or non fatal stroke, 
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CABG or angioplasty during the follow up period. Criteria for MI and stroke were as 
defined in the previous section.  
Incident MI was defined as fatal or non fatal MI during the follow up period. 
Incident stroke was defined as fatal or non fatal stroke during the follow up period. 
 
4.9.3 Descriptive and cross-sectional analysis 
The distributions of each cardiovascular risk factor, inflammatory marker and 
haemostatic marker were examined. Any extreme values/ outliers were investigated 
with the view of omitting from subsequent analysis. Any variable showing a skewed 
distribution was normalised using square root or log transformation as stated in the 
text. For skewed variables the median (IQR) is quoted in the text whereas for other 
continuous variables mean (SD) was used for descriptive statistics. 
 
A correlation analysis using Pearson correlation was performed on cardiovascular 
risk factors, inflammatory and haemostatic markers in order to examine any 
associations between these variables, with variables having a skewed distribution 
being transformed appropriately.  
 
The independent sample t-test was used to test differences between continuous 
cardiovascular risk factors, inflammatory and haemostatic markers and dichotomous 




Throughout the following analysis multivariable models were performed with 
adjustments for potential confounders. Conventional cardiovascular risk factors were 
selected including age, sex, smoking, cholesterol levels, BMI, hypertension, diabetes, 
physical activity levels. As it was described in the introductory chapters these 
variables were interrelated with inflammatory and haemostatic markers and with 
CVD.  
 
4.9.4   Progressive peripheral atherosclerosis 
Progression of peripheral atherosclerosis was defined as the ABI change from 
baseline to 5 and to 12 years after follow up. The statistical significance of the 
change between ABI at 5 years and ABI at baseline or ABI at 12 years and ABI at 
baseline was tested with the t-test for paired samples.  
 
Analysis of covariance (ANCOVA) was used to examine associations between 
cardiovascular risk factors, inflammatory and haemostatic markers and ABI at 
baseline, 5 years and 12 years. The partial correlation coefficients were used to test 
associations between cardiovascular risk factors, inflammatory and haemostatic 
markers and ABI at 5 years and 12 years adjusted for baseline ABI.  
 
Linear regression was used to test associations between each cardiovascular risk 
factor and ABI change at 5 and 12 years. Analyses were initially adjusted for 
baseline ABI and further adjusted for all available cardiovascular risk factors risk 
factors: age, sex, pack years of smoking, presence of diabetes, total/ HDL cholesterol 
ratio, BMI, physical activity and history of CVD at baseline. Also, linear regression 
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was used to test associations between each inflammatory or haemostatic marker and 
ABI change at 5 and at 12 years. Analyses were initially adjusted for baseline ABI 
and further adjusted for risk factors: age, sex, pack years of smoking, presence of 
diabetes, total/ HDL cholesterol ratio, BMI, physical activity and history of CVD at 
baseline.  
 
Different models with combinations of CRP, IL-6, fibrinogen and D-dimer as 
independent variables were investigated in order to find the model with the highest 
R
2
. Moreover, all inflammatory or all haemostatic markers were entered 
simultaneously into the linear regression model. Finally, the baseline population was 
divided in subgroups according to baseline history of CVD, total/ HDL cholesterol 
levels (above or below the median) and smoking status and linear regression was 
performed in each subgroup separately. In order to compare the effects of each 
marker on ABI change, the regression coefficients were standardised to represent the 
differences in ABI decline between the top and bottom tertiles of each marker. This 
was done by multiplying the regression coefficients by the inter-tertile range of the 
transformed distribution.  
 
Odds ratios for transition from normal (ABI>0.9) to low ABI (ABI 0.9) were 
calculated using logistic regression adjusted for age sex and further adjusted for 
cardiovascular risk factors. In this analysis only subjects with normal ABI (ABI>0.9) 
at baseline were included.  
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Also, subjects were divided into four mutually exclusive groups depending on their 
baseline levels of D-dimer and IL-6: subjects with D-dimer and IL-6 levels in the top 
tertiles, subjects with D-dimer and not IL-6 levels in the top tertile, subjects with 
IL-6 and not D-dimer levels in the top tertile and finally subjects with neither IL-6 
nor D-dimer levels in the top tertiles. Similarly subjects were divided into four 
mutually exclusive groups depending on their baseline levels of D-dimer and CRP: 
subjects with D-dimer and CRP levels in the top tertiles, subjects with D-dimer and 
not IL-6 levels in the top tertile, subjects with CRP and not D-dimer levels in the top 
tertile and finally subjects with neither CRP nor D-dimer levels in the top tertiles 
The trend between these groups and ABI change was tested for statistical 
significance using analysis of covariance adjusted for baseline ABI and for risk 
factors.  
 
The interaction between age, sex, and levels of haemostatic or inflammatory markers 
was tested but the interaction term was not significant in any analysis. For the 
analysis of ABI change, linear regression models were adjusted for baseline ABI. 
Regression models without such adjustment were also performed. In these models, 
the estimates of the regression coefficients were essentially unchanged but the 
confidence intervals were wider and therefore data are not presented. Also, analyses 
were not adjusted for systolic blood pressure of for hypertension due to the high 
correlation between brachial blood pressure and the ABI.   
 
Finally, mixed model analysis for repeated measures of ABI (baseline, 5 years and 
12 years) was used to confirm results obtained from the linear regression analysis. 
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For this analysis, only subjects with ABI measurements at all 3 time points were 
included. Different covariance structure models were tested. Inflammatory and 
haemostatic markers were fitted as categorical (tertiles) in the analysis and the 
interaction term between inflammatory or haemostatic markers and time (baseline, 5 
years, 12 years) was investigated.  
 
4.9.5 Incident PAD 
Only subjects without baseline IC were included in incident PAD analysis. To 
compare mean levels of risk factors at baseline in subjects who developed PAD and 
who did not, the independent sample t-test was used for continuous variables (after 
transformations where appropriate) and the chi-square test for categorical variables. 
A test for trend across disease categories and baseline risk factors was performed 
using analysis of variance. 
 
Duration of follow up was calculated in years by using the follow up of each 
participant from the baseline examination until death, PAD event or most recent 
follow up assessment. Cox proportional hazard models were used to estimate risk of 
PAD. If more than one event was recorded (for example both IC and CLI), the first 
event was used for the calculation of the disease free survival time. Hazard ratios 
(95% CI) for BMI, diabetes, total/ HDL cholesterol ratio, hypertension, pack years of 
smoking, physical activity and CVD (MI, stroke or angina) at baseline adjusted for 
age and sex and then for all variables were calculated with Cox regression.  
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All inflammatory and haemostatic markers were fitted as categorical in the model 
(tertiles: three approximately equal groups) according to their baseline levels due to 
evidence for non-linearity between some markers levels and incident PAD (e.g. CRP 
levels and incident PAD). However, when alternative models fitting markers as 
continuous were performed results were essentially unchanged. Tertiles are also 
presented here for ease of interpretation and comparability with published 
meta-analysis on these markers and CHD. The hazard ratio for PAD of each 
inflammatory and haemostatic variable adjusted for age and sex (1) plus BMI, 
diabetes, total/HDL cholesterol ratio, pack years smoking, physical activity and 
hypertension (2) history of CVD at baseline (MI, stroke or angina) was calculated.  
 
Cox regression with backward selection using inflammatory and haemostatic 
markers that were significant in univariable analysis was also performed. In this 
analysis cardiovascular risk factors and baseline CVD were forced to enter into the 
model.  
 
Subsequent Cox regression models were fitted adjusting for all inflammatory 
markers, all haemostatic markers and combinations of those. Also, the baseline 
population was divided into six groups according (1) to baseline levels of total/ HDL 
ratio cholesterol (below or above median) and fibrinogen (top, middle or bottom 
tertile) (b) never or ever (present and ex) smokers and fibrinogen (top, middle or 
bottom tertile). Hazard ratios (95% CI) were calculated in each subgroup using the 
group of people with total/ HDL cholesterol below the median and fibrinogen at the 
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bottom tertile or the group of people who were never smokers and had fibrinogen 
levels at the bottom tertile as the reference group. 
 
As in previous analysis, the interaction between age, sex, and levels of haemostatic 
or inflammatory markers was tested but the interaction term was not significant in 
any analysis. 
 
4.9.6 Incident major CVD 
The independent sample t-test was used to compare mean levels of risk factors at 
baseline in subjects who developed a cardiovascular event to those who did not, after 
data has been transformed as appropriate. Similarly, mean levels of all risk factors in 
subjects who developed MI or who developed stroke were compared to the group 
that remained healthy.  
 
Duration of follow up was calculated in years by using the follow up of each 
participant from the baseline examination until death, CVD event or most recent 
follow up assessment. Cox proportional hazard models were used to estimate risk of 
combined major CVD, risk of MI and risk of stroke. Multiple events such as two MIs 
were counted only once. For the major CVD group, if both an MI and a stroke 
occurred, the first of the two events was used for the calculation of the disease free 
survival time.  
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Hazard ratios (95% CI) for BMI, diabetes, total/ HDL cholesterol ratio, hypertension, 
pack years of smoking, physical activity and baseline CVD (MI, stroke or angina) at 
baseline adjusted for age and sex and then for all variables were calculated with Cox 
regression.  
 
Inflammatory and haemostatic variables were divided into tertiles (three 
approximately equal groups) according to their baseline levels. Hazard ratios (95% 
CI) between top and bottom tertiles of each marker were calculated and were 
subsequently adjusted for age and sex; (1) plus BMI, diabetes, total/HDL cholesterol 
ratio, pack years smoking, physical activity, history of CVD disease; and (2) plus 
ABI. Results from fitting markers as continuous were essentially unchanged and 
therefore tertiles are presented here for ease of interpretation and comparability with 
published meta-analysis. Subsequent Cox regression models were performed 
adjusting for all inflammatory markers, all haemostatic markers and combinations of 
those.  
 
Cox regression with backward selection using inflammatory and haemostatic 
markers that were significant in univariable analysis was also performed. In this 
analysis cardiovascular risk factors, baseline CVD and the ABI were forced to enter 
into the model. Also, a composite score ranging from 0 to 3 for elevated 
concentrations of IL-6, fibrinogen and t-PA was calculated. One point for a value in 
the top tertile of each of the three variables was assigned. Cox regression was used to 
calculate hazard ratios (95%) for incident CVD for one, two or three elevated 
markers compared to none elevated. In addition, the baseline population was divided 
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into six groups according (1) to baseline levels of total/ HDL ratio cholesterol (below 
or above median) and CRP, IL-6, fibrinogen or D-dimer (top, middle or bottom 
tertile) (2) never or ever (present and ex) smokers and CRP, IL-6, fibrinogen or D-
dimer (top, middle or bottom tertile). Hazard ratios (95% CI) were calculated in each 
subgroup using the group of people with total/ HDL cholesterol below the median 
and marker at the bottom tertile or the group of people who were never smokers and 
had CRP, IL-6, fibrinogen or D-dimer levels at the bottom tertile as the reference 
group. 
 
This analysis was not adjusted for systolic blood pressure or hypertension due to 
their high correlation with the ABI. However, separate models adjusting for systolic 
blood pressure or hypertension and cardiovascular risk factors but not ABI were 
performed. Results for these models were not meaningfully different and data was 
not presented.  
 
Finally, the interaction between age, sex, and levels of haemostatic or inflammatory 
markers was tested but the interaction term was not significant in any analysis. 
 
4.9.7  Model assumptions and statistical considerations 
Statistical analysis was performed using a predefined plan according to specific 
hypotheses that were to be tested each time. For every statistical test used, model 
assumptions were assessed and were found satisfactory unless otherwise stated in the 
text.  
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More specifically, normality of distributions was tested visually by plotting a 
histogram. Variables with skewed distributions were logarithmically or square root 
transformed as stated in the text. For the analysis of variance, the homogeneity of 
variance assumption was tested using the Levene’s test. For linear and logistic 
regression analysis, tests were made for collinearity by scanning the correlation 
matrix between dependent variables and by looking at the variance inflation factor. 
Also standardised residuals were examined and only 1% of cases were expected to 
have standardised residuals outside ± 3. Residual plots were investigated to look for 
heteroscedasticity. For Cox regression, the proportional hazards assumption
 
was 
visually assessed by plotting the log-log survival curves and found to be satisfactory
 
for all models constructed. A two sided p value < 0.05 was taken to denote statistical 




5 Results: The study sample and associations of 
inflammatory and haemostatic markers with 
progressive peripheral atherosclerosis 
5.1 Introduction 
This chapter describes the population of the Edinburgh Artery Study at baseline and 
the interrelationships of inflammatory and haemostatic markers and cardiovascular 
risk factors. Associations between inflammatory and haemostatic markers and CVD 
at baseline (cross-sectionally) are also presented here.  
 
In addition, in this chapter, the associations of inflammatory and haemostatic 
markers with peripheral progressive atherosclerosis after 5 and 12 years are 
presented. Progression of peripheral atherosclerosis was defined by the change in 
ABI after 5 and after 12 years. Each inflammatory and haemostatic marker has been 
associated with the progression of atherosclerosis in univariable analyses and in 
analyses adjusted for conventional cardiovascular risk factors. Models with all 
inflammatory and all haemostatic markers were also examined. The additive effect of 
these markers was tested and combinations of variables in relation to progressive 
atherosclerosis were investigated. Finally, their interaction with baseline 
cardiovascular risk factor levels was also tested.  
 
Tables and figures are presented at the end of each section.  
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5.2 The study sample 
This analysis describes the baseline population of the Edinburgh Artery Study and 
the characteristics of the subjects that participated in the 5 and 12 years clinical 
examination. 
 
5.2.1 Age, sex and social class at baseline 
At baseline 1,592 subjects were recruited. The mean age of the baseline population 
was 64.8 years and 51% of subjects were males. Table 13 shows that there was a 
slight under representation of subjects over 70 years old and of males aged 50-59 
years. The social class distribution was similar to that of Edinburgh population from 
the 1981 census and 10.5% of the baseline population were classified in social class 
I, 31.7% in class II, 44.3% in class III, 9.3% in class IV and 3.5 in class V (Table 
14). 
 
5.2.2 Cardiovascular risk factors and prevalence of CVD at 
baseline 
Conventional cardiovascular risk factors measured at baseline including BMI, 
diabetes status, smoking, cholesterol levels, blood pressure and physical activity are 
shown in Table 15. Six percent of the population suffered from diabetes mellitus and 
26% were self-reported current cigarette smokers and 36% were ex-smokers. Also, 
19% of the baseline population was receiving drugs to lower blood pressure and 57% 
were suffering from hypertension (defined as systolic blood pressure >120mmHg or 
diastolic blood pressure >90mmHg or use of anti-hypertensive drugs). Information 
on the use of other drugs such as aspirin or a statin was not available.  
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Also, 49 subjects (3 %) had suffered from stroke, 73 (4.6 %) had been diagnosed 
with MI and 158 (9.9 %) with angina prior to the baseline examination (Table 15). 
Finally, 73 (4.6 %) subjects were suffering from IC as identified by the WHO IC 
questionnaire. Of those with claudication, 32 (43.8%) had a grade 1 (severe pain), 24 
(32.9) had grade 2 (mild pain) and 17 (23.3) had grade 3 (calf pain but not fulfilling 
every WHO criterion).    
 
5.2.3 The study sample at 5 and 12 years follow up clinical 
examination 
From the 1,592 subjects who were recruited at baseline; 1,156 participated in the 5 
year follow up examination (131 additional subjects completed the questionnaire 
only); and 831 participated in the 12 year follow up (88 others completed the 
questionnaire only). Up to 5 years follow up, 203 deaths (12.8%) had occurred, 
making the total number of subjects with almost complete follow up data 1,490 
(93.6%). Of the remaining 102 subjects: 18 did not wish to take part; 14 were unable 
to attend due to illness or hospitalization; 7 subjects were given appointments but 
failed to attend; 9 letters were returned by the Post Office; and 54 failed to answer 
the correspondence. By the 12 year examination, 485 deaths had been recorded 
(30.5%). Of the remaining 270 subjects, 105 were unwilling to take part in the 
examination, 21 have moved and could not be contacted, 74 have not been able to 
take part due to illness or frailty and 69 did not reply to the invitation.   
 
Table 16 presents baseline characteristics for the baseline population and for the 
participants of each examination. There were not substantial differences between 
 155 
these two groups; this shows that the people who attended the clinical examinations 
were broadly representative of the baseline population. 
 
5.2.4 The study sample after 17 years of follow up 
The baseline sample has been followed up for a mean 17 years for cardiovascular 
event. During this period 689 subjects have died (43% of the baseline population). Of 
those, 281 (41%) subjects have died due to CVD. In particular, 129 (19%) deaths 
were due to MI, 65 (9%) due to stroke and 83 (12%) due to other cardiovascular 
events. Survival curves for all cause and cardiovascular mortality are shown in 
Figure 5.    
 
During the follow up, 648 subjects had at least one cardiovascular event recorded 
including MI, stroke, angina, IC, and other cardiovascular events. In detail, 147 non 
fatal events of MI and 106 of stroke were recorded whereas 209 subjects developed 
symptomatic PAD during the subsequent 17 years defined as IC, rest pain, gangrene 
ulcer, amputation or vascular surgery. 
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Table 13 Age by sex distribution of the baseline population 
Age (years) Males (%) Females (%) 
55-59 182 (22.5) 216 (27.6) 
60-64 205 (25.3) 201 (25.7) 
65-69 228 (28.2) 199 (25.4) 
70-74 194 (24.0) 167 (21.3) 
Total 809 (100.0) 783 (100.0) 
 
Table 14 Social class of study members and residents of Edinburgh city 
Social class Attenders 




(>16 years) (n=31,382) 
I 10.5 % 10.0 % 
II 31.5 % 25.0 % 
IIIN 16.0 % 16.0 % 
IIIM 28.0 % 28.0 % 
IV 9.3 % 13.0 % 
V 3.5 % 6.0 % 
Unclassified 1.2 % 2.0 % 
† Based on 10% sample of the 1981 census 
 157 
Table 15 Baseline population characteristics 
 N Mean (SD)/ Percent 
Age (years) 1,592 64.8 (5.67) 
Males (%) 809 50.9 
BMI (kg/m
2
) 1,591 25.6 (3.91) 
Total cholesterol (mmol/L) 1,573 7.03 (1.33) 
HDL cholesterol (mmol/L) 1,567 1.44 (0.41) 
Total/ HDL cholesterol ratio 1,567 5.24 (1.96) 
Pack years smoking (among smokers)
†
 1,592 23.9 (4.12) 
Diabetes (%) 91 6.0 
Blood Pressure 
           Systolic Blood Pressure (mmHg) 
           Diastolic Blood Pressure (mmHg) 


























Physical activity (%) 
           Light 
           Moderate 









† Pack years have been calculated from square root transformed variable and have 
been back transformed here 
‡ People receiving drugs to lower blood pressure 
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Table 16 Population characteristics at baseline of all subjects and of those who participated at 
each examination 











Age (years) 64.8 (5.7) 64.2 (5.6) 63.2 (5.3) 
Males (%) 50.9  49.8  48.3  
BMI (kg/m
2
) 25.6 (3.91) 25.6 (3.90) 25.5 (3.84) 
Total cholesterol (mmol/L) 7.03 (1.33) 7.06 (1.32) 7.06 (1.59) 
HDL cholesterol (mmol/L) 1.44 (0.41) 1.45 (0.39) 1.46 (0.39) 
Total/ HDL cholesterol ratio 5.24 (1.96) 5.18 (1.67) 5.12 (1.50) 
Pack years smoking
†
 23.9 (4.12) 22.0 (3.65) 20.43 (3.50) 
Diabetes (%) 6.0 4.4  3.6  
Blood Pressure (mmHg) 
        Systolic Blood Pressure  
        Diastolic Blood Pressure  
















        Myocardial Infarction 
        Stroke 
        Angina 
















† Pack years have been calculated from square root transformed variable and have 
been back transformed here 
‡ People receiving drugs to lower blood pressure 
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Figure 5 Survival curve for (a) all cause and (b) cardiovascular mortality over 17 years of follow 
up 
 
(a) all cause mortality 
(b) cardiovascular mortality 
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5.3 Inflammatory and haemostatic markers at 
baseline 
This analysis focuses on the distribution and the interrelationships of inflammatory 
and haemostatic markers measured at baseline. Also, it describes their associations 
with baseline cardiovascular risk factors and CVD. 
 
5.3.1 Distribution of inflammatory and haemostatic 
markers 
Histograms of all markers are shown in Figure 6. Fibrinogen had a frequency 
distribution close to normal. Distributions of t-PA and factor VII were positively 
skewed and were square root transformed in subsequent analyses that assume 
approximate normality. Distributions of IL-6, ICAM-1, VCAM-1, E-selectin, 
D-dimer, vWF, F1+2 and FpA displayed higher skewness and were logarithmically 
transformed. Also, 98 subjects with CRP levels above 10mg/l and 11 subjects with 
IL-6 levels above 100pg/ml were excluded from all analyses because these levels 
indicate presence of acute inflammatory disease.  
 
Median levels (interquartile range (IQR)) of each inflammatory and haemostatic 
marker in the general population and for males and females separately are shown in 
Table 17. Levels of CRP, ICAM-1, VCAM-1 and vWF did not show any significant 
differences between males and females. On the contrary, significantly higher levels 
in males than females were observed for IL-6, E-selectin, t-PA and FpA (p < 0.001). 
Fibrinogen (p < 0.001), D-dimer (p =0.02), factor VII (p < 0.001) and F1+2 (p 
< 0.001) were significantly higher in female subjects.      
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5.3.2 Correlations between inflammatory and haemostatic 
markers 
Overall, markers studied here were highly correlated (Table 18). The highest 
correlations were observed between CRP, IL-6 and fibrinogen which all had 
correlation coefficients close or greater to 0.5 (p < 0.001). Haemostatic markers, 
factor VII, FpA and F1+2, did not show strong associations with other markers 
studied here and displayed several non-significant correlations coefficients.   
 
5.3.3 Associations between inflammatory and haemostatic 
markers with cardiovascular risk factors 
Table 19 shows the correlation coefficients between inflammatory and haemostatic 
markers and cardiovascular risk factors. CRP, IL-6, ICAM-1, fibrinogen, D-dimer 
and t-PA were strongly correlated with these factors whereas other markers displayed 
weak correlations. Negative correlations were observed between CRP, IL-6, 
ICAM-1, fibrinogen, D-dimer, and t-PA and levels of HDL cholesterol. On the 
contrary these markers were positively correlated with total cholesterol levels and 
with systolic blood pressure. Correlations between these markers and diastolic blood 
pressure were much weaker.  
 
Smoking 
Also, inflammatory markers CRP, IL-6 and ICAM-1 showed strong correlations with 
pack years of smoking (r =0.2, 0.3 and 0.3 respectively) which were higher than 
those observed between haemostatic markers and smoking (for fibrinogen and 
D-dimer r =0.1). When the population was divided into never and ever (present and 
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ex) smokers, CRP, IL-6, ICAM-1, fibrinogen, t-PA, vWF and FpA were significantly 
higher in ever smokers than in never smokers. Median (IQR) levels of each marker 
according to smoking status are shown in Table 20.   
 
Diabetes 
Levels of all inflammatory markers showed a significant increase in subjects with 
diabetes at baseline compared to those without (Table 21). From the haemostatic 
markers, t-PA and vWF showed a significant increase in subjects with diabetes. 
Fibrinogen had higher levels in subjects with diabetes (media (IQR) 2.73 (2.12, 
3.32)) compared to those without (median (IQR) 2.63 (2.23, 3.10)) but this difference 
did not reach statistical significance. Similarly, levels of D-dimer, factor VII, F1+2 
and FpA did not show any significant differences between subjects with and without 
diabetes at baseline.  
 
Physical activity 
Moreover, inflammatory markers, except E-selectin, were lower with increasing 
physical activity categories from ‘no activity’ to ‘light’, ‘moderate’ and ‘strenuous 
activity’ and showed a significant trend across physical activity categories as 
presented in Table 22. From the haemostatic markers, only fibrinogen and D-dimer 







Median levels (IQR) of all markers except factor VII and FpA were significantly 
higher in subjects with hypertension compared to subjects without hypertension and 
their median (IQR) levels are shown in Table 23.   
 
5.3.4 Associations between inflammatory and haemostatic 
markers with CVD at baseline 
In general, plasma biomarkers were elevated in people suffering from CVD at 
baseline. Table 24 lists median (interquartile range) in the group of people with MI 
and/ or angina and stroke compared to those who were healthy (no MI, angina, stroke 
or IC at baseline). Inflammatory markers CRP, IL-6, ICAM-1 and VCAM-1 (p 
<0.01) were significantly elevated in the CHD group. These markers were also 
higher in subjects with stroke but only levels of IL-6 and VCAM-1 achieved 
statistical significance, probably due to the small sample size of the stroke group. For 
example median (IQR) of IL-6 2.03 (1.09, 2.97) in the group of people without 
baseline CVD but in those who had MI and/ or angina or stroke it was increased to 
3.20 (1.13, 5.27) and 2.29 (0.45, 4.14) respectively.  
 
Similarly, fibrinogen, D-dimer and t-PA were significantly higher in subjects 
suffering from MI and/ or angina or stroke compared to the group that were free of 
CVD at baseline (p <0.01). vWF (p <0.01) was significantly elevated in subjects with 
MI and/ or angina only. When the group of subjects with either MI or angina was 
divided to those with MI only or angina only, CRP, IL-6, VCAM-1, fibrinogen, D-
dimer and vWF (p <0.01) were significantly elevated in either the MI or the angina 
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group compared to the healthy group. Nevertheless, t-PA (p <0.01) and ICAM-1 
(p<0.05) were significantly higher in the group suffering from angina only and their 
median (IQR) was 7.98 (5.56, 10.4) and 134 (99, 168) respectively. 
   
Furthermore, in the 73 subjects suffering from IC at baseline, CRP (p < 0.001), IL-6 
(p <0.001), ICAM-1 (p =0.03), VCAM-1 (p =0.04), fibrinogen (p <0.001), D-dimer 
(p <0.001) and vWF (p =0.08) were significantly elevated compared to the healthy 
group of no CVD disease at baseline (Table 24). When individuals were classified as 
worsening PAD: from normal, asymptomatic (ABI  0.9) to symptomatic (WHO 
questionnaire) a significant trend was found between higher plasma levels of 
inflammatory markers: CRP (p <0.001), IL-6 (p <0.001), ICAM-1 (p <0.01) and 
VCAM-1 (p =0.03) (Table 25). In addition, haemostatic markers fibrinogen 
(p <0.001), D-dimer (p <0.001), t-PA (p <0.001) and vWF (p =0.008) displayed a 
significant trend across worsening PAD (Table 25). 
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CRP: C-reactive protein, IL-6: interleukin-6, ICAM-1: intercellular 
adhesion molecule 1, VCAM-1 : vascular adhesion molecule 1,  
t-PA: tissue plasminogen activator 1, vWF : vonWillebrand factor,  



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 20 Levels of inflammatory and haemostatic markers according to smoking status at baseline 
Ever Smokers Never smokers  






Inflammatory markers  
CRP (mg/L)  2.21 (1.02, 4.65) 1.40 (0.75, 2.91) < 0.001 
IL-6 (pg/mL) 2.35 (1.59, 3.96) 1.80 (1.20, 3.06) < 0.001 
ICAM-1 (ng/mL) 229 (195, 275) 203 (195, 275) < 0.001 
VCAM-1 (ng/mL) 368 (322, 433) 373 (330, 436) 0.65 
E-selectin (ng/mL)  42 (31, 51) 40 (31, 51) 0.39 
Haemostatic markers  
Fibrinogen (g/L) 2.71 (2.28, 3.20) 2.55 (2.13, 2.94) < 0.001 
D-dimer (ng/mL) 87 (59, 126) 80 (58, 116) 0.40 
t-PA (ng/mL) 7.60 (5.60, 10.00) 6.50 (4.90, 9.00) < 0.001 
vWF (IU/dl) 109 (82, 143) 103 (78, 133) 0.01 
Factor VII (IU/dl) 91 (69, 115) 90 (71, 119) 0.20 
F1+2  (ng/mL) 1.73 (1.35, 2.14) 1.66 (1.32, 2.12) 0.58 
FpA (nmol/L) 1.50 (1.00, 2.00) 1.30 (1.00, 1.80) 0.001 
CRP: C-Reactive Protein, IL-6: Interleukin-6, ICAM-1: Intracellular Adhesion 
Molecule-1, VCAM-1: Vascular Adhesion Molecule-1, t-PA: tissue plasminogen, 
vWF: vonWillebrand factor, FpA: fibrinopeptide A, F1+2: prothrombin fragments 1+2. 
† p value between ever and never smokers calculated with the t-test using 




Table 21 Levels of inflammatory and haemostatic markers according to diabetes status at 
baseline 
Normal Diabetes  






Inflammatory markers  
CRP (mg/L)  1.80 (0.87, 3.89) 3.35 (1.35, 5.36) 0.005 
IL-6 (pg/mL) 2.12 (1.41, 3.60) 2.61 (1.87, 4.00) 0.02 
ICAM-1 (ng/mL) 215 (187, 256) 238 (209, 311) < 0.001 
VCAM-1 (ng/mL) 370 (324, 432) 395 (354, 451) 0.001 
E-selectin (ng/mL)  41 (31, 51) 49 (36, 65) < 0.001 
Haemostatic markers  
Fibrinogen (g/L) 2.63 (2.23, 3.10) 2.73 (2.12, 2.32) 0.33 
D-dimer (ng/mL) 83 (58, 123) 90 (65, 126) 0.25 
t-PA (ng/mL) 7.10 (5.00, 9.50) 8.95 (7.00, 10.60) < 0.001 
vWF (IU/dl) 106 (80, 139) 127 (98, 158) < 0.001 
Factor VII (IU/dl) 90 (70, 115) 91 (67, 131) 0.57 
F1+2  (ng/mL) 1.70 (1.33, 2.12) 1.64 (1.36, 2.24) 0.10 
FpA (nmol/L) 1.4 (1.0, 2.0) 1.5 (1.0, 2.1) 0.80 
CRP: C-Reactive Protein, IL-6: Interleukin-6, ICAM-1: Intracellular Adhesion 
Molecule-1, VCAM-1: Vascular Adhesion Molecule-1, t-PA: tissue plasminogen, 
vWF: vonWillebrand factor, FpA: fibrinopeptide A, F1+2: prothrombin fragments 1+2. 
† p values between subjects with and without diabetes calculated with the t-test using 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 Normal blood pressure  






Inflammatory markers  
CRP (mg/L)  2.16 (1.01, 3.97) 1.54 (0.76, 3.63) < 0.001 
IL-6 (pg/mL) 2.34 (1.53, 4.32) 1.93 (1.29, 3.18) < 0.001 
ICAM-1 (ng/mL) 223 (194, 265) 210 (182, 250) 0.002 
VCAM-1 (ng/mL) 386 (335, 447) 356 (315, 413) 0.001 
E-selectin (ng/mL)  42 (31, 53) 39 (30, 51) 0.05 
Haemostatic markers  
Fibrinogen (g/L) 2.69 (2.28, 3.20) 2.58 (2.17, 2.94) < 0.001 
D-dimer (ng/mL) 92 (59, 126) 75 (51, 116) < 0.001 
t-PA (ng/mL) 7.80 (5.60, 10.00) 6.50 (4.70, 9.00) < 0.001 
vWF (IU/dl) 109 (83, 145) 104 (78, 133) < 0.001 
Factor VII (IU/dl) 92 (70, 119) 89 (70, 119) 0.10 
F1+2  (ng/mL) 1.72 (1.35, 2.22) 1.66 (1.32, 2.12) 0.01 
FpA (nmol/L) 1.40 (1.00, 2.00) 1.50 (1.00, 1.80) 0.90 
CRP: C-Reactive Protein, IL-6: Interleukin-6, ICAM-1: Intracellular Adhesion 
Molecule-1, VCAM-1: Vascular Adhesion Molecule-1, t-PA: tissue plasminogen, 
vWF: vonWillebrand factor, FpA: fibrinopeptide A, F1+2: prothrombin fragments 1+2. 
† defined as systolic blood pressure 140 mmHg or diastolic blood pressure  90 
mmHg or use of drugs to lower blood pressure. 
‡ between subjects with hypertension and normal blood pressure calculated with the 




Table 24 Levels of inflammatory and haemostatic markers according to cardiovascular disease 
status at baseline 








Inflammatory markers   
CRP (mg/L)  3.20 (1.13, 5.27)** 2.29 (0.45, 4.14) 1.68 (0.27, 3.09) 
IL-6 (pg/mL) 3.02 (1.52, 4.52)** 3.34 (2.38, 3.20)** 2.03 (1.09, 2.97) 
ICAM-1 (ng/mL) 230.0 (188, 272)** 235.0 (195.5, 274.5) 214.0 (179, 249) 
VCAM-1 (ng/mL) 389.0 (321, 457)** 404.0 (348.2, 459.7)* 368.0 (315.5, 420.5) 
E-selectin (ng/mL) 42.0 (30.0, 50.0) 44.0 (32, 56) 41.0 (30.5, 51.5) 
Haemostatic markers   
Fibrinogen (g/L) 2.88 (2.45, 3.31)** 2.89 (1.44, 3.49)** 2.60 (2.17, 3.03) 
D-dimer (ng/mL) 101.5 (55.6, 157.1)** 103.5 (64.6, 142.4)** 80.0 (50.5, 109.5) 
t-PA (ng/mL) 8.10 (5.86, 10.35)** 9.7 (8.6, 11.9)** 7.0 (5.85, 9.15) 
vWF (IU/dl) 123.0 (92.2, 153.7)** 118.5 (94.6, 142.4) 104.0 (74.5, 133.5) 
Factor VII (IU/dl) 91 (63, 119) 102.0 (61.5, 142.5) 90.0 (67.0, 123.0) 
F1+2  (ng/mL) 1.75 (1.31, 2.18) 1.65 (1.28, 2.02) 1.68 (1.28, 2.08) 
FpA (nmol/L) 1.50 (1.0, 2.0) 1.50 (0.9, 2.1)* 1.40 (1.35, 1.45) 
CRP: C-Reactive Protein, IL-6: Interleukin-6, ICAM-1: Intracellular Adhesion 
Molecule-1, VCAM-1: Vascular Adhesion Molecule-1, t-PA: tissue plasminogen, 
vWF: vonWillebrand factor, FpA: fibrinopeptide A, F1+2: prothrombin fragments 
1+2, MI: myocardial infarction 
† No MI, angina, stroke or IC at baseline. 
** p value for difference between MI and/or angina or stroke group with the healthy 
group < 0.01, p values have been calculated using the transformed distributions of 
inflammatory and haemostatic markers.  
* p value for difference between MI and/or angina or stroke group with the healthy 
group < 0.05 level, p values have been calculated using the transformed distributions of 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.4 Peripheral atherosclerosis measured by the ABI
This analysis describes the distribution of ABI at three time points along the follow 
up period and the mean ABI change along these periods.  
 
5.4.1 The ABI at three time points 
The ABI was measured at the baseline, 5 years and 12 years follow up of the 
Edinburgh Artery Study. Valid ABI measurements were available for 1,582 subjects 
(99% of participants) at baseline, for 1,081 subjects (93.1%) at the 5 year follow up 
and for 816 subjects (98.2%) at the 12 year follow up. Three, 5 and 8 subjects at 
baseline, 5 years and 12 years, respectively, had values of ABI above 1.50 and were 
excluded from all analyses due to probable arterial rigidity. However, those 3 
subjects with ABI >1.5 at baseline were not among those 5 with ABI >1.5 at 5 years. 
Similarly, those 5 with ABI >1.5 at 5 years were not among the 8 with ABI>1.5 at 12 
years.  
 
Figure 7 presents the frequency distributions of the ABI measured at each time point. 
It illustrates a negative skew of the ABI distributions which increases at each time 
point reflecting the presence and progression of peripheral atherosclerosis over time. 
In total, 747 subjects had valid ABI measurements at all three clinical examinations 
and their distributions were similar to those of subjects with measurement of ABI at 
each time point as shown in Figure 8.  
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5.4.2 Mean change in ABI after 5 and after 12 years 
The mean ABI declined over time (Figure 9). This drop was similar for all subjects 
measured at each time point and in the subgroup of subjects who had an ABI 
measured at all three time points (Table 26). In fact, the mean (SD) change from 
baseline to 5 years was -0.04 (0.18) in those 1,075 subjects who had measurement of 
ABI at baseline and 5 years and -0.03 (0.17) in 747 subjects who had ABI 
measurements at baseline, 5 and 12 years. The mean (SD) change from baseline to 
12 years examination was -0.06 (0.19) and -0.07 (0.19) in those 1,075 subjects who 
had measurement of ABI at baseline and 12 years and in those subjects who had ABI 
measurements at baseline, 5 and 12 years, respectively. (Table 26) All changes were 
statistically significant (p <0.001).  
 
Figure 10 shows the mean ABI (95% CI) for males and females separately. Females 
had consistently lower mean (SD) ABI at each time point (1.04 (0.13) at baseline, 
1.01 (0.15) at 5 years, 0.98 (0.16) at 12 years) compared to males (1.04 (0.13) at 
baseline, 1.01 (0.15) at 5 years, 0.98 (0.16) at 12 years). However, there were no 
statistically significant differences in mean ABI change after 5 and after 12 years 
between males and females. For the 382 females who have measures at all time 
points the mean change was -0.03 (0.16) after 5 years and -0.06 (0.18) after 12 years. 
On the other hand, the 365 males with ABI measurements at all 3 time points had 
mean change (SD) -0.04 (0.17) after 5 years and -0.06 (0.18) after 12 years.     
 
Finally, among the 747 subjects with valid ABI measurements across all clinical 
examinations, 10.3%, 16.3% and 22.6% had ABI  0.9 at baseline, 5 years and 12 
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years respectively. Also, 670 of the 747 subjects had normal ABI at baseline (ABI 
>0.9) and of those the ABI declined below 0.9 in 89 (13.3%) at 5 year examination 
and in 124 (18.5%) at 12 years examination. 
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Figure 7 Frequency distribution of ankle brachial index (ABI) of all subjects who participated 




Figure 8 Frequency distribution of ankle brachial index (ABI) at baseline, 5 years and 12 years 
examination of the 747 subjects who participated in all examinations 
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Figure 9 Mean ankle brachial index (ABI) (95% CI) of the 754 subjects who had measures of 
ABI at baseline, 5 and 12 years examination 
 
 
Table 26 Mean (SD) ankle brachial index (ABI) and mean (SD) ABI change between baseline, 5 
years and 12 years of follow up both in subjects with ABI at each time point and in 747 subjects 
with an ABI at all time points 
Subjects with ABI  
at each time point 
Subjects with ABI  
at all time points 
 
N Mean (SD) N Mean (SD) 
ABI baseline 1,579 1.03 (0.18) 747 1.07 (0.14) 
ABI 5 years 1,076 1.02 (0.17) 747 1.04 (0.16) 
ABI 12 years 805 1.00 (0.19) 747 1.01 (0.19) 
 









ABI change at 12 years 804 -0.07 (0.18)** 747 -0.06 (0.18)** 
** p value for change  0.001 
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Figure 10 Mean ankle brachial index (ABI) (95% CI) of the 365 males and 382 females that had 








5.5 Cardiovascular risk factors and progressive 
peripheral atherosclerosis 
This part describes the associations between cardiovascular risk factors measured at 
baseline and progression of peripheral atherosclerosis measured by the ABI decline 
after 5 and after 12 years of follow up.   
 
5.5.1 Cardiovascular risk factors and baseline ABI 
Traditional cardiovascular risk factors including cholesterol, ratio of total to HDL 
cholesterol and pack years of smoking were strongly and significantly (p <0.001) 
associated with baseline ABI. Pearson correlation coefficients are listed in Table 27. 
Also, baseline ABI was lower in subjects with diabetes (p <0.001) and mean (SD) 
0.97 (0.26) compared to 1.04 (0.17) in subjects with normal glucose levels. Mean 
(SD) ABI was 0.98 (0.19) in subjects who were self-reported as having no physical 
activity, 1.02 (0.18) in subjects with light activity, 1.04 (0.18) in subjects with 
moderate activity and 1.07 (0.18) in subjects with strenuous activity. This decrease in 
ABI across decreasing physical activity categories had a statistically significant trend 
(p for trend <0.001). No clear associations with BMI were observed.     
 
5.5.2 Cardiovascular risk factors and ABI decline after 5 
and after 12 years 
Conventional cardiovascular risk factors were associated with ABI measured at 5 and 
12 years and with ABI decline (Table 27, Table 28). Table 28 lists the correlation 
coefficients adjusted for baseline ABI between risk factors and ABI after 5 and 12 
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years. Cholesterol levels and smoking were significantly associated with decline in 
ABI. However, BMI did not show any significant correlations. Subjects with 
diabetes had mean (95% CI) ABI change after 12 years -0.10 (-0.16, -0.03) and those 
without -0.07 (-0.08, -0.05) (p for difference not significant). Table 29 presents the 
results of linear regression for ABI change after 12 years adjusted for baseline ABI. 
In univariable analysis, age, sex, total/ HDL cholesterol ratio, smoking and baseline 
CVD were significantly associated with ABI decline. Most of these associations 
were strengthened in multivariable (adjusting for all factors) analysis. Similar 
patterns were seen in regression analyses with ABI change after 5 years as the 
outcome variable. However, due to smaller mean ABI change at 5 years the effect of 
each predictor variable was reduced.  
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Table 27 Pearson correlation coefficients between baseline cardiovascular risk factors and ankle 
brachial index (ABI) measured at baseline, 5 and 12 years after follow up 
 ABI baseline ABI 5 years ABI 12 years 
Age (years) -0.18 -0.19 -0.21 
Pack years smoking (
) -0.22 -0.09 -0.17 
BMI (kg/m
2
) 0.02 0.05 0.01 
Total cholesterol (mmol/L) -0.12 -0.15 -0.16 
HDL cholesterol (mmol/L) 0.05 -0.04 0.03 
Total/ HDL cholesterol -0.10 -0.06 -0.12 
Correlation coefficient in bold are significant at 0.01 level. 
 
Table 28 Pearson correlation coefficients adjusted for baseline ankle brachial index (ABI) 
between baseline cardiovascular risk factors and ABI change after 5 and after 12 years of follow 
up 
 ABI change after 5 years ABI change after 12 years 
Age (years) -0.12 -0.20 
Pack years smoking (
) 0.01 -0.11 
BMI (kg/m
2
) 0.06 0.05 
Total cholesterol (mmol/L) -0.10 -0.08 
HDL cholesterol (mmol/L) -0.04 0.03 
Total/ HDL cholesterol -0.02 -0.08 
Correlation coefficient in bold are significant at 0.01 level 
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Table 29 Regression coefficient (95% CI) of cardiovascular risk factors for change in ankle 
brachial index (ABI) after 12 years  
ABI change after 12 years adjusted for baseline ABI  
Univariable Multivariable 
Age (years) -0.006 (-0.009, -0.004)** -0.006 (-0.009, -0.004)**
Sex (males vs. females) -0.031 (-0.056, -0.006)** -0.064 (-0.093, -0.040)** 




-0.038 (-0.057, -0.014)** -0.052 (-0.075, -0.028)** 
BMI (top vs. bottom tertile)
†
 0.005 (-0.003, 0.015) 0.008 (0.0001, 0.020)* 
Diabetes (yes vs. no) -0.034 (-0.101, 0.033) -0.031 (-0.097, 0.034) 
Total/ HDL cholesterol 
(top vs. bottom tertile)
†
 
-0.014 (-0.024, -0.004)* -0.016 (-0.028, 0.005)** 
MI, stroke or angina 
(yes vs. no) 
-0.076 (-0.119, -0.033)** -0.052 (-0.093, -0.011)* 
Physical activity 
(strenuous vs. no activity) 
0.003 (-0.024, 0.086) 0.010 (-0.046, 0.066) 
† variables have been fitted as continuous in the model and regression coefficients 
have been multiplied by the inter-tertile range (difference between the bottom and 
top tertile) to represent difference between top and bottom tertile of the distribution. 
** p value significant at 0.01 level, * p value significant at 0.05 level. 
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5.6 Inflammatory markers and progressive peripheral 
atherosclerosis 
This part describes the associations between inflammatory markers measured at 
baseline and progression of peripheral atherosclerosis measured with ABI decline 
after 5 and after 12 years of follow up.   
 
5.6.1 Associations with baseline ABI 
Baseline ABI was negatively associated with levels of CRP, IL-6 and ICAM-1 
(r= -0.17 and corresponding p value <0.001 using transformed distributions). 
VCAM-1 levels were modestly associated with baseline ABI (r= -0.06 and 
corresponding p value =0.04 using transformed distributions) and E-selectin did not 
show any significant associations. 
 
5.6.2 Univariable associations with ABI after 5 and 12 
years 
The mean ABI change from baseline to 5 and 12 years of follow up by tertiles of 
inflammatory marker levels is demonstrated graphically on Figure 11. Subjects with 
CRP, IL-6, ICAM-1 and VCAM-1 in the top tertile had a greater ABI decline by 5 
years compared to subjects in the bottom tertile. This difference became more 
prominent after 12 years of follow up. In fact, subjects in the bottom tertiles of CRP 
and IL-6 did not show any significant change in mean ABI between 5 and 12 years, 
whereas those in the middle and top tertiles of CRP and IL-6 showed further decline 
in mean ABI (mean (SD) ABI change -0.02 (0.19) and -0.04 (0.20) for top tertiles of 
CRP and IL-6 respectively). Substantial differences were also observed for ICAM-1. 
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After 12 years, the mean change (SD) in ABI from baseline for subjects in the 
bottom ICAM-1 tertile was -0.04 (0.18) while for those in the top tertile was -0.11 
(0.21). There was no evidence for a relationship between ABI change and E-selectin 
tertiles.    
 
5.6.3 Multivariable associations with ABI after 5 and 12 
years 
Separate linear regression analysis was performed for ABI change from baseline to 5 
years and from baseline to 12 years with each inflammatory marker as a predictor 
variable (Table 30). CRP and IL-6 were significant predictors of ABI change at 5 
years (CRP: p= 0.03, IL-6: p 0.001) and at 12 years of follow up (CRP: p= 0.002, 
IL-6: p 0.001) in analysis adjusted for both age and for baseline ABI. Little change 
in these associations was found after adjusting for baseline ABI and risk factors: age, 
sex, pack years of smoking, diabetes, total/ HDL cholesterol ratio, BMI, physical 
activity and history of CVD. However, CRP had borderline non-significant (p= 0.08) 
associations with ABI at 5 years in risk factor adjusted analysis. ICAM-1 was 
significantly inversely associated with ABI change at 5 years (p= 0.02) and at 12 
years follow up (p 0.001) in analysis adjusted for age and baseline ABI. On further 
adjustments for baseline risk factors, ICAM-1 remained an independent predictor of 
ABI change at 12 years (p= 0.01) only.   
 
To compare the effects of each marker on ABI change standardised regression 
coefficients representing the differences in ABI decline between the top and bottom 
tertiles of each marker are shown in Table 30. The magnitude of this difference up to 
5 years of follow up was greatest for IL-6. However, at 12 years, increased levels of 
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CRP, IL-6 and ICAM-1 had effects of similar strength on ABI change. Moreover, to 
examine the simultaneous effect of all inflammatory markers on ABI change at 5 and 
12 years, linear regression was used with all inflammatory markers and baseline risk 
factors simultaneously entered into the model. In this final analysis, IL-6 was the 
only significant inflammatory marker that independently predicted ABI change at 5 
years (p= 0.002) and at 12 years (p= 0.02) and the difference (95% CI) in ABI 
decline between subjects in the top and bottom tertiles of IL-6 was -0.017 (-0.120, 
-0.008) and -0.016 (-0.034, -0.001) at 5 and 12 years respectively (Table 31).  
 
Finally, the possible effect modification between each marker and sex or age was 
tested by fitting interaction terms for age or sex and each inflammatory marker. None 
of the interaction terms tested were statistical significant. 
 
5.6.4 Repeated measures analysis  
The aforementioned analysis was also confirmed by mixed model analysis for 
repeated measures of ABI. In this analysis, only subjects with ABI measurements at 
all three time points were included. The interaction term of inflammatory markers 
with follow up time (baseline, 5 or 12 years) was examined. A compound symmetry 
covariance structure was used since more complex patterns did not lead to any 
significant improvements in the likelihood function. Using this covariance pattern, 
levels of IL-6 and ICAM-1 showed a significant interaction term with time (baseline, 
5 and 12 years) in both age and sex adjusted (p=0.02 and p=0.008) and in risk factors 
adjusted analyses (p=0.03 and p=0.02).  
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5.6.5 Sensitivity analysis 
Finally, subgroup analysis of those 1,273 subjects with normal ABI (ABI>0.9) and 
no PAD at baseline was performed. In this subgroup, the odds ratio for transition 
from normal (ABI >0.9) to low ABI (ABI  0.9) was calculated. Results are listed in 
Table 32. The odds ratios were calculated for each inflammatory marker unadjusted 
and adjusted for age and sex and then for cardiovascular risk factors. Table 32 lists 
the odds ratios standardised to represent differences between top and bottom tertile 
of each marker for crude and age and sex adjusted analyses. Crude odd ratios for 
CRP, IL-6 and ICAM-1 were significant showing that people with normal ABI but 
with any of these markers in the top tertile were at increased risk of having an ABI  
0.9 after 5 and 12 years. However, subsequent adjustments for risk factors attenuated 
the odds ratios which all became non-significant, probably due to the small sample 
size of this analysis.  
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Figure 11 Mean (± 1SE) of ankle brachial index (ABI) change from baseline to 5 years and to 12 
years of follow up across tertiles of C-reactive protein (CRP), interleukin-6 (IL-6), soluble 





























(c) ICAM-1 tertiles 
(a) CRP tertiles (b) IL-6 tertiles 
(d) VCAM-1 tertiles 
(e) E-selectin tertiles 
Bottom tertile (), Middle 
tertile () and Top tertile (	). 
Cut-off points for tertiles were 
1.11 and 2.88 mg/L for CRP, 
1.65 and 2.96 pg/ml for IL-6, 
197 and 242 ng/ml for ICAM-1, 
341 and 410 ng/ml for 
VCAM-1 and 34 and 48 ng/ml 
for E-selectin. 
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Table 30 Multiple regression for ankle brachial index (ABI) change from baseline to 5 years and 
to 12 years of follow up and inflammatory markers 
 Standardised difference (95% CI) in ABI change between 
the top and bottom tertiles of inflammatory markers
 †
 
  Baseline to 5 years Baseline to 12 years 
 Adjusted for baseline ABI and age 
CRP  -0.013 (-0.025, -0.001)* -0.022 (-0.036, -0.008)** 
IL-6  -0.018 (-0.028, -0.009)** -0.023 (-0.034, -0.011)** 
ICAM-1  -0.010 (-0.017, -0.002)* -0.021 (-0.031, -0.011)** 
VCAM-1  -0.005 (-0.014, 0.004) -0.010 (-0.021, 0.001) 
E-selectin  -0.001 (-0.011, 0.008) -0.009 (-0.021, 0.002) 
  
Adjusted  for baseline ABI, risk factors and CVD
§ 
CRP  -0.011 (-0.024, -0.001)* -0.018 (-0.034, -0.004)** 
IL-6  -0.017 (-0.027, -0.007)** -0.019 (-0.031, -0.007)** 
ICAM-1  -0.006 (-0.014, 0.003) -0.014 (-0.024, -0.003)** 
VCAM-1  -0.004 (-0.014, 0.005) -0.008 (-0.019, 0.002) 
E-selectin  -0.003 (-0.013, 0.006) -0.011 (-0.022, 0.0004) 
CRP: C-Reactive Protein, IL-6: Interleukin-6, ICAM-1: Intracellular Adhesion 
Molecule-1, VCAM-1: Vascular Adhesion Molecule-1. 
†Regression coefficients have been multiplied by the inter-tertile range (difference 
between the logarithmically transformed bottom and top tertile).  
** p value significant at 0.01 level, * p value significant at 0.05 level. 
§ adjusted for age, sex, pack years of smoking, diabetes, BMI, total/ HDL cholesterol 
ratio, physical activity and history of CVD. 
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Table 31 Multiple regression for ankle brachial index (ABI) change from baseline to 5 years and 
to 12 years of follow up and inflammatory markers entered simultaneously in the model 
Standardised difference (95% CI) in ABI change between the 




 Baseline to 5 years Baseline to 12 years 
 Adjusted for baseline ABI and age 
CRP  0.002 (-0.013, 0.017) 0.001 (0.017, 0.019) 
IL-6  -0.020 (-0.035, 0.005)** -0.019 (0.036, -0.002)* 
ICAM-1  -0.003 (-0.015, 0.009) -0.022 (0.037, -0.007) 
VCAM-1  -0.003 (-0.018, 0.011) 0.0004 (0.017, 0.018) 
E-selectin  0.012 (-0.002, 0.025) 0.006 (0.011, 0.022) 
  
Adjusted  for baseline ABI, risk factors and CVD
§ 
CRP  -0.001 (0.017, 0.015) 0.001 (0.018, 0.020) 
IL-6  -0.018 (0.033, 0.003)* -0.016 (0.034, -0.001)* 
ICAM-1  0.002 (0.011, 0.015) -0.014 (0.030, 0.003) 
VCAM-1  -0.004 (0.019, 0.010) -0.001 (0.019, 0.017) 
E-selectin  0.006 (0.009, 0.020) 0.0002 (0.018, 0.017) 
CRP: C-Reactive Protein, IL-6: Interleukin-6, ICAM-1: Intracellular Adhesion 
Molecule-1, VCAM-1: Vascular Adhesion Molecule-1. 
†Regression coefficients have been multiplied by the inter-tertile range (difference 
between the logarithmically transformed bottom and top tertile). 
** p value significant at 0.01 level, * p value significant at 0.05 level. 
§ adjusted for age, sex, pack years of smoking, diabetes, BMI, total/ HDL cholesterol 










Table 32 Odds ratios for transition from normal baseline ankle brachial index (ABI) (ABI>0.9) 
to low ABI (ABI  0.9) at 5 and 12 years 
Odds ratio
†
 (95% CI) for ABI transition from normal to low 
between top and bottom tertile of each marker 
 
 Baseline to 5 years Baseline to 12 years 
 Crude 
CRP  1.22 (1.07, 1.52)** 1.33 (1.06, 1.68)** 
IL-6  1.28 (1.07, 1.52)** 1.22 (1.01, 1.47)* 
ICAM-1  1.18 (1.03, 1.36)* 1.24 (1.06, 1.45)** 
VCAM-1  1.07 (0.89, 1.28) 1.06 (0.87, 1.29) 
E-selectin  1.05 (0.88, 1.26) 1.03 (0.84, 1.25) 
  
Adjusted  for age and sex 
CRP  1.11 (0.89, 1.38) 1.23 (0.97, 1.57) 
IL-6  1.25 (1.04, 1.51)* 1.17 (0.96, 1.43) 
ICAM-1  1.14 (0.99, 1.32) 1.22 (1.03, 1.43) 
VCAM-1  0.99 (0.82, 1.19) 0.97 (0.79, 1.20) 
E-selectin  1.10 (0.91, 1.33) 1.09 (0.88, 1.34) 
CRP: C-Reactive Protein, IL-6: Interleukin-6, ICAM-1: Intracellular Adhesion 
Molecule-1, VCAM-1: Vascular Adhesion Molecule-1. 
†Regression coefficients have been multiplied by the inter-tertile range (difference 
between the logarithmically transformed bottom and top tertile).  
** p value significant at 0.01 level, * p value significant at 0.05 level.
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5.7 Haemostatic markers and progressive peripheral 
atherosclerosis 
This part describes the associations between haemostatic markers measured at 
baseline and progression of peripheral atherosclerosis measured with ABI decline 
after 5 and after 12 years of follow up.   
 
5.7.1 Associations with baseline ABI 
Transformed levels of fibrinogen and D-dimer were strongly and negatively 
associated with baseline ABI with Pearson correlation coefficients -0.23 (p <0.001) 
and -0.26 (p <0.001) respectively. Levels of t-PA and vWF were also negatively 
associated with baseline ABI (Pearson correlation coefficients -0.10 and p <0.001 
using the transformed distributions) whereas factor VII, F1+2 and FpA had non-
significant associations.  
 
5.7.2 Associations with ABI after 5 and 12 years 
The mean ABI change from baseline to 5 and 12 years of follow up by tertiles of 
haemostatic markers levels is demonstrated graphically in Figure 12. Decline of ABI 
after 5 years showed weak associations with increasing tertiles of t-PA, vWF, factor 
VII and FpA but not for fibrinogen, D-dimer and F1+2. The mean change in ABI 
after 12 years was generally greater in subjects falling in the top tertiles of 
fibrinogen, D-dimer, t-PA, factor VII and FpA than in subjects falling in the bottom 
tertiles of these markers. Also, subjects in the top tertile of fibrinogen, D-dimer and 
t-PA showed substantial drop in their mean ABI from 5 to 12 years compared to 
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those falling in the top tertile. For example people falling in the bottom tertile of 
D-dimer at baseline had mean (SD) ABI change -0.03 (0.18) after 5 years and -0.01 
(0.20) further mean ABI decline from 5 to 12 years. On the other hand, people falling 
in the top tertile of D-dimer at baseline had mean (SD) ABI change -0.03 (0.19) after 
5 years and -0.06 (0.21) further mean ABI decline from 5 to 12 years. 
 
5.7.3 Multivariable associations with ABI after 5 and 12 
years 
Separate linear regression analysis for ABI change from baseline to 5 and to 12 years 
with each haemostatic factor as a predictor variable (Table 33) was performed. To 
allow comparisons between markers, Table 33 presents the mean difference (95% 
CI) between the top and bottom tertiles of each marker on ABI change.  
 
None of the haemostatic variables significantly predicted ABI decline after 5 years. 
Associations were in the expected direction but they did not reach statistical 
significance. Fibrinogen (p  0.001) and D-dimer (p  0.001) were significantly 
associated with ABI change after 12 years in analyses adjusted for baseline ABI and 
baseline age. However, D-dimer had a marginally greater effect with mean difference 
(95% CI) between top and bottom tertile of -0.017 (-0.029, -0.006). Moreover, in 
analyses adjusted for baseline ABI, conventional risk factors (age, sex, BMI, 
diabetes, pack years of smoking, total/ HDL cholesterol ratio, physical activity) and 
baseline CVD, D-dimer remained significantly and independently associated with 
ABI change (p = 0.003). Nevertheless, its effect was reduced and the mean (95 % CI) 
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difference between tertiles was -0.015 (-0.027, -0.004). Fibrinogen had borderline 
significance (p= 0.05) in this risk factor adjusted analysis.  
 
Next, the corresponding effect of all haemostatic markers on ABI change at 5 and at 
12 years was examined by entering all haemostatic markers simultaneously into the 
linear regression model (Table 34). In the analysis for change after 12 years, D-dimer 
(p= 0.015) and fibrinogen (p= 0.025), were significantly and independently 
associated with ABI change. When further adjustments for known risk factors were 
performed, only D-dimer was significantly associated with ABI change 
independently of other haemostatic markers and cardiovascular risk factors. Mean 
(95% CI) difference in ABI change between top and bottom tertiles of D-dimer in 
this final analysis was -0.021 (-0.038, -0.004). A significant result was also found for 
FpA in the 5 years analysis. Given the fact that FpA did not show any associations 
with ABI even in the cross-sectional analysis, this result is probably a statistical 
artefact.  
 
Finally, the possible effect modification between each haemostatic markers and sex 
or age was tested by fitting interaction terms for age or sex and each haemostatic 
factor. None of the interaction terms tested were statistical significant. 
 
5.7.4 Repeated measures analysis 
The aforementioned analysis was also confirmed by mixed model analysis of 
repeated measures of ABI as was previously done for inflammatory markers. In this 
analysis, only subjects with ABI measurements at all three time points were 
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included. The interaction term of haemostatic markers with follow up time (baseline, 
5 or 12 years) was examined. A compound symmetry covariance structure was used 
since more complex patterns did not lead to any significant improvements in the 
likelihood function. Using this covariance pattern, levels of fibrinogen and D-dimer 
showed a significant interaction with time of ABI measurement (baseline, 5 and 12 
years) in both age and sex adjusted (p=0.01 and p=0.006) and in risk factors adjusted 
analysis (p=0.02 and p=0.006).  
 
5.7.5 Sensitivity analysis 
Subgroup analysis of those 1,273 subjects with normal ABI (ABI>0.9) and no PAD 
at baseline was performed. In this subgroup the odds ratio for transition from normal 
(ABI>0.9) to low ABI (ABI  0.9) was calculated. Results in Table 23 show the 
standardised odds ratios for ABI transition between the top and bottom tertile of each 
marker. The odds ratios were calculated for each haemostatic factor unadjusted and 
adjusted for age and sex and then cardiovascular risk factors. Odds ratios of 
fibrinogen, D-dimer and t-PA were statistically significant for ABI transition from 
normal to low after 5 and after 12 years. Subsequent adjustments for risk factors 
attenuated these associations.  
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Figure 12 Mean (± 1SE) of ankle brachial index (ABI) change from baseline to 5 years and to 12 
years of follow up across tertiles of fibrinogen, D-dimer, tissue plasminogen activator (t-PA), 








(a) Fibrinogen tertiles 
(d) vWF tertiles 
(b) D-dimer tertiles 
(c) t-PA tertiles 
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Bottom tertile (), Middle tertile () and Top tertile (	). Cut off point for tertiles: 
2.38-2.92 g/L for fibrinogen, 67-107 ng/mL for D-dimer, 6.0-8.8 ng/mL for t-PA, 89-
129 IU/dl for vWF, 77-105 IU/dl for Factor VII, 1.48-1.95 ng/mL for F1+2, 1.00-





  (f) F1+2 tertiles 
  (g) FpA tertiles 
  (e) Factor VII 
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Table 33 Multiple regression for ankle brachial index (ABI) change from baseline to 5 years and 
to 12 years of follow up and haemostatic markers 
Standardised difference (95% CI) in ABI change between 




 Baseline to 5 years Baseline to 12 years 
 Adjusted for baseline ABI and age 
Fibrinogen -0.001(-0.009, 0.008) -0.016 (-0.026, -0.006)** 
D-dimer -0.001 (-0.011, 0.008) -0.017 (-0.029, -0.006)** 
t-PA -0.003 (-0.013, 0.008) -0.001 (-0.022, 0.003) 
vWF -0.001 (-0.008, 0.006) 0.005 (-0.004, 0.013) 
Factor VII -0.001 (-0.011, 0.009) 0.006 (-0.006, 0.018) 
F1+2 -0.006 (-0.015, 0.003) -0.008 (-0.019, 0.004) 
FpA -0.009 (-0.020, 0.003) -0.004 (-0.020, 0.012) 
 Adjusted  for baseline ABI, risk factors and CVD
§ 
Fibrinogen  0.003 (-0.009, 0.008) -0.010 (-0.021, -0.001)* 
D-dimer -0.001 (-0.011, 0.008) -0.015 (-0.027, -0.004)** 
t-PA -0.005 (-0.016, 0.006) -0.008 (-0.022, 0.005) 
vWF  0.004 (-0.006, 0.007) 0.007 (-0.001, 0.016) 
Factor VII -0.006 (-0.010, 0.009) 0.009 (-0.003, 0.022) 
F1+2 -0.006 (-0.015, 0.003) -0.008 (-0.019, 0.004) 
FpA -0.009 (-0.021, 0.002) -0.005 (-0.020, 0.010) 
t-PA: tissue plasminogen, vWF: vonWillebrand factor, FpA: fibrinopeptide A, F1+2: 
prothrombin fragments 1+2. 
†Regression coefficients have been multiplied by the inter-tertile range (difference 
between the logarithmically transformed bottom and top tertile).  
** p value significant at 0.01 level, * p value significant at 0.05 level. 
§ adjusted for age, sex, pack years of smoking, diabetes, BMI, total/ HDL cholesterol 
ratio, physical activity and history of CVD. 
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Table 34 Multiple regression for ankle brachial index (ABI) change from baseline to 5 years and 
to 12 years of follow up with all haemostatic markers entered simultaneously in the model 
Standardised difference (95% CI) in ABI change between the 
top and bottom tertiles of haemostatic factor* 
 
 Baseline to 5 years Baseline to 12 years 
 Adjusted for baseline ABI and age 
Fibrinogen -0.003 (-0.016, 0.011) -0.015 (-0.032, -0.002)* 
D-dimer -0.002 (-0.016, 0.012) -0.020 (-0.037, -0.003)* 
t-PA 0.007 (-0.003, 0.017) 0.010 (-0.003, 0.022) 
vWF -0.009 (-0.023, 0.005) -0.008 (-0.025, 0.009) 
Factor VII 0.002 (-0.010, 0.013) 0.012 (-0.002, 0.026) 
F1+2 -0.006 (-0.017, 0.004) -0.002 (-0.016, 0.012) 
FpA -0.023 (-0.042, -0.004)* -0.002 (-0.026, 0.022) 
 Adjusted  for baseline ABI, risk factors and CVD
§ 
Fibrinogen -0.002 (-0.016, 0.012) -0.012 (-0.028, 0.005) 
D-dimer -0.004 (-0.018, 0.010) -0.022 (-0.040, -0.005)* 
t-PA 0.010 (-0.0001, 0.020) 0.012 (-0.0001, 0.025) 
vWF -0.010 (-0.025, 0.005) -0.005 (-0.023, 0.014) 
Factor VII 0.0005 (-0.011, 0.012) 0.010 (-0.004, 0.025) 
F1+2 -0.005 (-0.016, 0.006) -0.002 (-0.016, 0.012) 
FpA -0.024 (-0.043, -0.005)* -0.002 (-0.025, 0.022) 
t-PA: tissue plasminogen, vWF: vonWillebrand factor, FpA: fibrinopeptide A, F1+2: 
prothrombin fragments 1+2. 
†Regression coefficients have been multiplied by the inter-tertile range (difference 
between the logarithmically transformed bottom and top tertile).  
** p value significant at 0.01 level, * p value significant at 0.05 level. 
§ adjusted for age, sex, pack years of smoking, diabetes, BMI, total/ HDL cholesterol 
ratio, physical activity and history of CVD. 
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Table 35 Odds ratio (95% CI) for transition from normal ABI at baseline (ABI>0.9) to low ABI  
(ABI  0.9) 
Odds ratio (95% CI) for ABI transition from normal to low 
between top and bottom tertile of each marker 
 
 Baseline to 5 years Baseline to 12 years 
 Crude 
Fibrinogen 1.17 (1.02, 1.36)*  1.25 (1.07, 1.47)** 
D-dimer 1.28 (1.09, 1.50)** 1.32 (1.11, 1.57)** 
t-PA 1.26 (1.06, 1.50)** 1.20 (1.00, 1.44)* 
vWF 1.09 (0.91, 1.29) 0.96 (0.78, 0.17) 
Factor VII 1.04 (0.88, 1.25) 1.03 (0.85, 1.24) 
F1+2 1.09 (0.92, 1.30) 1.17 (0.98, 1.41) 
FpA 1.14 (0.94, 1.38) 1.09 (0.86, 1.37) 
  
Adjusted  for age and sex 
Fibrinogen 1.06 (0.91, 1.47) 1.15 (0.97, 1.42) 
D-dimer 1.11 (0.93, 1.32) 1.15 (0.95, 1.39) 
t-PA 1.22 (1.02, 1.47) 1.17 (0.98, 1.35) 
vWF 0.98 (0.82, 1.17) 0.86 (0.69, 1.06) 
Factor VII 1.00 (0.83, 1.20) 0.97 (0.80, 1.18) 
F1+2 0.98 (0.82, 1.18) 1.07 (0.88, 1.30) 
FpA 1.13 (0.93, 1.97) 1.11 (0.87, 1.40) 
t-PA: tissue plasminogen, vWF: vonWillebrand factor, FpA: fibrinopeptide A, F1+2: 
prothrombin fragments 1+2. 
** p value significant at 0.01 level, * p value significant at 0.05 level.
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5.8 Additive effect of inflammatory and haemostatic 
markers on progressive peripheral 
atherosclerosis 
In this part, the additive effect between inflammatory variables, CRP and IL-6, and 
haemostatic variables fibrinogen and D-dimer was investigated.  
 
5.8.1 Independent and joint effect of CRP, IL-6, D-dimer 
and fibrinogen 
The previous analyses showed that the inflammatory markers, CRP and IL-6, and the 
haemostatic markers, fibrinogen and D-dimer, were significant and independent 
predictors of ABI decline, especially after the 12 years period. These four makers 
were subsequently compared and their additive effect was further investigated. Table 
36 (Model 1) shows the separate effect of each of these four variables on ABI change 
and the corresponding R
2
 in models adjusted for baseline ABI and age and further 
adjusted for cardiovascular risk factors and baseline CVD. IL-6 had marginally the 
greatest individual effect, explaining 23% of the variance in ABI change in the 
multivariable model. All four variables explained 23.4% of the variance in mean ABI 
change after 12 years of follow up in risk factor adjusted analysis (Table 36 (model 
2)). IL-6 was the only one of the four variables that was significantly (p= 0.03) 
associated with ABI changes independently of the other three variables, of 
cardiovascular risk factors and of baseline CVD.        
 
Then these variables were adjusted for each other and all possible combinations of 
them as predictors of ABI change were examined. Table 37 lists selected 
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combinations and shows that the joint effect of CRP and D-dimer on ABI change 
increased the variance explained by the model from 18.1% (when D-dimer was 
assessed alone) to 23.3% (Table 37). However, both CRP and D-dimer failed to 
retain their significant associations when they were adjusted for each other in risk 
factor adjusted analysis. Fibrinogen did not add to any other variable in any analysis 
as model 3 and 6 show in Table 37. On the other hand, the combined effect of IL-6 
and D-dimer further increased the R
2
 to 24 % (Model 4). This was the highest R
2
 
observed from all models that we examined, despite the fact that D-dimer was not 
significantly associated with ABI change in this model.  
 
5.8.2 Combined variables 
Finally, the combined effect of D-dimer and IL-6 and D-dimer and CRP on ABI 
change was investigated further since these combinations increased the R
2
 of each 
model. Individuals were divided into 4 mutually exclusive groups according to their 
baseline levels of D-dimer and IL-6:  levels of IL-6 and D-dimer in the top tertile 
(171 subjects), levels of IL-6 in the top tertile and levels of D-dimer in the middle or 
bottom tertile (180 subjects), levels of D-Dimer in the top tertile and levels of IL-6 in 
the middle or bottom tertile (170 subjects) and finally levels of both D-dimer and 
IL-6 in the middle or bottom tertile (506 subjects). Similarly 4 mutually exclusive 
groups for CRP and D-dimer were constructed. Here, 134 subjects had both D-dimer 
and CRP at the top tertile at baseline, 188 CRP only, 158 D-dimer only and 489 
subjects had none of these markers at the top tertile of their distribution.  
The unadjusted means (± 1SE) of ABI change of each of these four groups are 
presented in Figure 13 and Figure 14. A significant trend with subjects in the top 
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tertiles of both D-dimer and IL-6 having the greatest ABI decline was found in 
analysis adjusted for baseline ABI (p = 0.004) and further adjusted for cardiovascular 
risk factors (p = 0.04). Combined tertiles of CRP and D-dimer presented a less clear 
trend which was significant (p=0.01) in baseline ABI adjusted analysis only.    
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Table 36 Predicted mean (95% CI) difference in ABI change between subjects in the top and 
bottom tertiles of D-dimer, fibrinogen, CRP and IL-6   
ABI change after 12 years
†
 
(N= 547 - 706) 
 




Adjusted baseline ABI 
and baseline risk 
factors
‡






Model 1: Each marker individually 
 
 
Fibrinogen -0.016 (-0.026, -0.006)** 13.8% -0.010 (-0.021, -0.001)* 17.9% 
D-dimer  -0.017 (-0.029, -0.006)** 13.4% -0.015 (-0.027, -0.004)** 18.1% 
IL-6  -0.022 (-0.036, -0.008)** 18.3% -0.018 (-0.034, -0.004)** 23.0% 
CRP  -0.023 (-0.034, -0.011)** 16.9% -0.019 (-0.031, -0.007)** 21.6% 
  
Model 2: All markers simultaneously 
 
 
D-dimer -0.009 (-0.024, 0.005) -0.009 (-0.023, 0.006) 
Fibrinogen -0.003 (-0.019, 0.014)  0.006 (-0.010, 0.023) 
IL-6 -0.020 (-0.035, -0.002)* -0.020 (-0.033, -0.002)* 
CRP -0.003 (-0.021, 0.016) 
18.6% 
-0.002 (-0.021, 0.016) 
23.4% 
CRP: C-Reactive Protein, IL-6: Interleukin-6 
‡ age, sex, pack years of smoking, diabetes, BMI, total/ HDL cholesterol, physical 
activity and history of CVD. 
** p value significant at 0.01 level, * p value significant at 0.05 level. 
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Table 37 Predicted mean (95% CI) difference in ABI change between subjects in the top and 
bottom tertiles of D-dimer, fibrinogen, CRP and IL-6   
ABI change after 12 years
†
 
(N= 547 - 706) 
 




Adjusted baseline ABI 








Model 3: Fibrinogen and D-dimer simultaneously 
 
 
-0.012 (-0.023, 0.001) -0.007 (-0.018, 0.005) Fibrinogen 
D-dimer -0.014 (-0.026, -0.002)* 
14.1% 
-0.013 (-0.025, 0.002)* 
18.5% 
 
 Model 4: IL-6 and D-dimer simultaneously  
 
 
-0.017 (-0.031 –0.004)* -0.014 (-0.028, -0.001)* IL-6  
 
D-dimer -0.012 (-0.026, 0.001) 
19.3% 
-0.011 (-0.025, 0.002) 
24.0% 
  
Model 5: CRP and D-dimer simultaneously 
 
 
-0.012 (-0.027, 0.004) -0.007 (-0.024, 0.009) CRP 
 
D-dimer -0.016 (-0.030, -0.002)* 
18.4% 
-0.014 (-0.028, 0.0002) 
23.3% 
  
Model 6: IL-6 and fibrinogen simultaneously 
 
 
-0.017 (-0.031, -0.004)* -0.017 (-0.031, -0.003)* IL-6 
 
Fibrinogen -0.009 (-0.022, 0.004) 
18.5% 
-0.003 (-0.016, 0.010) 
23.0% 
CRP: C-Reactive Protein, IL-6: Interleukin-6. 
‡RF: age, sex, pack years of smoking, diabetes, BMI, total/ HDL cholesterol, 
physical activity and history of CVD. 
** p value significant at 0.01 level, * p value significant at 0.05 level. 
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Figure 13 Unadjusted mean (± 1SE) of ankle brachial index (ABI) change from baseline to 12 
years of follow up across combined tertiles of interleukin 6 (IL-6) and D-dimer 
 
None high D-dimer high 
only
IL-6 high only Both high



































Figure 14 Unadjusted mean (± 1SE) of ankle brachial index (ABI) change from baseline to 12 
years of follow up across combined tertiles of C-reactive protein (CRP) and D-dimer 
 
None high D-dimer high 
only
CRP high only Both high































None high: 506 subjects 
D-dimer high only: 170 subjects 
IL-6 high only: 180 subjects 
Both high: 171 subjects 
None high: 489 subjects 
D-dimer high only: 158 subjects 
CRP high only: 188 subjects 
Both high: 134 subjects 
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5.9 Inflammatory or haemostatic markers and 
progressive peripheral atherosclerosis according 
to cardiovascular risk factors status 
In this part, the effect of the aforementioned markers was further investigated in 
relation to baseline cardiovascular risk factors. From the previous analysis, ratio of 
total/ HDL cholesterol and smoking had greater effect in predicted ABI decline in 
multivariable analysis than other cardiovascular risk factors. Similarly, D-dimer, 
IL-6, CRP and to a lesser extent fibrinogen, had significant associations with ABI 
decline which were independent of conventional risk factors. Therefore, the effect of 
these markers on ABI change was investigated further according to baseline levels of 
cholesterol and smoking status.  
 
5.9.1 Cholesterol levels 
In order to examine the relative effect of fibrinogen, D-dimer, IL-6 and CRP in 
individuals with high vs. low cholesterol levels the baseline population was divided 
into two groups according to their ratio of total cholesterol to HDL cholesterol 
measured at baseline (below median and above median). The effect of each marker 
was then examined in each subgroup separately. Subjects with increased CRP levels 
(top tertile) showed substantial decline in ABI over time (12 years) (mean ABI 
change -0.12 (0.20)) when they had elevated total/ HDL cholesterol at baseline but 
not if their ratio levels were below the median (mean (SD) ABI change -0.06 (0.20)) 
(Figure 15).  
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The other markers showed comparable associations between increasing tertiles and 
ABI decline in both groups (total/ HDL cholesterol below median or above median). 
For example, mean (SD) ABI change after 12 years of follow up for the top tertile of 
IL-6 was -0.10 (0.17) for individuals with total/ HDL ratio below the median and 
-0.010 (0.19) for individuals with total/ HDL cholesterol above the median at 
baseline.  
 
Linear regression with each of these markers (CRP, IL-6, fibrinogen and D-dimer) as 
predictor variable in the two subgroups confirmed this descriptive analysis. The 
mean (95% CI) difference in ABI decline between people falling in the top and 
bottom tertile of CRP at baseline was -0.033 (-0.055, -0.010) (p=0.004) if they their 
total/ HDL cholesterol was above the median (analysis was adjusted for baseline ABI 
and age). On the contrary, if their total/ HDL cholesterol was below the median the 
effect CRP was not significant and the difference in ABI decline between people 
falling in the top and bottom tertile of CRP at baseline was 0.001 (-0.018, 0.020) 
(p=0.91) (Figure 16). Fibrinogen showed similar results since it failed to reach 
statistical significance in the group of people with total/ HDL cholesterol below the 
median (mean (95% CI) ABI decline between people falling in the top and bottom 
tertile 0.005 (-0.02, 0.010) p=0.49). On the other hand, in people with ratio of total 
over HDL cholesterol above the median, the mean (95% CI) ABI decline between 
people falling in the top and bottom tertile was -0.021 (-0.039, -0.007) (p=0.02) 
(analysis was adjusted for baseline ABI and age). 
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D-Dimer had smaller differences in its effect between people in the below or above 
the median of total/HDL cholesterol: mean (95% CI) ABI decline between people 
falling in the top and bottom tertile was -0.010 (-0.024, 0.007) (p=0.29) and -0.023 
(-0.040, -0.006) (p=0.01) respectively (analysis was adjusted for baseline ABI and 
age). 
 
Finally, for the IL-6, no apparent difference in its effect was found in people with 
high or low cholesterol ratio at baseline. For example, the mean (95% CI) difference 
in ABI decline (adjusted for baseline ABI and age) between people falling in the top 
and bottom tertile of IL6 at baseline was -0.015 (-0.032, 0.002) (p=0.09) and -0.019 
(-0038, -0.001) (p=0.04) when their total/ HDL cholesterol was above or below the 
median respectively.  
 
5.9.2 Smoking 
When the baseline population was divided into smokers (current and ex) and never 
smokers there considerable differences were seen in the effect of CRP and fibrinogen 
on ABI change (Figure 17). Less clear evidence for IL-6 and D-dimer was observed 
(Figure 17).  
  
All four variables had significant regression coefficients for ABI change after 12 
years when analysis was limited to those people who were current smokers or who 
were ex smokers at baseline. The corresponding regression coefficients representing 
the difference (95% CI) between top and bottom tertile in ABI change after 12 years 
of follow up for CRP and fibrinogen were: -0.027 (-0.047, -0.007) (p=0.01) and 
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-0.023 (-0.037, -0.009) (p=0.002) in analysis adjusted for baseline ABI and age, 
respectively. On the other hand, in never smokers, the corresponding regression 
coefficients for CRP and fibrinogen were -0.002 (-0.021, 0.021) (p=0.85) and -0.004 
(-0.019, 0.011) (p=0.60). IL-6 and D-dimer, although had significant and higher 
regression coefficient in analysis including only smokers they did not display 
considerable difference between the two groups. In detail, the regression coefficients 
representing the difference (95% CI) between top and bottom tertile in ABI change 
after 12 years of follow up for IL-6 and D-dimer were -0.020 (-0.038, -0.002) 
(p=0.027) and -0.017 (-0.033, -0.001) (p=0.04) in smokers and -0.012 (-0.030, 0.005) 
(p=0.15) and -0.014 (-0.031, 0.002) (p=0.10) in never smokers. 
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Figure 15 Mean changes in ankle brachial index (ABI) according to baseline levels of total/ HDL 












































Cut-off point for median total/ HDL cholesterol: 4.96, tertiles of CRP: 1.11 and 2.88 
mg/L, IL-6: 1.65 and 2.96 pg/mL, fibrinogen 2.38 and 2.92 g/L and D-dimer: 6.0 and 





















































































































Figure 16 Predicted mean (95% CI) difference in ankle brachial index (ABI) change between 
subjects in the top and bottom tertiles of C-reactive protein (CRP) according to baseline total/ 
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Figure 17 Mean changes in ankle brachial index (ABI) according to smoking status and 





Never smokers: 605 subjects, current/ ex smokers: 987 subjects, tertiles of CRP: 1.11 
and 2.88 mg/L, IL-6: 1.65 and 2.96 pg/mL, fibrinogen 2.38 and 2.92 g/L and D-
























































































































































5.10 Summary of results 
In the aforementioned analysis, inflammatory and haemostatic markers showed 
strong associations between them and with cardiovascular risk factors and CVD at 
baseline. These associations were stronger for CRP, IL-6, ICAM-1, fibrinogen, 
D-dimer and t-PA whereas E-selectin, factor VII, FpA and F1+2 showed in general 
weak associations.  
 
The study population had a significant (p <0.001) progression of peripheral 
atherosclerosis after 12 years measured by the decline in ABI (mean (SD) change 
after 12 years -0.07 (0.18)). From inflammatory markers, CRP (p <0.01), IL-6 (p 
<0.001) and ICAM-1 (p <0.01) were associated with atherosclerotic progression after 
12 years, independently of baseline ABI and of cardiovascular risk factors. Also, 
from haemostatic markers, fibrinogen (p = 0.05) and D-dimer (p  0.05) were 
significantly associated with atherosclerotic progression independently of baseline 
ABI and cardiovascular risk factors. Moreover, subjects with higher levels of both 
D-dimer and IL-6 at baseline had the greatest ABI decline. IL-6 showed the stronger 
independent effect on atherosclerotic progression and retained statistical significance 
after adjustments for all inflammatory markers and for fibrinogen and D-dimer. The 
associations of IL-6 with atherosclerotic progression did not seem to differ according 
to baseline levels of total/HDL cholesterol or smoking. However, the association of 
CRP with atherosclerotic progression was considerably stronger among those who 




6 Results: Inflammatory and haemostatic markers 
and incident PAD and CVD 
6.1 Introduction 
In this chapter the associations between inflammatory and haemostatic markers with 
incident PAD were examined. The incidence of PAD over 17 years was described. 
Associations between conventional cardiovascular risk factors and incident PAD 
were investigated in univariable and multivariable analyses. Inflammatory and 
haemostatic markers were examined as risk factors for incident PAD in analyses 
adjusted for conventional risk factors. Multivariable models with several 
inflammatory and haemostatic markers and combined variables were performed. In 
addition, their effect was examined according to cardiovascular risk factors status at 
baseline. In the second part of this chapter, inflammatory and haemostatic markers 
were examined as risk factors for incident major CVD, MI or stroke in order to 
compare their effect on different manifestations of the disease. Analyses were 
adjusted for conventional cardiovascular risk factors and baseline subclinical CVD. 
Finally, analyses looking at combined variables, multivariable models and 
interactions with cardiovascular risk factors status as in incident PAD analysis were 
performed.      
 
Tables and figures are presented at the end of each section.  
 219 
6.2 Incident PAD 
In this part the incidence of PAD during the follow up period is described. 
 
6.2.1 Incidence of moderate and severe PAD  
At baseline, 73 subjects were suffering from PAD diagnosed by the WHO IC 
questionnaire. From the 1,519 subjects who were free of PAD, 209 developed 
symptomatic PAD during the subsequent 17 years. Of them, 169 (81%) were 
diagnosed with moderate PAD (IC only). Moreover, 40 (19%) subjects experienced 
severe PAD defined as CLI (rest pain, gangrene or ulcer) or intervention (amputation 
or vascular surgery).  In detail, 11 (27%) experienced CLI, 26 (65%) amputation and 
9 (22%) vascular surgery, whereas 6 subjects (1.5%) experienced more than one 
severe PAD event. Finally, of those 40 with severe PAD, 26 (65%) had also been 
diagnosed with IC.  
 
The mean time to diagnosis of incident PAD for the study population was 84 months 
(range 7-188 months). Also, from the 209 events of PAD, 113 (54%) have occurred 
in males and 96 (46%) in females (p for difference =0.33). The Kaplain-Meier (KM) 
curve for PAD events for males and females separately is shown in Figure 18. The 
steep drop in the line at 5 and 12 years is due to the fact that all participants 
completed the WHO IC questionnaire at the 5 and 12 years of follow up and thus 
many events were recorded at those two time points.  
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6.2.2 Prevalence of moderate PAD at 5 and 12 years 
At 5 and 12 years after follow up, participants completed the WHO IC questionnaire. 
At 5 years, 1,279 subjects completed the questionnaire and of them 10 (0.8%) had 
grade I claudication, 19 (1.5%) grade II and 42 (3.3%) probable claudication. The 
overall IC prevalence was 7.2%. At 12 years, 925 subjects completed the WHO IC 
questionnaire and the overall disease prevalence was 6.4%. In detail, 14 (1.5%) 
subjects had grade I claudication, 18 (1.9%) had grade II claudication and 27 (2.9%) 
had probable claudication.    
 
6.2.3 Comorbidity of PAD with major CVD 
From the 73 subjects with IC at baseline, 35 (48%) experienced either a fatal or 
non-fatal event of MI or stroke. On the other hand, from those 209 subjects who 
developed new PAD after 17 years of follow up, 89 (43%) subjects also experienced 
an MI or stroke event. 
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Figure 18 Survival curves for incident peripheral arterial disease (PAD) over 17 years of follow 
up for males and females. The p value corresponds to the log rank test 
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p = 0.33 
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6.3 Traditional risk factors and incident PAD 
In this part, the association between traditional cardiovascular risk factors and the 
incidence of PAD was examined. Throughout this analysis only the 1,519 subjects 
without baseline PAD were included in the analysis. 
 
6.3.1 Descriptive analysis 
Table 38 lists the means (SD) of cardiovascular risk factors measured at baseline in 
those subjects who developed or did not develop PAD. Subjects who developed PAD 
were generally older (mean age 65.6 years) and had higher percentage of males 
(54%) compared to those that did not develop PAD (mean age 64.6 years, 50% 
males). Moreover, mean levels of total cholesterol, ratio of total/ HDL cholesterol, 
pack years of smoking and systolic blood pressure and prevalence of hypertension 
and baseline CVD were all significantly higher at baseline among subjects who 
developed PAD. On the contrary, levels of HDL cholesterol were significantly lower 
in those who developed PAD. Moreover, of those who developed PAD, 7.3% 
suffered from diabetes at baseline compared to 5.5% subjects with diabetes in the 
healthy group. No statistically significant differences were found for BMI, diastolic 
blood pressure and physical activity (Table 38). 
 
Then the population was split into those who remained free of PAD, those who 
developed moderate PAD (IC only) and to those who developed severe PAD (CLI or 
intervention) and mean levels of cardiovascular risk factors were calculated across 
disease categories (Table 39). A significant trend across worsening disease categories 
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was found for HDL cholesterol (p=0.002), which had lower levels in the moderate 
PAD group (mean 1.4 mmol/L) and even lower levels (mean 1.3 mmol/L) compared 
to the healthy group (mean 1.5 mmol/L). Despite the fact that total cholesterol and 
total/ HDL cholesterol ratio had higher levels in the disease groups (either moderate 
or severe PAD) compared to the healthy group, there was no clear trend across 
worsening disease categories (p for trend =0.06). On the other hand, mean systolic 
blood pressure and percentage of hypertensives were higher in the modest PAD 
group and even higher in the severe PAD group. However, diastolic blood pressure 
did not show evidence for a dose response relationship with PAD severity. Similarly, 
those who developed moderate or severe PAD had 25.4% and 27.5% prevalence of 
CVD at baseline, respectively. Finally, percentage of diabetes was 6.0% in the 
moderate PAD group and 13.2% in the group that developed severe PAD.  
 
6.3.2 Univariable associations with incident PAD 
Survival curves for incident PAD across levels of most baseline risk factors along 
with p values for the log rank test are shown in Figure 19. All variables except BMI, 
diastolic blood pressure and physical activity were associated with incident PAD. For 
example, older subjects had greater risk of developing PAD and their hazard ratio 
(95% CI) was 1.28 (1.13, 1.46) (p <0.001) per one age band increase (5 years). 
Figure 19 shows that the ratio of total/ HDL cholesterol had a clear trend across 
tertiles in relation to PAD survival and people in the top tertile of total/ HDL ratio 
had hazard ratio (95% CI) 2.62 (1.82, 3.76) (p <0.001) compared to those in the 
bottom tertile. Moreover, current or ex smokers, hypertensives and people with 
increased systolic blood pressure were significantly associated with incident PAD. 
 224 
Finally, the 204 subjects with history of MI, stroke or angina had a 3 fold increase in 
the risk of developing PAD (hazard ratio (95% CI) 3.45 (2.52, 4.70) (p <0.001)) 
compared to those 1,315 subjects who were free of CVD at baseline.  
 
6.3.3 Multivariable associations with incident PAD  
Cox regression was used to calculate age and sex adjusted and risk factors-adjusted 
hazard ratios (95% CI) for PAD and total/ HDL cholesterol, pack years of smoking, 
hypertension, diabetes, BMI, physical activity and baseline CVD (Table 40). 
Total/HDL cholesterol ratio, pack years of smoking, hypertension and baseline CVD 
were significant predictors of PAD development in both age and sex adjusted and 
multivariable adjusted analyses (p <0.001). In particular, subjects with baseline CVD 
had more than a 2-fold increase in their risk for developing a PAD (hazard ratio 
(95% CI) 2.37 (1.70, 3.31)). Similarly, those with total/ HDL cholesterol ratio or 
with pack-years of smoking in the top tertile of their distribution had more than 
2-fold increase in their risk for incident PAD (hazard ratio (95% CI) 2.30 (1.57, 3.38) 
and 2.34 (1.67, 3.30), respectively). Total cholesterol and smoking were fitted as 3 
level categorical variables to enable comparability with following analysis of 
inflammatory and haemostatic markers. Models with these variables were examined 
and results were essentially unchanged. For example, the hazard ratio per 1 SD 
increase in total/HDL cholesterol was 2.17 (2.00, 2.36) in the multivariable analysis. 
In addition, when smoking status (ever vs. never smokers) was fitted in the model 
instead of pack years of smoking, the results were almost the same and the HR (95% 
CI) for incident PAD in ever compared to never smokers was 1.62 (1.18, 2.22) 
(p=0.003).   
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The assumption of proportional hazards was tested by stratifying the Cox regression 
with each covariate and then plotting the log-log plot. All plots did not show serious 
violations of the proportional hazards assumption since the hazard ratios between 
different categories seemed constant over time. For example, the log-log plot of total/ 
HDL cholesterol ratio on Figure 20 shows that the hazard ratio between tertiles of 
total/ HDL cholesterol was approximately constant over time although the 
instantaneous hazards varied.   
 
6.3.4 Sensitivity analysis 
Similar results, although with wider CI, were found in analyses limited to 1,315 
subjects without baseline CVD (MI, stroke or angina). In this subgroup the hazard 
ratio (95% CI) for total/ HDL cholesterol (top vs. bottom tertile) was 2.57 (1.67, 
3.98), for pack years of smoking (top vs. bottom tertile) 2.57 (1.75, 3.79) and for 
hypertension (yes vs. no) 2.14 (1.50, 3.06). 
 
Furthermore, when the analysis was limited to those 1,273 subjects without baseline 
evidence of subclinical atherosclerosis (defined by an ABI >0.9) the hazard ratios 
(95% CI) were also essentially unchanged. For total/ HDL cholesterol (top vs. 
bottom tertile) the hazard ratio (95% CI) was 2.10 (1.32, 3.33), for pack years of 
smoking (top vs. bottom tertile) 2.03 (1.36, 3.02), for hypertension (yes vs. no) 1.83 
(1.26, 2.66) and for baseline CVD (yes vs. no) 2.74 (1.82, 4.11). 
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Table 38 Cardiovascular risk factors in subjects who did or did not develop peripheral arterial 
disease (PAD) over the 17 years of follow up 
 Mean (SD)/ Percent 
 




P value for 
difference 
Age (years) 64.6 (5.71) 65.6 (5.30) 0.01 
Males 50.4 % 54. 1 % 0.32 
Smoking 
        Never smokers 
        Ever smokers 
















) 25.6 (3.91) 25.7 (3.89) 0.81 
Diabetes 5.5 % 7.3 % 0.31 
Cholesterol/ HDL ratio 5.1 (1.88) 5.6 (1.72) < 0.001 
Total cholesterol (mmol/L) 7.0 (1.29) 7.2 (0.42) 0.01 
HDL cholesterol (mmol/L) 1.5 (0.42) 1.3 (0.34) < 0.001 
Systolic blood pressure (mmHg)  143.3 (23.64) 148.3 (24.27) 0.004 
Diastolic blood pressure (mmHg)  77.3 (12.33) 78.0 (12.84) 0.44 
















       Myocardial infarction 
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Table 39 Cardiovascular risk factors in people who did not develop peripheral arterial disease 
(PAD), who developed moderate PAD and who developed severe PAD 
















Age (years) 64.6 (5.71) 65.1 (5.35) 67.8 (4.50) < 0.001 
Males 50.4 % 52 % 65 % 0.19 
Smoking  
   Never smokers 
   Ever smokers 




















) 25.6 (3.91) 25.6 (3.86) 25.8 (4.07) 0.79 
Diabetes 5.5 % 5.9 % 13 % 0.14 
Cholesterol/ HDL ratio 5.1 (1.88) 5.6 (1.67) 5.7 (1.93) 0.06 
Total cholesterol (mmol/L) 7.0 (1.29) 7.3 (1.45) 6.8 (1.22) 0.43 
HDL cholesterol (mmol/L) 1.5 (0.42) 1.4 (0.36) 1.3 (0.26) 0.002 
Systolic blood pressure 
(mmHg)  
143.3 (23.64) 147.4 (23.7) 152.2 (26.34) 0.02 
Diastolic blood pressure 
(mmHg)  
77.3 (12.33) 78.0 (12.88) 78.0 (12.86) 0.69 
Hypertension  67.5 % 68.6 % 75.0 % < 0.001 
Physical activity 
   Light 
   Moderate 















   Myocardial infarction 
   Stroke 
   Angina 





















† For categorical variables p values was calculated with the chi-square test for trend.    
For continuous variable with ANOVA test for trend.
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Figure 19 Survival curves for peripheral arterial disease (PAD) for different levels of baseline 





























































































p =0.001 p <0.001 
p <0.001 p <0.001 
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1: bottom tertile, 2: middle tertile, 3: top tertile.  
MI: myocardial infarction.  
Cut-off points for age groups: 55-59, 60-64, 65-69, 70-75 years, for HDL 
cholesterol: 1.23, 1.59 mmol/L, for total cholesterol: 6.40, 7.49 mmol/L, total/ HDL 
cholesterol ratio: 4.32, 5.60.  Never smokers: 930 subjects, current/ ex smokers: 547 
subjects, hypertensives: 815 subjects, non-hypertensive: 704 subjects, MI, stroke or 
angina at baseline: 204 subjects, no cardiovascular disease at baseline: 1,315 
subjects. 
p =0.001 p <0.001 
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Table 40 Hazard ratios (95% CI) of cardiovascular risk factors for the development of peripheral 
arterial disease (PAD) 
Hazard ratio (95% CI) for development of PAD  
Age, sex adjusted Multivariable 
Total/ HDL cholesterol 
(top vs. bottom tertile) 
2.54  (1.75, 3.69)** 2.30  (1.57, 3.38)** 
BMI (1SD increase) 1.02  (0.89, 1.17) 0.89  (0.77, 1.04) 
Pack years of smoking 
(top vs. bottom tertile) 
2.31  (1.65, 3.23)** 2.34  (1.67, 3.30)** 
Diabetes (yes vs. no) 1.46  (0.86, 2.48) 0.99  (0.56, 1.74) 
Hypertension (yes vs. no) 1.85  (1.37, 2.49)** 1.77  (1.30, 2.42)** 
Leisure activity  
(no activity vs. strenuous)  
1.67  (0.86, 3.28) 1.51  (0.75, 3.07) 
MI, stroke or angina  
(yes vs. no) 
3.16  (2.30, 4.32)** 2.37  (1.70, 3.31)** 
** p value significant at 0.01 * p value significant at 0.05 
 



































1: bottom tertile. 2 middle tertile, 3: top tertile 
Cut-off points for total/ HDL cholesterol 6.40 and 7.49 mmol/L
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6.4 Inflammatory markers and incident PAD 
In this part, the associations between inflammatory markers and incident PAD were 
examined. Throughout this analysis only the 1,519 subjects without baseline PAD 
were included. 
 
6.4.1 Descriptive analysis 
Inflammatory markers, CRP, IL-6 and ICAM-1 but not VCAM-1 and E-selectin 
were significantly elevated at baseline in those subjects who experienced 
symptomatic PAD during the follow up period (Table 41). When the PAD events 
were further categorized in moderate PAD and severe PAD, only ICAM-1 had a 
significant response dose relationship with disease severity (Figure 21). Median 
(interquartile range) ICAM-1 was 235 (201, 275) and 248 (206, 290) in subjects who 
developed modest and severe PAD respectively compared to 213 (184, 254) for the 
healthy group. On the contrary, subjects who experience moderate PAD and severe 
PAD had median IL-6 (interquartile range) 2.58 pg/mL (1.77, 3.93) and 2.51 pg/mL 
(1.68, 3.52) compared to 2.08 pg/mL (1.36, 3.41) in the healthy group (Figure 21).     
  
6.4.2 Univariable associations with incident PAD 
Survival curves for PAD development per tertile of each inflammatory marker are 
shown in Figure 22 along with the corresponding p value for the log rank test. The 
survival curves along with the log rank tests showed that top tertiles of CRP, IL-6 
and ICAM-1 were associated with increased risk of developing PAD. The crude 
hazard ratio (95% CI) for people in the top tertile of these markers was 2.02 (1.33, 
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3.08) for CRP, 2.49 (1.61, 3.85) for IL-6 and 2.87 (1.92, 430) for ICAM-1. Figure 22 
shows tertiles of VCAM-1 and E-selectin which did not differ in their risk of PAD 
development as their survival curves did not seem to separate over time. 
   
6.4.3 Multivariable associations with incident PAD 
Hazard ratios (95% CI) for PAD between top and bottom tertile of each marker and 
with various degrees of adjustments are shown for all inflammatory markers in Table 
42. CRP and IL-6 showed significant associations in analysis adjusted for age and 
sex and both predicted a 2-fold or greater increase in the risk of having a PAD event 
in subjects falling in the top tertile of their distribution compared to those in the 
bottom tertile. However, their hazard ratios were gradually attenuated by adjustments 
for cardiovascular risk factors and then for CVD at baseline. Therefore, at the final 
multivariable analysis their hazard ratios lost statistical significance. For example, 
the hazard ratio (95% CI) of IL-6 was reduced from 2.14 (1.37, 3.35) to 1.48 (0.93, 
2.35) after adjustments for risk factors and baseline CVD (top vs. bottom tertile). 
Likewise, the hazard ratio (95% CI) of CRP was reduced from 2.00 (1.30, 3.08) in 
the age and sex adjusted analysis to 1.46 (0.92, 2.32) in the multivariable analysis.  
 
The considerable effect of cardiovascular risk factors on the association between 
either CRP or IL-6 with incident PAD was further investigated. Figure 23 shows the 
individual effect of each cardiovascular factor and of baseline CVD on the 
associations between PAD and IL-6 or CRP. Although none of these cardiovascular 
risk factors reduced the effect of the association below statistical significance, the 
effect of smoking and of baseline CVD was substantial and reduced the effect of the 
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associations in both CRP (hazard ratio: 1.69) and IL-6 (hazard ratio: 1.84). The ratio 
of total/ HDL cholesterol reduced the hazard ratio of CRP for PAD progression from 
2.00 (age and sex adjusted analysis) to 1.72. Nevertheless, the hazard ratio of IL-6 
was little changed after adjustment for total/HDL cholesterol ratio (from 2.14 to 
2.09).  
 
On contrast, ICAM-1 retained significant associations in all analyses and had hazard 
ratio (95% CI) between top and bottom tertile (1.78 (1.16, 2.73) p =0.008) in analysis 
adjusted for risk factors and CVD at baseline. Unlike for CRP and IL-6, the 
associations of ICAM-1 with PAD were little affected by baseline CVD adjustments 
and for example the age and sex adjusted hazard ratio (95% CI) for ICAM-1 was 
reduced from 2.54 (1.68, 3.84) to 2.49 (1.65, 3.74) after adjustments for baseline 
CVD. However, smoking attenuated considerably the associations between ICAM-1 
and PAD reducing the hazard ratio (95% CI) to 2.17 (1.42, 3.32) (adjusted for age, 
sex and pack years of smoking). Likewise, ratio of total cholesterol reduced the 
hazard ratio (95% CI) to 2.35 (1.56, 3.56).  
 
VCAM-1 and E-selectin did not show any significant associations with incident PAD 
in either the univariable or the multivariable analysis and their hazard ratios in age 
and sex adjusted analysis were 1.14 (0.78, 1.66) and 1.27 (0.86, 1.87) respectively.  
Finally, when all inflammatory variables were entered simultaneously in the model, 
ICAM-1 retained statistical significant associations and its hazard ratio (95 %CI) was 
2.42 (1.39, 4.21) in age and sex adjusted analysis and 1.83 (1.02, 3.20) in the 
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multivariable analysis. Results for other inflammatory markers are shown in Table 
42(b). 
 
The assumption of proportional hazards was tested by stratifying the Cox regression 
by tertiles of each inflammatory marker and then plotting the log-log plot. All plots 
did not show serious violations of the proportional hazards assumption since the 
hazard ratios between different categories seemed constant over time. For example, 
the log-log plot of tertiles of IL-6 on Figure 24 shows that the hazard ratio between 
tertiles were approximately constant over time. 
 
6.4.4 Sensitivity analysis 
When the baseline population was limited to 1,315 subjects without baseline CVD 
(MI, stroke or angina) the aforementioned associations were not meaningfully 
changed but the CI were wider. In the age and sex adjusted analysis the hazard ratios 
(95% CI) between top and bottom tertile of CRP, IL-6 and ICAM-1 were 1.94 (1.18, 
3.19), 2.24 (1.32, 3.80) and 1.72 (1.01, 2.94). These hazard ratios (95% CI) were 
reduced to 1.72 (1.01, 2.94), 1.69 (0.98, 2.92) and 1.41 (0.85, 2.33) for CRP, IL-6 
and ICAM-1 in the analysis adjusted for cardiovascular risk factors.   
 
Furthermore, when the baseline population was limited to those 1,273 subjects 
without subclinical atherosclerosis (defined by the ABI >0.9) the effect of the 
inflammatory markers was not very much changed. In the age and sex adjusted 
analysis the hazard ratios (95% CI) between top and bottom tertile of CRP, IL-6 and 
ICAM-1 were 1.79 (1.06, 3.03), 1.82 (1.08, 3.05) and 2.16 (1.33, 3.52). These hazard 
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ratios (95% CI) were reduced to 1.37 (0.78, 2.41), 1.27 (0.74, 2.18) and 1.59 (0.95, 
2.66) for CRP, IL-6 and ICAM-1 in the analysis adjusted for cardiovascular risk 
factors.   
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Table 41 Median (interquartile range) of inflammatory markers measured at baseline according 
to incident peripheral arterial disease (PAD) 
Median (interquartile range)  N 










1.70 (0.87, 3.65) 
 
2.81 (1.10, 6.02) 
 
< 0.001 
IL-6 (pg/mL) 1,038 2.08 (1.36, 3.41) 2.60 (1.77, 3.89) 0.003 
ICAM-1 (ng/mL) 1,182 213 (184, 254) 235 (202, 277) 0.001 
VCAM-1(ng/mL) 1,182 368 (324, 431) 381 (328, 441) 0.69 
E-selectin (ng/mL) 1,179 41 (31, 52) 42 (33, 51) 0.64 
CRP: C-Reactive Protein, IL-6: Interleukin-6, ICAM-1: Intracellular Adhesion 
Molecule-1, VCAM-1: Vascular Adhesion Molecule-1. 
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Figure 21 Median (interquartile range) of C-reactive protein (CRP), interleukin-6 (IL-6), 
intercellular adhesion molecule 1 (ICAM-1), vascular adhesion molecule 1 (VCAM-1) and 
E-selectin in people who remained free of peripheral arterial disease (PAD) and in those who 
developed moderate PAD and severe PAD after 17 years. The vertical bars denote those values 

























































p for trend =0.16 
p for trend =0.28 
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p for trend =0.001 
p for trend =0.41 

































































































































Figure 22 Survival curves for incident peripheral arterial disease (PAD) per 
tertiles of inflammatory markers, p values correspond to the log rank test 
 
1: bottom tertile, 2: middle tertile, 
3: top tertile. CRP: C-Reactive 
Protein, IL-6: Interleukin-6, 
ICAM-1: Intracellular Adhesion 
Molecule-1, VCAM-1: Vascular 
Adhesion Molecule-1. Cut-off 
points for tertiles were 1.11 and 
2.88 mg/L for CRP, 1.65 and 2.96 
pg/ml for IL-6, 197 and 242 ng/ml 
for ICAM-1, 341 and 410 ng/ml for 
VCAM-1 and 34 and 48 ng/ml for 
E-selectin. 
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Table 42 Hazard ratios (95% CI) for development of peripheral arterial disease (PAD)  
Hazard ratio for PAD when each marker is entered independently in the 




+ age, sex + risk factors
†





CRP 2.00 (1.30, 3.08)** 1.62 (1.02, 2.56)* 
 
1.46 (0.92, 2.32) 
IL-6 2.14 (1.37, 3.35)** 1.63 (1.03, 2.60)* 1.48 (0.93, 2.35) 
ICAM-1 2.54 (1.68, 3.84)** 1.73 (1.12, 2.67)** 1.78 (1.16, 2.73)** 
VCAM-1 1.14 (0.78, 1.66)   1.01 (0.69, 1.48) 0.99 (0.68, 1.46) 
E-selectin 1.27 (0.86, 1.87)   1.27 (0.86, 1.87) 1.10 (0.74, 1.64) 
Hazard ratio for PAD when all markers are entered simultaneously in the 
model adjusted for:  
 
 
(b) + age, sex + risk factors
†





CRP 1.38 (0.82, 2.34) 1.43 (0.81, 2.50) 
 
1.32 (0.75, 2.33) 
IL-6 1.46 (0.83, 2.56) 1.34 (0.76, 2.37) 1.28 (0.72, 2.27) 
ICAM-1 2.42 (1.39, 4.21)** 1.77 (0.98, 3.19) 1.83 (1.02, 3.30)* 
VCAM-1 0.92 (0.56, 1.52)   0.86 (0.51, 1.43) 0.83 (0.50, 1.39) 
E-selectin 0.64 (0.37, 1.08)   0.61 (0.35, 1.08) 0.60 (0.34, 1.07) 
CRP: C-Reactive Protein, IL-6: Interleukin-6, ICAM-1: Intracellular Adhesion 
Molecule-1, VCAM-1: Vascular Adhesion Molecule-1. 
† pack years smoking, total/ HDL cholesterol, BMI, diabetes, physical activity, 
hypertension 
‡ myocardial infarction, stroke, angina 
**p <0.01, *p <0.05. 
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Figure 23 Hazard ratios (95% CI) for peripheral arterial disease (PAD) between top and bottom 
tertile of (a) C-reactive protein (CRP) and (b) interleukin-6 (IL-6) after adjustments for 
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(a) CRP (top (3.07 mg/L)  
vs. bottom (1.13 mg/L) tertile) 
(b) IL-6 (top (2.96 gr/ml)  
vs. bottom (1.65 pg/ml) tertile) 
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1: bottom, 2: middle, 3: top tertile 
Cut-off points for IL-6 tertiles: 1.65 and 2.96 pg/ml 
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6.5 Haemostatic markers and incident PAD 
In this part, the association between haemostatic markers and incident PAD was 
examined. Throughout this analysis only the 1,519 subjects without baseline PAD 
were included in the analysis. 
 
6.5.1 Descriptive analysis 
Levels of fibrinogen, D-dimer and t-PA were higher in subjects who developed PAD 
than in those who did not develop PAD (Table 43). No significant elevations were 
found in levels of vWF, factor VII, FpA and F1+2 between subjects who developed 
and did not develop PAD as shown in Table 43. Figure 25 illustrates levels of 
haemostatic markers according to the severity of developed PAD. As this figure 
shows, D-dimer had a response dose relationship with disease severity with median 
(interquartile range) 90 (64, 133) and 97 (87, 140) in people who developed 
moderate and severe PAD respectively as opposed to 80 (57, 119) in those who did 
not develop PAD (p for trend =0.009). Plasma levels of t-PA showed similar results 
and were also higher with increasing disease severity (p for trend =0.02). Finally, as 
Figure 25 illustrates, other haemostatic markers failed to show a significant dose 
response relationship with disease severity. 
 
6.5.2 Univariable associations with incident PAD 
Survival curves for PAD development per tertile of each haemostatic marker are 
shown in Figure 26 along with the corresponding p value for the log rank test. 
Fibrinogen, D-dimer and t-PA had significant associations with PAD development. 
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Their crude hazard ratio (95% CI) between top and bottom tertile was 2.82 (1.99, 
4.06) for fibrinogen, 2.39 (1.66, 3.44) for D-dimer and 2.23 (1.55, 3.20) for t-PA. As 
Figure 26 illustrates, small differences across tertiles of either vWF or factor VII 
were observed which were not statistically significant.    
   
6.5.3 Multivariable associations with incident PAD 
Hazard ratios (95% CI) for PAD between top and bottom tertile of each marker are 
shown for all haemostatic markers in Table 44. Fibrinogen and D-dimer showed 
significant associations in analysis adjusted for age and sex and both predicted a 
2 fold or greater increase in the risk of having a PAD event in subjects falling in the 
top tertile of their distribution compared to those falling in the bottom tertile. 
However, their hazard ratios were gradually decreased by adjustments for 
cardiovascular risk factors and then for CVD at baseline. Nevertheless, they did not 
loose statistical significance and at the multivariable adjusted analysis their hazard 
ratios (95% CI) was 2.18 (1.48, 3.23) for fibrinogen and 1.73 (1.16, 2.57) for 
D-dimer (top vs. bottom tertile).  
 
Levels of t-PA were also significantly associated with incident PAD in age and sex 
adjusted analysis. However, its hazard ratio (95% CI) was attenuated after 
adjustments for CVD risk factors and baseline CVD from 1.80 (1.23, 2.62) to 1.26 
(0.84, 1.89) (top vs. bottom tertile). Levels of vWF, factor VII, FpA, F1+2 did not 
show any significant associations with incident PAD in either the univariable or the 
multivariable analysis. Finally, when all inflammatory variables were entered 
simultaneously in the model, none retained statistical significant associations in age 
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and sex adjusted analysis or the cardiovascular risk factors adjusted analysis. Results 
for this analysis are shown in Table 44(b). 
 
The assumption of proportional hazards was tested by stratifying the Cox regression 
by tertiles of each haemostatic marker and then plotting the log-log plot. All plots did 
not show serious violations of the proportional hazards assumption since the hazard 
ratios between different categories seemed constant over time. For example, the log-
log plot of tertiles of fibrinogen on Figure 27 shows that the hazard ratio between 
tertiles was approximately constant over time although the instantaneous hazards 
varied.   
 
6.5.4 Sensitivity analysis 
When the baseline population was limited to 1,315 subjects without baseline CVD 
(MI, stroke or angina) the aforementioned associations were not meaningfully 
changed but the CI were wider. For example, in the age and sex adjusted analysis the 
hazard ratios (95% CI) between top and bottom tertile of fibrinogen, D-dimer and 
t-PA were 2.80 (1.37, 3.23), 2.11 (1.37, 3.23) and 1.90 (1.24, 2.91). These hazard 
ratios (95% CI) were reduced to 2.25 (1.37, 3.69), 2.58 (1.49, 4.47) and 1.45 (0.82, 
2.54) for fibrinogen, D-dimer and t-PA in the analysis adjusted for cardiovascular 
risk factors.   
 
Furthermore, when the baseline population was limited to those 1,273 subjects 
without subclinical atherosclerosis (defined by the ABI >0.9) the effect of the 
haemostatic markers was little changed. In the risk factors adjusted analysis the 
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hazard ratios (95% CI) between top and bottom tertile of fibrinogen and D-dimer 
were higher than the corresponding hazard ratios of the total population. In detail the 
hazard ratios (95% CI) for fibrinogen and D-dimer were 3.08 (1.78, 5.54) and 2.73 
(1.51, 4.92).  
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Table 43 Median (interquartile range) of haemostatic markers measured at baseline according 
to incident peripheral arterial disease (PAD) 
Median (Interquartile range)  N 












2.6 (2.2, 3.03) 
 
2.8 (2.4, 3.3) 
 
< 0.001 
D-dimer (ng/mL) 1,436 80 (57, 119) 94 (68, 134) 0.03 
t-PA (ng/mL) 1,362 7.0 (5.0, 9.5) 8.2 (6.1, 10.5) < 0.001 
vWF (IU/dl) 1,446 106 (80, 139) 110 (84, 139) 0.58 
Factor VII (IU/dl) 1,031 90 (70, 115) 65 (70, 125) 0.32 
F1+2 (nmol/L) 1,062 1.7 (1.3, 2.1) 1.7 (1.4, 2.1) 0.88 
FPA (ng/mL) 1,580 1.4 (1.0, 2.0) 1.5 (1.0, 2.0) 0.37 
t-PA: tissue plasminogen, vWF: vonWillebrand factor, FpA: fibrinopeptide A, F1+2: 
prothrombin fragments 1+2. 
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Figure 25 Median (interquartile range) of fibrinogen,  D-dimer, tissue plasminogen activator (t-
PA), von Willebrand factor (vWF), factor VII, fibrinopeptide A (FpA) and prothrombin 
fragments 1+2 (F1+2) in people who remained free of peripheral arterial disease (PAD) and in 
those who developed moderate PAD and severe PAD after 17 years. The vertical bars denote 
those values of each marker that lie within 1.5 interquartile ranges of the limit of the 


































































p for trend =0.14 
p for trend =0.009 
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p for trend =0.022 
p for trend =0.50 
p for trend =0.38 
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p for trend =0.55 




















































































































Figure 26 Survival curves for incident peripheral arterial disease (PAD) per tertiles 
of haemostatic markers, p values correspond to the log rank test 
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1: bottom tertile, 2: middle tertile, 3: 
top tertile.  
t-PA: tissue plasminogen, vWF: 
vonWillebrand factor, FpA: 
fibrinopeptide A, F1+2: prothrombin 
fragments 1+2.  
Cut off point for tertiles: 2.38-2.92 g/L 
for fibrinogen, 67-107 ng/mL for D-
dimer, 6.0-8.8 ng/mL for t-PA, 89-129 
IU/dl for vWF, 77-105 IU/dl for 
Factor VII, 1.48-1.95 ng/mL for F1+2, 
1.00-1.70 nmol/L for FpA.
p =0.49 p =0.01 
p =0.03 
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Table 44 Hazard ratios (95% CI) for development of peripheral arterial disease (PAD) between 




Hazard ratio  (95% CI) for PAD when each marker is entered 
independently in the model adjusted for: 
 + age, sex + risk factors
†




Fibrinogen 2.93 (2.03, 4.22)** 2.25 (1.54, 3.29)** 2.18 (1.48, 3.23)** 
D-dimer 2.18 (1.48, 3.23)** 1.80 (1.21, 2.68)** 1.73 (1.16, 2.57)** 
t-PA 1.80 (1.23, 2.62)** 1.30 (0.87, 1.95) 1.26 (0.84, 1.89) 
VWF 1.17 (0.81, 1.67) 1.04 (0.73, 1.50) 1.01 (0.71, 1.45) 
Factor VII 1.17   (0.77, 1.77) 1.20 (0.78, 1.83) 1.21 (0.79, 1.85) 
F1+2 1.03 (0.65, 1.62) 1.03 (0.65, 1.63) 1.38 (0.99, 1.90) 
FpA 1.35 (0.98, 1.86) 1.39 (1.00, 1.92) 1.03 (0.65, 1.62) 
(b) 
Hazard ratio for PAD when all markers are entered simultaneously in 
the model adjusted for: 
 + age, sex + risk factors
†




Fibrinogen 1.48  (0.77, 2.82) 1.38 (0.72, 2.64) 1.31  (0.68, 2.52) 
D-dimer 1.95  (0.97, 3.96) 1.56 (0.75, 3.23) 1.65  (0.79, 3.43) 
t-PA 1.15 (0.64, 2.09) 0.95 (0.50, 1.81) 0.99  (0.52, 1.88) 
vWF 0.76 (0.40, 1.46) 0.64 (0.33, 1.24) 0.69  (0.35, 1.33) 
Factor VII 0.99   (0.55, 1.80) 1.16 (0.62, 2.18) 1.15    (0.62, 2.17) 
F1+2 1.03 (0.57, 1.88) 1.09 (0.58, 2.04) 1.12  (0.67, 2.34) 
FpA 1.64 (0.94, 2.86) 1.66  (0.94, 2.92) 1.73  (0.99, 3.04) 
t-PA: tissue plasminogen, vWF: vonWillebrand factor, FpA: fibrinopeptide A, F1+2: 
prothrombin fragments 1+2. 
† pack years smoking, diabetes, BMI, total/ HDL cholesterol ratio, physical activity 
and hypertension. 
‡ myocardial infarction, stroke, angina. 
** p  0.01 and * p  0.05.
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1:top, 2:middle, 3:top tertile 
Cut-off points for fibrinogen: 2.38, 2.92 g/L 
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6.6 Additive effect of inflammatory and haemostatic 
markers on incident PAD 
In this part, the additive effect between inflammatory and haemostatic markers on 
their associations with incident PAD was investigated. 
 
6.6.1 Independent and joint effect 
The previous analyses showed that the inflammatory marker ICAM-1 and the 
haemostatic markers fibrinogen and D-dimer were significant and independent 
predictors of PAD development after 17 years of follow up period. A stepwise Cox 
regression model was also conducted. All cardiovascular risk factors and history of 
CVD were forced into the model whereas inflammatory and haemostatic variables 
that had significant hazard ratios in the univariable analysis were selected using 
backward selection process. In the final step, only ICAM-1 and D-dimer were 
included in the model.  
 
The additive effect of ICAM-1 and D-dimer along with fibrinogen, which had the 
greatest single independent effect with incident PAD, was further investigated. When 
fibrinogen was adjusted for D-dimer, its effect was attenuated and had borderline 
significance at the multivariable analysis (Table 45). At the same model D-dimer 
remained statistical significant with hazard ratio (95% CI) 1.94 (1.15, 3.27) (top vs. 
bottom tertile). Similarly, D-dimer retained significant associations when adjusted 
for ICAM-1 levels and its hazard ratio (95% CI) was 2.35 (1.35, 4.10) (top vs. 
bottom tertile) in the multivariable analysis.  
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Moreover, D-dimer was an independent predictor of PAD when all 3 markers, 
fibrinogen, D-dimer and ICAM-1, were entered simultaneously into the Cox 
regression model with hazard ratio (95% CI) 1.87 (1.05, 3.35) (top vs. bottom tertile) 
in the multivariable analysis. The same was not true for fibrinogen and ICAM-1, 
which had weaker association in this model and failed to reach statistical significance 
in the adjusted analysis (Table 33). 
 
6.6.2 Combined variables: ICAM-1, fibrinogen and D-dimer 
The combined effect of fibrinogen, D-dimer and ICAM-1 was investigated further. 
The population at baseline was divided into 4 mutually exclusive groups according to 
their baseline levels of D-dimer and fibrinogen: levels of fibrinogen and D-dimer in 
the top tertile (219 subjects), levels of fibrinogen in the top tertile and levels of 
D-dimer in the middle or bottom tertile (211 subjects), levels of D-Dimer in the top 
tertile and levels of fibrinogen in the middle or bottom tertile (223 subjects) and 
finally levels of both D-dimer and fibrinogen in the middle or bottom tertile (696 
subjects). Compared to the reference group of people with both variables at the 
bottom or middle tertile, people with only D-dimer elevated had hazard ratio (95% 
CI) 1.58 (0.92, 2.73), people with only fibrinogen elevated had hazard ratio (95% CI) 
2.35 (1.47, 3.77) and people with both variables elevated had hazard ratio (95% CI) 
2.62 (1.64, 4.19) in analysis adjusted for CVD risk factors and baseline CVD.   
 
The baseline population was also divided according to fibrinogen and ICAM-1 levels 
and according to D-dimer and ICAM-1 levels into 4 groups respectively but here a 
linear trend between increasing number of elevated variables was less apparent. 
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People falling in the top tertile of fibrinogen and ICAM-1 had hazard ratio (95% CI) 
2.69 (1.63, 4.46) compared to those in the bottom or middle tertile of both variables.  
Similarly, people falling in the top tertile of both D-dimer and ICAM-1 had hazard 
ratio (95% CI) 2.18 (1.24, 3.82) compared to those in the bottom or middle tertile of 
both variables, in the multivariable analysis. 
 
6.6.3 Combined variables: IL-6 and D-dimer 
Moreover, analysis on inflammatory and haemostatic markers and the progression of 
peripheral atherosclerosis showed an additive effect of D-dimer and IL-6 on ABI 
decline. This effect was tested in relation to PAD development also. Again, 
individuals were divided into 4 mutually exclusive groups according to their baseline 
levels of D-dimer and IL-6:  levels of IL-6 and D-dimer in the top tertile (171 
subjects), levels of IL-6 in the top tertile and levels of D-dimer in the middle or 
bottom tertile (180 subjects), levels of D-Dimer in the top tertile and levels of IL-6 in 
the middle or bottom tertile (170 subjects) and finally levels of both D-dimer and IL-
6 in the middle or bottom tertile (506 subjects). However, there was not a clear trend 
across groups and IL-6 did not seem to add to the effect of D-dimer on PAD 
prediction. More specifically, in age and sex adjusted analysis, the hazard ratio for 
people with elevated D-dimer only was 2.41 (1.34, 4.34), with elevated IL-6 only 
was 1.81 (0.99, 3.28) and with elevated both variables was 2.40 (1.35, 4.25).  
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Table 45 Hazard ratios (95% CI) for development of peripheral arterial disease (PAD) between 
top and bottom tertile of ICAM-1, fibrinogen and D-dimer 
 
 
Hazard ratio for PAD when each marker is entered independently 
in the model adjusted for: 
 
 
+ age, sex + risk factors
†





Fibrinogen and ICAM-1 entered simultaneously 
Fibrinogen 2.10 (1.26, 3.51)** 2.04 (1.21, 3.42)** 1.94 (1.15, 3.27)* 
ICAM-1 2.34 (1.32, 4.15)** 1.68 (0.93, 3.02) 1.80 (0.99, 3.25) 
 
Fibrinogen and D-dimer entered simultaneously 
Fibrinogen 1.88 (1.19, 2.98)** 1.75 (1.09, 2.80)* 1.80 (0.99, 3.25) 
D-dimer 2.40 (1.44, 3.99)** 1.98 (1.18, 3.34)* 1.94 (1.15, 3.27)* 
 
ICAM-1 and D-dimer entered simultaneously 
ICAM-1 2.36 (1.36, 4.08)** 1.65 (0.93, 2.92) 1.77 (1.00, 3.15) 
D-dimer 2.83 (1.64, 4.89)** 2.50 (1.44, 4.35)** 2.35 (1.35, 4.10)** 
 
ICAM-1, fibrinogen and D-dimer entered simultaneously 
ICAM-1 2.17 (1.22, 3.86)** 1.58 (0.87, 2.85) 1.70 (0.94, 3.09) 
Fibrinogen 1.70 (1.00, 2.89)* 1.76 (1.03, 3.01)* 1.71 (0.99, 2.93) 
D-dimer 2.27 (1.29, 4.01)** 1.98 (1.11, 3.52)** 1.87 (1.05, 3.35)* 
ICAM-1: Intracellular Adhesion Molecule-1. 
† pack years smoking, diabetes, BMI, total/ HDL cholesterol ratio, physical activity 
and hypertension. 
‡ myocardial infarction, stroke, angina. 
** p <0.01, *p<0.05.
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6.7 Fibrinogen, smoking, cholesterol levels and 
incident PAD 
Fibrinogen had the strongest association with future PAD in both age and sex and the 
multivariable analysis among the other markers studied here. In addition, fibrinogen 
along with cholesterol and smoking were the only markers that predicted a 2 fold or 
greater increase in the risk of developing PAD compared to the other conventional 
and non-conventional markers studied here (top vs. bottom tertile). In detail, the 
hazard ratio (95% CI) for the top vs. the bottom tertile of fibrinogen was 2.18 (1.48, 
3.23) (p <0.001), of total/HDL cholesterol was 2.05 (1.39, 3.02) (p <0.001) and of 
smoking was 2.09 (1.47, 2.97) (p <0.001) in the multivariable analysis. This relative 
importance of fibrinogen along with traditional risk factors smoking and cholesterol 
was investigated further.  
 
6.7.1 Cholesterol levels 
The baseline population was stratified according to total/ HDL cholesterol levels and 
fibrinogen into 6 groups: people with total/ HDL cholesterol ratio below the median 
and with fibrinogen at bottom, middle or top tertile (293, 266, 211 subjects 
respectively) and people with total/ HDL cholesterol ratio above the median with 
fibrinogen at bottom, middle or top tertile (221, 248, 303 subjects respectively). 
Figure 28 shows the hazard ratio for each group compared to the group of people 
with total/ HDL cholesterol below the median and fibrinogen levels at the bottom 
tertile (reference group). People with increased fibrinogen levels (top tertile) had 
significant associations with PAD development in the multivariable analysis whether 
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their total/ HDL cholesterol ratio was below or above the median. In fact, the hazard 
ratio (95% CI) was 3.46 (1.66, 7.21) (p =0.001) for people with fibrinogen at the top 
tertile and total/ HDL cholesterol ratio below the median and 2.49 (1.16, 5.32) 
(p =0.02) for people with fibrinogen at the top tertile and total/ HDL cholesterol ratio 
above the median compared to the reference group. 
 
6.7.2 Smoking 
Moreover, the baseline population was divided into 6 groups according to smoking 
status and fibrinogen levels: never smokers with fibrinogen levels at top, bottom or 
top tertile (218, 191, 141 subjects respectively) and ever (present and ex) smokers 
with fibrinogen levels at top, middle or bottom tertile (281, 310, 364 subjects 
respectively). As shown in Figure 28, people with increased fibrinogen levels were at 
increased risk of developing PAD whether they were smokers (hazard ratio (95% CI) 
3.76 (2.11, 6.72)) (p <0.001) or never smokers (hazard ratio (95% CI) 2.30 (1.14, 
4.63)) (p =0.020). 
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Figure 28 Hazard ratios (95% CI) for peripheral arterial disease (PAD) according to tertiles of 
fibrinogen and (a) total/ HDL cholesterol and (b) smoking status at baseline 
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The hazard ratios are adjusted for age, sex, BMI, diabetes, hypertension, physical 
activity, cardiovascular disease at baseline and (a) pack years smoking or (b) total/ 
HDL cholesterol. Reference group was the group of people with fibrinogen at the 
bottom tertile and (a) total/ HDL cholesterol below the median or (b) never smoker. 
Median for total/ HDL cholesterol: 4.96. Current/ ex smokers: 720 subjects, never 
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6.8 Incident CVD 
In this part the incidence of CVD, including myocardial infarction and stroke, in the 
baseline population over 17 years of follow up is described.   
 
6.8.1 Incidence of myocardial infarction and stroke 
After 17 years of follow up, 702 participants (44%) of the baseline population died 
From those, 129 have died (18%) due to MI and 65 (9%) due to stroke. In addition, 
146 subjects experienced at least one non fatal MI and 106 at least one stroke. From 
the 248 subjects that experience either fatal or no fatal MI, 33 (13%) subjects had 
two MIs recorded (fatal or non fatal) and 10 (4%) more than two MIs (fatal or non 
fatal). Also, from those 168 that experienced either fatal or non-fatal event of stroke, 
24 (14%) experienced two events and 4 (2%) more than two stroke events. 
Moreover, 29 subjects (12% from those with MI and 17% from those with stroke) 
experienced both an event of MI and of stroke.   
 
The mean time to diagnosis of incident MI for the study population was 135 months 
(range 3-198 months). The KM curve for MI and stroke for the males and females 
separately is shown in Figure 29. From the 248 events of MI, 168 (68%) have 
occurred in males and 80 (32%) in females (p for difference <0.001). The mean time 
to diagnosis for incident stroke was 91 months (range 4-203 months). Ninety two 
stroke events (55%) occurred in males and 76 (45%) in females (p for difference 
=0.11).  
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At baseline, 277 (17.4 %) subjects had a history of CVD defined as MI, stroke, 
angina or IC. Of them, 96 (34.6%) had an event of MI and 55 (19.9%) had an event 
of stroke during the follow up. On the other hand, from the 1,315 without clinical 
CVD at baseline, 152 (11.6 %) developed MI and 113 stroke (8.6 %). 
 
6.8.2 Incidence of major CVD 
During the 17 years of follow up, 35 (2.2%) subjects had had a CABG and 36 (2.3%) 
had had an angioplasty (64 or 4.0% had either of them). Of those 64, 31 (48.4%) had 
also been diagnosed with MI and 6 (9.4%) had also been diagnosed with stroke. A 
composite group of major CVD which included subjects who developed either MI, 
stroke or who had a CABG or an angioplasty was created. In total, 415 (26.1%) 
subjects developed at least one of those events during the follow up period. Of those 
events, 148 occurred in the 277 people with history of CVD at baseline (53.4% of 
them was diagnosed with major CVD during the follow up). The KM curve for major 
CVD for males and females separately is shown in Figure 29. In total, 258 (62%) 
major CVD events occurred in males and 157 (38%) in females (p for difference 
<0.001). The mean time to diagnosis was 82 months (range 1-202 months). 
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Figure 29 Survival curves for incident myocardial infarction (MI), stroke and major 
cardiovascular disease (CVD) over 17 years of follow up for males and females. P values 

































































6.9 Cardiovascular risk factors and incident CVD 
In this part, the association between traditional cardiovascular risk factors and 
incident major CVD, MI and stroke was examined.  
 
6.9.1 Descriptive analysis 
Table 46 lists the means (SD) of cardiovascular risk factors measured at baseline in 
those subjects who developed or did not develop major CVD. Subjects who 
developed major CVD were generally older and had higher percentage of males 
compared to those that did not develop PAD. Moreover, mean ratio of total/ HDL 
cholesterol and pack years of smoking were all significantly higher at baseline 
among subjects who developed major CVD compared to those who remained free of 
major CVD. On the contrary, no significant difference was seen for total cholesterol. 
Levels of HDL cholesterol were significantly lower in those who developed major 
CVD. Also, 9.0% suffered from diabetes at baseline among those who developed 
major CVD compared to 4.8% subjects with diabetes in the healthy group.  
 
When the major CVD events were divided in MIs and strokes, total cholesterol levels 
and the ratio of total cholesterol was significantly higher in the MI group compared 
to the healthy group but not in the group of people who developed stroke. Finally, 
subjects with diabetes at baseline did not differ between those who developed stroke 
and who remained free of major CVD. On the other hand people with MI had 
increased percentage of subjects with diabetes (10.9 %) compared to the no major 
CVD group (5.0%) (p <0.001). 
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6.9.2 Univariable and multivariable associations with 
incident CVD 
Cox regression was used to calculate crude, age and sex adjusted and multi-adjusted 
hazard ratios (95% CI) for major CVD, MI or stroke and total/ HDL cholesterol, 
pack years of smoking, diabetes, BMI, physical activity, baseline CVD and ABI. 
Table 47 lists the multivariable analyses for major CVD and  
Table 48 for MI and stroke separately.  
 
Hazard ratios for major CVD unadjusted and adjusted for age and sex were 
significant for all variables except for physical activity. In the multivariable analysis 
(all variables entered simultaneously in the model) total/ HDL cholesterol, pack 
years of smoking, baseline CVD and ABI were significant and independent 
predictors of future major CVD (Table 47). In particular, subjects with baseline 
history of CVD had more than a 2 fold increase in their risk for developing a major 
CVD (hazard ratio (95% CI) 2.58 (2.05, 3.25)). Similarly, those with total/ HDL 
cholesterol ratio or with pack-years of smoking in the top tertile of their distribution 
had hazard ratio (95% CI) 1.68 (1.27, 2.21) and 1.46 (1.13, 1.90), respectively. In 
addition, when smoking status (ever vs. never smokers) was fitted in the model 
instead of pack years of smoking, the results were almost the same and the HR (95% 
CI) for incident CVD in ever compared to never smokers was 1.39 (1.09, 1.77) 
(p=0.007).   
 
When the events were divided in MI or stroke, hazard ratios were little changed. 
Total/ HDL cholesterol, pack years of smoking, baseline CVD and ABI were 
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significant and independent predictors of future MI (Table 48). Again, subjects with 
baseline history of CVD had more than a 2-fold increase in their risk for developing 
a major CVD (hazard ratio (95% CI) 2.80 (2.09, 3.74)). Also, those with total/ HDL 
cholesterol ratio or with pack-years of smoking in the top tertile of their distribution 
had hazard ratio (95% CI) 1.96 (1.35, 2.84) and 1.43 (1.01, 2.01), respectively. In 
addition, BMI, pack years of smoking, baseline history of CVD and ABI but not the 
ratio of total/ HDL cholesterol were independently associated with incident stroke 
(Table 48). 
 
Proportional hazard assumption was examined for the all the variables entered in the 
Cox regression by stratifying the Cox regression with each covariate and by plotting 
the log-log survival plot. No serious deviations were observed. As an example, the 
log –log plot on Figure 30 shows that hazard ratios for major CVD between tertiles 
of total/ HDL cholesterol were constant over time.  
 
6.9.3 Sensitivity analysis 
When the analysis was limited to 1,315 subjects without history of CVD, results of 
Cox regression did not meaningfully change. In multivariable analysis, the hazard 
ratio (95% CI) for incident major CVD between top and bottom tertile of total/ HDL 
cholesterol was 1.87 (1.34, 2.61) and of pack years of smoking 1.80 (1.30, 2.49). 
Also, per 1SD decrease of ABI the hazard ratio (95% CI) for future major CVD was 
1.25 (1.09, 1.45) and per 1SD increase of BMI 1.12 (0.99, 1.26). Diabetes status and 
leisure activity did not show any significant associations with incident major CVD as 
in the previous analyses. 
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Table 46 Cardiovascular risk factors in subjects who did or did not developed major 
cardiovascular disease (CVD) over the 17 years of follow up 
 Mean (SD)/ Percent 
  
 














Males 46.8 % 62.2 % < 0.001 
Smoking 
  Never smokers 
  Ever smokers 
















) 25.5 (4.02) 26.0 (3.57) 0.01 
Diabetes 4.8 % 9.0 % 0.002 
Cholesterol/ HDL ratio 5.1 (2.04) 5.7 (1.67) < 0.001 
Total cholesterol (mmol/L) 7.0 (1.32) 7.1 (1.36) 0.13 















ABI 1.05 (0.16) 0.98 (0.22) < 0.001 
Cardiovascular disease 
       Myocardial infarction 
       Stroke 
       Angina 
       IC 



















ABI: Ankle brachial index, IC: intermittent claudication. 
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Table 47 Hazard ratio (95% CI) for incident major cardiovascular disease (CVD) and baseline 
cardiovascular risk factors adjusted for all other factors in the model 
 Hazard ratio (95% CI) for development of 
major CVD 
Total/ HDL cholesterol 
(top vs. bottom tertile) 
1.68 (1.27, 2.21)** 
BMI (1SD increase) 1.06 (0.95, 1.17) 
Pack years of smoking 
(top vs. bottom tertile) 
1.46 (1.13, 1.90)** 
Diabetes (yes vs. no) 0.74 (0.38, 1.43) 
Leisure activity  
(no activity vs. strenuous)  
1.51  (0.75, 3.07) 
ABI (1SD decrease) 1.18 (1.06, 1.30)** 
History of cardiovascular disease 
(yes vs. no) 
2.58 (2.05, 3.25)** 
ABI: Ankle brachial index 
** p value <0.01 
 
Table 48 Hazard ratio (95% CI) for incident myocardial infarction (MI) or stroke and baseline 
cardiovascular risk factors adjusted for all other factors in the model 
Hazard ratio (95% CI) for development of  
MI Stoke 
Total/ HDL cholesterol 
(top vs. bottom tertile) 
2.80  (2.09, 3.74)** 1.53 (0.99, 2.35) 
BMI (1SD increase) 0.95  (0.83, 1.10) 1.24 (1.06, 1.44)** 
Pack years of smoking 
(top vs. bottom tertile) 
1.35 (0.96, 1.91) 1.59 (1.07, 2.36)* 
Diabetes (yes vs. no) 1.43  (0.91, 2.25) 0.74 (0.38, 1.43) 
Leisure activity  
(no activity vs. strenuous)  
1.36  (0.77, 2.41) 1.16 (0.53, 2.56) 
ABI (1SD decrease) 1.18 (1.03, 1.33)* 1.18 (1.01, 1.37)*
  
History of cardiovascular disease  
(yes vs. no) 
2.80  (2.09, 3.74)** 1.60 (1.11, 2.31)* 
ABI: ankle brachial index 
** p value <0.01 
 270 
Figure 30 Log –log plot survival curve for major cardiovascular disease (CVD) per tertiles of 





































1: bottom, 2: middle, 3: top tertile  
Cut-off points for total/ HDL cholesterol 6.40 and 7.49 mmol/L. 
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6.10 Inflammatory markers and incident CVD 
In this part, the association between inflammatory markers with incident major CVD, 
MI or stroke was examined.  
 
6.10.1 Descriptive analysis 
Table 49 lists the median (interquartile range) of baseline levels of inflammatory 
markers in people who subsequently developed CVD and in those who remained free 
of CVD during the follow up. Subjects who developed CVD were further categorised 
into those who experienced MI (either fatal or non fatal) and those who experienced 
stroke (fatal or non fatal). Median CRP and IL-6 was consistently higher in people 
who developed major CVD, MI and stroke compared to the reference group of 
people with no CVD disease (Table 49). Adhesion molecules, E-selectin (p =0.03) 
and ICAM-1 (p =0.03) were elevated only in the group who developed stroke 
compared to the group of people who did not developed CVD. On the other hand, 
VCAM-1 did not differ significantly across different groups. 
  
6.10.2 Univariable associations with incident CVD 
Survival curves for incident major CVD development per tertile of each 
inflammatory marker are shown in Figure 31 along with the corresponding p value 
for the log rank test. All inflammatory markers had significant associations with 
incident CVD and subjects falling in their top tertile of their distributions had 
increasing risk of developing major CVD. For example, people falling in the top 
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tertile of CRP or IL-6 compared to those in the bottom tertile had hazard ratio (95% 
CI) 2.36 (1.75, 3.20) and 2.69 (1.99, 3.65), respectively. 
 
Adhesion molecules showed smaller differences between their tertiles for major 
CVD survival as illustrated by their survival curves on Figure 31. ICAM-1 and 
VCAM-1 had hazard ratios (95% CI) 1.56 (1.19, 2.05) and 1.42 (1.08, 1.85) between 
top and bottom tertile respectively. Finally subjects on the bottom or middle tertile of 
E-selectin had hazard ratio (95 % CI) for major CVD 1.38 (1.06, 1.79). 
 
Survival curves for MI and stroke separately were essentially unchanged with the 
exception of E-selectin which showed relatively greater associations with stroke 
events (hazard ratio (95% CI) 1.67 (1.12, 2.49)) compared to MI (1.28 (0.91, 1.82)).  
 
6.10.3 Multivariable associations with incident CVD 
Table 50 presents the hazard ratios (95% CI) between the top and bottom tertile of 
each inflammatory marker for major CVD and for MI and stroke separately. Hazard 
ratios were adjusted for age and sex, then conventional risk factors (diabetes, total/ 
HDL cholesterol ratio, BMI, pack years of smoking, physical activity), history of 
CVD and finally for ABI. CRP and IL-6 had significant hazard ratios for CVD in all 
analyses; nevertheless, their effect was attenuated after adjustments for conventional 
risk factors and history of CVD at baseline. Adjustment for subclinical disease after 
accounting for cardiovascular risk factors did not seem to alter considerably the 
magnitude of these associations. As shown in Table 50, hazard ratio (95% CI) for 
people in the top vs. the bottom tertile of CRP at baseline was 1.67 (1.19, 2.34) in 
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analysis adjusted for CVD risk factors and baseline CVD which was changed to 1.65 
(1.18, 2.32) in the multivariable analysis. Likewise, IL-6 had hazard ratio (95% CI) 
1.91 (1.37, 2.65) in risk factors and baseline CVD adjusted analysis which was 
decreased to 1.85 (1.33, 2.58) in the multivariable analysis.  
 
When the effect of CRP and IL-6 was examined in MI and stroke separately some 
differences were observed. CRP was significantly and independently associated with 
stroke events with hazard ratio (95 % CI) 1.98 (1.13, 3.46) in the multivariable 
model. However, its hazard ratio (95% CI) with incident MI was considerably 
smaller (1.36 (0.89, 2.09)). On the other hand, IL-6 showed comparable effects for 
MI and stroke.  
 
ICAM-1 had only significant hazard ratios (95% CI) at the age and sex adjusted 
analysis for major CVD (1.53 (1.16, 2.03)) and for stroke (2.04 (1.29, 3.22)) but not 
for MI. VCAM-1 did not show any evidence for associations with incident major 
CVD, MI or stroke. Finally, E-selectin showed significant associations with incident 
major CVD at the age and sex adjusted analysis (hazard ratio (95% CI) 1.47 (1.12, 
1.93)) and with incident stroke even in the multivariable analysis with hazard ratio 
(95% CI) 1.71 (1.11, 2.64). 
 
When all inflammatory markers were entered simultaneously in the Cox regression 
model, only IL-6 retained significant associations. Its hazard ratio (95% CI) for 
major CVD between top and bottom tertile was 1.82 (1.21, 2.76) (p=0.004) in 
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analysis adjusted for age and sex and 1.71 (1.12, 2.61) (p =0.01) in multivariable 
analysis. 
 
The proportional hazard assumptions were tested for all Cox regression models 
performed. This was done by plotting the log-log curves for each inflammatory 
markers and looking for non-constant hazard ratios over time. No serious deviations 
were observed and the log-log plot of IL-6 on Figure 32 is presented as an example. 
Figure 32 shows that the hazard ratios between tertiles of CRP were approximately 
constant over time. 
  
6.10.4 Sensitivity analysis 
When the analysis was limited to those 1,315 subjects without history of CVD (MI, 
stroke, angina or IC) at baseline the results did not meaningfully change. CRP and 
IL-6 had still significant associations with incident major CVD. Their hazard ratios 
(95% CI) between top and bottom tertile for incident major CVD in analysis adjusted 
for CVD risk factors and ABI at baseline were 1.58 (1.06, 2.36) and 1.81 (1.22, 2.69) 
respectively. 
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Table 49 Median (interquartile range) of inflammatory markers measured at baseline according 
to group of cardiovascular events occurring during follow up 






























     































     






























CRP: C-Reactive Protein, IL-6: Interleukin-6, ICAM-1: Intracellular Adhesion 
Molecule-1, VCAM-1: Vascular Adhesion Molecule-1. 
** p <0.01 *p <0.05. 
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Figure 31 Survival curves for tertiles for incident major cardiovascular disease (CVD) per 












1: bottom tertile, 2: middle 
tertile, 3: top tertile. CRP: 
C-Reactive Protein, IL-6: 
Interleukin-6, ICAM-1: 
Intracellular Adhesion 
Molecule-1, VCAM-1: Vascular 
Adhesion Molecule-1. Cut-off 
points for tertiles were 1.11 and 
2.88 mg/L for CRP, 1.65 and 
2.96 pg/ml for IL-6, 197 and 242 
ng/ml for ICAM-1, 341 and 410 
ng/ml for VCAM-1 and 34 and 
48 ng/ml for E-selectin. 
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Table 50 Hazard ratios (95 % CI) for (a) cardiovascular disease, (b) myocardial infarction and (c) 
stroke between top and bottom tertiles of each marker 

















CRP 2.18 (1.59, 2.98)** 1.67 (1.19, 2.34)** 1.65 (1.18, 2.32)** 
IL-6 2.31 (2.08, 3.88)** 1.91 (1.37, 2.65)** 1.85 (1.33, 2.58)** 
ICAM-1 1.53 (1.16, 2.03)** 1.18 (0.88, 1.59) 1.15 (0.86, 1.55) 
VCAM-1 1.27 (0.96, 1.68) 1.21 (0.91, 1.61) 1.22 (0.92, 1.62) 





CRP 1.74 (1.17, 2.58)** 1.37 (0.89, 2.10) 1.36 (0.89, 2.09) 
IL-6 2.10 (1.40, 3.16)** 1.78 (1.16, 2.72)** 1.71 (1.11, 2.62)* 
ICAM-1 1.43 (1.00 2.04) 1.15 (0.79, 1.68) 1.12 (0.76, 1.64) 
VCAM-1 1.31 (0.91, 1.89) 1.23 (0.85, 1.78) 1.23 (0.85, 1.78) 





CRP 2.86 (1.69, 4.87)** 2.08 (1.19, 3.62)** 1.98 (1.13, 3.46)* 
IL-6 2.35 (1.38, 4.00)** 1.81 (1.04, 3.14)* 1.72 (0.98, 3.00) 
ICAM-1 2.04 (1.29, 3.22)** 1.54 (0.96, 2.49) 1.51 (0.93, 2.43) 
VCAM-1 1.23 (0.79, 1.93) 1.16 (0.74, 1.82) 1.17 (0.74, 1.83) 
E-selectin 2.07 (1.36, 3.15)** 1.74 (1.12, 2.68)** 1.71 (1.11, 2.64)* 
CRP: C-Reactive Protein, IL-6: Interleukin-6, ICAM-1: Intracellular Adhesion 
Molecule-1, VCAM-1: Vascular Adhesion Molecule-1. 
† age, sex, pack years smoking, diabetes, BMI, total/ HDL cholesterol ratio and 
physical activity. 
‡myocardial infarction, stroke or angina. 
§ ankle brachial index. 
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1: bottom, 2: middle, 3: top tertile. 
Cut-off points for IL-6: 1.65 and 2.96 pg/ml. 
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6.11 Haemostatic markers and incident CVD 
In this part, the association between haemostatic markers with incident major CVD, 
MI and stroke was examined.  
 
6.11.1 Descriptive analysis 
Table 51 lists the median (interquartile range) of baseline levels of inflammatory 
markers in people who subsequently developed CVD and in those who remained free 
of CVD during the follow up. Subjects who developed CVD were further categorised 
into those who experienced MI (either fatal or non fatal) and those who experienced 
stroke (fatal or non fatal). Median fibrinogen, D-dimer and t-PA were consistently 
higher in people who developed CVD (p <0.001), MI (p <0.001) and stroke 
(p <0.001) compared to the reference group of people with no CVD disease (Table 
51).  
 
Similarly, median of vWF was significantly higher in people who developed CVD (p 
<0.001), MI (p =0.003) or stroke (p =0.006). On the contrary, levels of factor VII, 
FpA and F1+2 did not show any differences in people who did not develop CVD and 
in those who developed major CVD, MI or stroke. 
  
6.11.2 Univariable associations with incident CVD 
Survival curves for incident major CVD development per tertile of each haemostatic 
marker are shown in Figure 33 along with the corresponding p value for the log rank 
test. Haemostatic markers fibrinogen, D-dimer, t-PA and vWF had significant (p 
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<0.001) associations with incident CVD with subjects falling in their top tertile 
showing increased risk of incident major CVD than those falling in the bottom 
tertile. Top tertiles of fibrinogen, D-dimer and t-PA were associated with greater than 
2 fold increase in the risk of developing major CVD with corresponding hazard ratios 
(95% CI) 2.23 (1.74, 2.84), 2.26 (1.75, 2.92) and 2.67 (2.03, 3.53), respectively. 
Levels of vWF had a smaller effect on the risk of major CVD and the hazard ratio 
(95% CI) between to and bottom tertile was 1.68 (1.31, 2.16).  
 
Factor VII and F1+2 levels did not show any evidence for associations with incident 
major CVD (Figure 33). Furthermore, subjects on the top tertile of FpA compared to 
those in the bottom tertile had a small increase in their risk of developing major CVD 
(hazard ratio (95% CI) 1.29 (1.03, 1.62)).   
 
Survival curves for MI and stroke showed essentially similar results as the combined 
CVD analysis.  
 
6.11.3 Multivariable associations with incident CVD 
Table 52 presents the hazard ratios (95% CI) between the top and bottom tertile of 
each inflammatory marker for major CVD and for MI and stroke separately. Hazard 
ratios were adjusted for age and sex, then conventional risk factors (diabetes, total/ 
HDL cholesterol ratio, BMI, pack years of smoking, physical activity), history of 
CVD, and finally for ABI. Fibrinogen retained significant associations after 
adjustments for CVD risk factors and baseline CVD and was significantly associated 
with major CVD and with MI and stroke separately and showed comparable effect 
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across different disease groups. Further adjustment for subclinical atherosclerosis 
had small impact on these associations and the hazard ratio (95% CI) for major CVD 
between top and bottom tertile was 1.85 (1.41, 2.42) in analyses adjusted for CVD 
risk factors and history of CVD and 1.76 (1.35, 2.31) at the ABI adjusted analysis. 
Weaker associations were found for D-dimer and incident major CVD, MI or stroke 
with hazard ratios (95% CI) 1.56 (1.17, 2.09) for major CVD, 1.59 (1.09, 2.33) for 
MI and 1.53 (0.94, 2.48) for stroke in the multivariable model (top vs. bottom 
tertile). 
 
Moreover, t-PA had marginally the greatest independent effect for major CVD 
compared to the other haemostatic markers in the multivariable analysis with hazard 
ratio (95% CI) 1.86 (1.36, 2.55) (top vs. bottom tertile). Same was true when the 
analysis was limited to MI events. For stroke events, the effect of t-PA was much 
limited with hazard ratio (95% CI) 1.47 (0.90, 2.41) (top vs. bottom tertile). 
Moreover, vWF presented modest associations with incident major CVD and MI and 
it did not show any significant associations with future stroke even in the age and sex 
adjusted analysis. Finally, factor VII, FpA and F1+2 did not show any significant 
associations either with major CVD or with MI and stroke separately.  
 
When all the haemostatic markers were entered simultaneously into the Cox 
regression model, t-PA and D-dimer retained significant associations with incident 
major CVD in analysis adjusted for age and sex only with hazard ratio (95% CI) 
between top and bottom tertile 2.04 (1.37, 3.03) (p <0.001) and 1.60 (1.03, 2.49) (p 
=0.04) respectively. However, in the final analysis only t-PA retained significant 
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associations with hazard ratio (95% CI) between top and bottom tertile 2.01 (1.31, 
3.08) (p =0.001).  
 
The assumption of proportional hazards was tested for all Cox regression models by 
plotting the log- log plot for each haemostatic markers and examining the hazard 
ratios between tertiles over time. For all models no serious deviations were observed. 
On Figure 34 the log-log plot of fibrinogen is shown as an example. The hazard 
ratios between tertiles do not differentiate over time.  
 
6.11.4 Sensitivity analysis 
When the analysis was limited to those 1,315 subjects without history of CVD (MI, 
stroke, angina or IC) at baseline the results did not meaningfully change. Fibrinogen, 
D-dimer, t-PA and vWF had still significant associations with incident major CVD. 
Their hazard ratios (95% CI) between top and bottom tertile for incident major CVD 
in analysis adjusted for CVD risk factors and ABI at baseline were 1.69 (1.22, 2.34), 
1.63 (1.09, 2.38), 1.61 (1.09, 2.38) and 1.07 (0.78, 1.48), respectively.  
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Table 51 Median (interquartile range) of haemostatic markers measured at baseline according 
to group of cardiovascular events occurring during follow up 










2.58 (2.18, 3.01) 
 
2.83 (2.39, 3.34) 
 
< 0.001 
D-dimer (ng/mL) 1436 80 (87, 116) 94 (68, 141) < 0.001 
t-PA (ng/mL) 1362 7.0 (5.0, 9.2) 8.4 (6.5, 10.5) < 0.001 
vWF (IU/dl) 1446 105 (78, 137) 115 (87, 148) < 0.001 
Factor VII (IU/dl) 1031 90 (70, 116) 91 (70, 119) 0.41 
F1+2 (nmol/L) 1062 1.4 (1.0, 2.0) 1.5 (1.0, 2.0) 0.72 
FPA (ng/mL) 1580 1.7 (1.3, 2.1) 1.7 (1.3, 2.1) 0.15 
     











2.58 (2.18, 3.01) 
 
2.86 (2.33, 3.35) 
 
< 0.001 
D-dimer (ng/mL) 1436 80 (87, 116) 96 (69, 143) 0.001 
t-PA (ng/mL) 1362 7.0 (5.0, 9.2) 8.4 (6.5, 10.7) < 0.001 
vWF (IU/dl) 1446 105 (78, 137) 116 (87, 155) 0.003 
Factor VII (IU/dl) 1031 90 (70, 116) 91 (71, 122) 0.32 
F1+2 (nmol/L) 1062 1.4 (1.0, 2.0) 1.5 (1.0, 2.0) 0.74 
FPA (ng/mL) 1580 1.7 (1.3, 2.1) 1.7 (1.4, 2.1) 0.09 










2.58 (2.18, 3.01) 
 
2.90 (2.50, 3.43) 
 
< 0.001 
D-dimer (ng/mL) 1436 80 (87, 116) 97 (73, 146) < 0.001 
t-PA (ng/mL) 1362 7.0 (5.0, 9.2) 7.9 (6.4, 10.5) < 0.001 
vWF (IU/dl) 1446 105 (78, 137) 117 (87, 157) 0.006 
Factor VII (IU/dl) 1031 90 (70, 116) 89 (69, 113) 0.84 
F1+2 (nmol/L) 1062 1.4 (1.0, 2.0) 1.4 (1.0, 2.1) 0.85 
FPA (ng/mL) 1580 1.7 (1.3, 2.1) 1.7 (1.3, 2.1) 0.97 
t-PA: tissue plasminogen, vWF: vonWillebrand factor, FpA: fibrinopeptide A, F1+2: 
prothrombin fragments 1+2. 
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Figure 33 Survival curves for tertiles for incident major cardiovascular disease (CVD) per 































































































































































1: bottom tertile, 2: middle tertile, 3: top tertile.  
t-PA: tissue plasminogen, vWF: vonWillebrand factor, FpA: fibrinopeptide A, F1+2: 
prothrombin fragments 1+2.  
Cut off point for tertiles: 2.38-2.92 g/L for fibrinogen, 67-107 ng/mL for D-dimer, 
6.0-8.8 ng/mL for t-PA, 89-129 IU/dl for vWF, 77-105 IU/dl for Factor VII, 1.48-
1.95 ng/mL for F1+2, 1.00-1.70 nmol/L for FpA
p =0.86 
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Table 52 Hazard ratios (95% CI) for (a) cardiovascular disease, (b) myocardial infarction and 
(c) stroke between top and bottom tertiles of each marker 
Adjusted for: + age, sex + cardiovascular risk 
factors
†








(a) Cardiovascular disease 
Fibrinogen 2.33 (1.80, 3.01)** 1.85 (1.41, 2.42)** 1.76 (1.35, 2.31)** 
D-dimer 1.95 (1.47, 2.57)** 1.65 (1.24, 2.19)** 1.56 (1.17, 2.09)** 
t-PA 2.26 (1.68, 3.04)** 1.90 (1.39, 2.60)** 1.86 (1.36, 2.55)** 
VWF 1.42 (1.09, 1.85)** 1.34 (1.03, 1.75)* 1.33 (1.02, 1.74)* 
F VII 1.05 (0.77, 1.30) 1.01 (0.73, 1.40) 1.01 (0.74, 1.40) 
F1+2 1.07 (0.79, 1.46) 1.00 (0.73, 1.36) 1.00 (0.44, 1.37) 
FpA 1.16 (0.91, 1.47) 1.12 (0.88, 1.42) 1.11 (0.87, 1.41) 
(b) Myocardial infarction 
Fibrinogen 2.17 (1.57, 3.00)** 1.79 (1.27, 2.52)** 1.70 (1.20, 2.39)** 
D-dimer 1.96 (1.36, 2.83)** 1.69 (1.16, 2.47)** 1.59 (1.09, 2.33)* 
t-PA 2.16 (1.46, 3.19)** 1.92 (1.27, 2.91)** 1.87 (1.24, 2.83)** 
VWF 1.62 (1.15, 2.28)** 1.54 (1.09, 2.18)* 1.53 (1.08, 2.16)* 
F VII 1.71 (0.77, 1.77) 1.12 (0.73, 1.71) 1.12 (0.73, 1.71) 
F1+2 1.00 (0.67, 1.49) 0.92 (0.62, 1.38) 0.92 (0.61, 1.37) 
FpA 1.38 (1.01, 1.89)* 1.36 (0.99, 1.87) 1.36 (0.99, 1.87) 
(c) Stroke 
Fibrinogen 2.62 (1.70, 2.03)** 2.08 (1.33, 3.24)** 1.95 (1.25, 3.06)** 
D-dimer 1.98 (1.24, 3.15)** 1.63 (1.01, 2.62)* 1.53 (0.94, 2.48) 
t-PA 2.00 (1.26, 3.18)** 1.50 (0.91, 2.45) 1.47 (0.90, 2.41) 
VWF 1.10 (0.73, 1.65) 1.04 (0.69, 1.56) 1.02 (0.68, 1.54) 
F VII 0.94 (0.57, 1.55) 0.85 (0.51, 1.42) 0.86 (0.51, 1.43) 
F1+2 1.03 (0.63, 1.67) 0.95 (0.58, 1.55) 0.98 (0.60, 1.60) 
FpA 0.83 (0.59, 1.24) 0.85 (0.58, 1.24) 0.83 (0.57, 1.21) 
t-PA: tissue plasminogen, vWF: vonWillebrand factor, FpA: fibrinopeptide A, F1+2: 
prothrombin fragments 1+2. 
* p <0.01, ** p <0.05. 
† age, sex, pack years smoking, diabetes, BMI, total/ HDL cholesterol ratio and 
physical activity. 
‡myocardial infarction, stroke or angina. 
§ ankle brachial index. 
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1:top, 2:middle, 3:bottom 
Cut-off points for D-dimer: 67 and 107 ng/ ml
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6.12 Additive effect of inflammatory markers and 
haemostatic markers on incident CVD 
In this part, the additive effect between inflammatory and haemostatic markers on 
their associations with incident major CVD was investigated. 
 
6.12.1 Composite score: IL-6, fibrinogen and t-PA 
The previous analysis showed the inflammatory markers CRP and IL-6 and 
haemostatic factor fibrinogen, D-dimer and t-PA were independent predictors of 
major CVD after 17 years of follow up. In particular, IL-6, fibrinogen and t-PA had 
the highest hazard ratio associated with 1.8 fold or greater increase in risk of major 
CVD development (upper vs. lower tertile). Next, all variables that have shown a 
significant effect with incident CVD in the univariable analysis were entered in the 
Cox regression model with backward selection. In this analysis, cardiovascular risk 
factors, history of CVD at baseline and ABI were forced to enter in the model. 
Interestingly, IL-6, fibrinogen and t-PA were the only inflammatory/ haemostatic 
markers that stayed in the model. 
 
In order to examine the impact of concomitant variables on the long term risk of 
major CVD a composite score for elevated concentrations of IL-6, fibrinogen and 
t-PA was calculated. Five percent of the population had all 3 markers in the top 
tertile, 11.4% had 2 markers and 19.5% one marker. The risk of major CVD rose 
with increasing number of these markers within the top tertile of their distribution 
(Figure 35). People having three markers elevated compared to those having none 
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had hazard ratio (95% CI) 2.30 (1.44, 3.67) (p=0.001) of developing major CVD. 
This was independent of conventional risk factors, history of disease and baseline 
ABI. People having 2 and 1 markers elevated only compared to those who had none 
elevated had hazard ratio (95% CI) 1.85 (1.287, 2.69) (p <0.001) and 1.37 (0.97, 
1.92) (p =0.07).  
  
6.12.2 Combined variables: IL-6 and D-dimer 
Recall that IL-6 and D-dimer had shown an additive effect in relation to progression 
of peripheral atherosclerosis in previous analysis. Here this additive effect was 
examined in relation to major CVD. Individuals were divided into 4 mutually 
exclusive groups according to their baseline levels of D-dimer and IL-6:  levels of 
IL-6 and D-dimer in the top tertile (171 subjects), levels of IL-6 in the top tertile and 
levels of D-dimer in the middle or bottom tertile (180 subjects), levels of D-Dimer in 
the top tertile and levels of IL-6 in the middle or bottom tertile (170 subjects) and 
finally levels of both D-dimer and IL-6 in the middle or bottom tertile (506 subjects). 
The hazard ratio (95% CI) for people having both IL-6 and D-dimer at the top tertile 
compare to the group of subjects with neither of them at the top tertile was 1.70 
(1.20, 2.39) (p =0.003) in analyses adjusted for CVD risk factors, history of CVD 
and subclinical atherosclerosis. Similarly, people having IL-6 elevated only or 
D-dimer elevated only had hazard ratio (95% CI) compared to subjects with neither 
of them elevated  1.51 (1.07, 2.13) (p=0.01) and 1.31 (0.90, 1.90) (p=0.11) 
respectively. The p value for trend was highly significant (p<0.001) and therefore the 
additive effect between IL-6 and D-dimer observed in analysis for ABI change in the 
previous chapter was also confirmed here in relation to incident major CVD.  
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Figure 35 Hazard ratio (95% CI) for CVD associated with increasing numbers of elevated (top 







The hazard ratio of CVD was computed using subjects with baseline levels of IL-6, 
fibrinogen and t-PA at the bottom tertile as the reference group. Risk factors included 
BMI, diabetes, pack years of smoking, total/ HDL cholesterol ratio and physical 
activity. History of CVD included myocardial infarction, stroke, angina or IC at 






























 	 One marker elevated (311 subjects) 
  Two markers elevated (182 subjects) 
 Three markers elevated (80 subjects) 
 
Adjusted for age, sex      + risk factors and history   + subclinical 
                                               CVD disease                     disease 
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6.13 Inflammatory and haemostatic markers and 
incident CVD according to cardiovascular risk factors 
status at baseline 
In the previous analysis on peripheral atherosclerotic progression and on incident 
PAD, the associations between inflammatory and haemostatic markers CRP, IL-6, 
D-dimer and fibrinogen has been examined according to major cardiovascular risk 
factors status at baseline. Here the analysis is repeated on incident major CVD for 
comparison.  
 
6.13.1 Cholesterol levels 
The baseline population was stratified according to total/ HDL cholesterol levels and 
CRP into 6 groups: people with total/ HDL cholesterol ratio below the median and 
with CRP at bottom, middle and top tertile and people with total/ HDL cholesterol 
ratio above the median with CRP at bottom, middle or top tertile. Similarly, 6 other 
groups were created according to IL-6 and total/ HDL cholesterol ratio, fibrinogen 
and total/ HDL cholesterol ratio or D-dimer and total/ HDL cholesterol ratio.  
 
Figure 36 illustrates the hazard ratios (adjusted for cardiovascular risk factors, 
history of CVD and ABI) for each group compared to the group of subjects with 
total/ HDL cholesterol below the median and either, CRP, IL-6, fibrinogen or 
D-dimer at the bottom tertile (reference group). As the figure shows, subjects with 
increased levels (top tertile) of any of these 4 variables had increased risk of 
developing major CVD especially if their cholesterol/ HDL ratio was above the 
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median. If their cholesterol levels were below the median, increased levels of CRP, 
IL-6 and D-dimer were still significantly associated with incident major CVD but 
their effect was reduced. Levels of fibrinogen showed similar effects on incident 
CVD whether the total/ HDL cholesterol ratio was below or above the median with 




The baseline population was stratified according to smoking status (never and 
current/ ex smokers) and CRP into 6 groups: never smokers and CRP at bottom, 
middle and top tertile and current or ex smokers and CRP at bottom, middle or top 
tertile. Similarly, 6 other groups were created according to IL-6 and smoking status, 
fibrinogen and smoking status or D-dimer and smoking status.  
 
Figure 37 illustrates the hazard ratios (adjusted for cardiovascular risk factors, 
history of CVD and ABI) for each group compared to the group of never smokers 
with CRP, IL-6, fibrinogen or D-dimer at the bottom tertile (reference group). As the 
figure shows, there was little difference on the effect of these markers according to 
smoking status. The hazard ratios for the top tertile of CRP, IL-6 or fibrinogen were 
approximately the same whether subjects were never or current/ ex smokers. Only 
D-dimer showed small differences, its hazard ratio (95% CI) in never smokers was 
only 1.32 (0.76, 2.28) (top tertile vs. reference group) but among current or ex 
smokers it was considerably higher (2.17 (1.36, 3.46)).    
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Figure 36 Hazard ratios (95% CI) for major cardiovascular disease (CVD) according to tertiles 
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The hazard ratios are adjusted for age, sex, BMI, diabetes, pack years smoking, 
physical activity, cardiovascular disease and ankle brachial index. Reference group 
was the group of people with CRP, IL-6, fibrinogen or D-dimer at the bottom tertile 
and total/ HDL cholesterol below the median. Median for total/ HDL cholesterol: 
4.96. Cut-off point for tertiles of CRP: 1.13, 3.07 mg/L, IL-6: 1.65, 2.69 ng/ml, 
fibrinogen 2.38, 2.92 g/L and D-dimer 67, 107 ng/ ml. 
Total/ HDL cholesterol   Total/ HDL cholesterol 
        below median              above median 
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Figure 37 Hazard ratios (95% CI) for major cardiovascular disease (CVD) according to tertiles 



































Never smokers                    Current / Ex smokers 
Low  Medium  High       Low     Medium    High 
                
Low  Medium  High       Low     Medium    High 
                
 296 



























The hazard ratios are adjusted for age, sex, BMI, diabetes, pack years smoking, 
physical activity, cardiovascular disease and ankle brachial index. Reference group 
was the group of people with CRP. IL-6, fibrinogen or D-dimer at the bottom tertile 
and never smokers. Never smokers: 561 and current/ ex smokers 986 subjects. Cut-
off point for tertiles of CRP: 1.13, 3.07 mg/L, IL-6: 1.65, 2.69 ng/ml, fibrinogen 
2.38, 2.92 g/L and D-dimer 67, 107 ng/ ml. 
Fibrinogen 
D-dimer 
Low  Medium  High       Low     Medium    High 
                
Low  Medium  High       Low     Medium    High 
                
Never smokers                    Current / Ex smokers 
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6.14 Summary of results 
Approximately 14% of the baseline population developed PAD defined as IC, CLI or 
surgical intervention after 17 years of follow up. Smoking, total/ HDL cholesterol, 
hypertension and pre-existing CVD (p <0.01) were strong and independent predictors 
of incident PAD. Inflammatory markers, CRP and IL-6 showed modest associations 
with PAD. On the other hand, ICAM-1, fibrinogen and D-dimer (p <0.01) had 
stronger associations which were independent of cardiovascular risk factors and 
baseline CVD. In particular, fibrinogen had the greatest independent effect compared 
to other markers, which was not changed in the absence of increased cholesterol or 
smoking. Other inflammatory and haemostatic markers examined here did not show 
any significant associations with incident PAD.  
 
Moreover, 26% of the baseline population developed at least one event of major 
CVD defined as fatal/ non-fatal MI, fatal/ non fatal stroke, CABG or angioplasty. 
CRP, IL-6, ICAM-1, fibrinogen, D-dimer and t-PA (p <0.01) had significant 
associations with major CVD which were independent of cardiovascular risk factors 
and history of CVD. Further adjustments for subclinical atherosclerosis measured by 
the ABI little affected these associations. Also their effect was little changed in the 
absence of high cholesterol or in never smokers. Other markers did not show 
significant associations with major CVD. An incremental risk between people with 
one, two or all of fibrinogen, IL-6 or t-PA at the top tertile was found. Finally, when 
the events of MI or stroke were examined separately, CRP and E-selectin had 






The aforementioned analysis described results from the Edinburgh Artery Study on 
the associations between inflammatory and haemostatic markers with the presence 
and progression of PAD. The principal finding of this study was that several 
inflammatory and haemostatic markers showed associations with progression of 
peripheral atherosclerosis and with incident PAD. CRP, IL-6, fibrinogen and to a 
lesser extent D-dimer and ICAM-1 showed the strongest and most consistent 
associations. In this section, the principal results of the analysis described in this 
thesis are discussed. Prior to this discussion, the strengths and limitations of the 
methods employed are evaluated.  
 
7.2 Strengths and limitations 
7.2.1 Strengths 
Analyses presented in this thesis are based on the Edinburgh Artery Study. This is a 
relatively large cohort study of men and women almost exclusively of white origin 
who lived in Edinburgh. Sampling was population based reducing the bias from 
selected, hospital based recruitment. Other advantages of the Edinburgh Artery Study 
included the equal representation of both men and women across a range of adult 
groups and the long duration of follow up. A variety of risk factors were measured at 
baseline which enabled the adjustment for several confounders. All risk factor 
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measurements were performed using standard protocols and strict quality control 
measures.  
 
Another major strength of this cohort is its prospective design. The subjects were 
followed up for 17 years for cardiovascular events and all cause mortality. Most 
importantly, 2 clinical examinations after the baseline examination took place after 5 
and after 12 years. The latter enabled the measurement of the ABI over three time 
points for the first time in the general population. The events ascertainment was 
ensured by a standardized quality assurance protocol. Also, a key strength of the 
Edinburgh Artery Study was the careful follow up of the subjects via multiple 
methods. The Information Statistics Division of the Scottish Executive (Scotland's 
national organization for health information) was used which collects amongst the 
best health service data in the world. This service is able to link data to allow patient 
based analysis and follow up and therefore provides high quality and reliable data of 
national coverage (Scottish Health Statistics 2006). Subjects of the Edinburgh Artery 
Study would be lost to follow up only if they had left the country (UK) and this 
number is expected to be very small. Also, information on cardiovascular events was 
collected from general practitioners and retrieval of hospital records as well as from 
the subjects themselves via annual questionnaires.   
 
Moreover, the Edinburgh Artery Study ranks among the few epidemiological studies 
that focused on PAD. Contrary to many other cohorts which evaluated PAD only by 
the ABI or by the WHO IC questionnaire, here a variety of diagnostic methods were 
used including the ABI, the WHO IC questionnaire and most importantly the 
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assessment of more severe forms of PAD such as rest pain, gangrene, ulceration and 
surgical intervention. A further strength was the evaluation of incident PAD events in 
the general population since many studies on PAD have either a cross sectional 
design or focus just on patients with IC.  
 
7.2.2 Limitations  
Measurement of inflammatory and haemostatic markers 
The inflammatory and haemostatic markers were measured only once, and intra-
individual variation therefore could not be taken into account. Nevertheless, this 
would tend to result in an underestimation of the true effects, yielding
 
underestimates 
of the actual risk associated with these measures.  
 
Moreover, not all subjects had measurements for all of the haemostatic and 
inflammatory markers studied here. Data on some markers is missing due to attrition 
or decreasing availability of the plasma sample. This was mostly due to the volume 
of the original sample and would not be expected to be associated with the 
demographic and cardiovascular risk profile of the patients. Thus, the data was 
considered as missing ‘at random’. This can be further explored by examining the 
distribution of cardiovascular risk factors of the cohort in subjects with and without 
missing markers, for example CRP. As expected, the numbers fluctuated slightly 
between the two groups but no major differences were observed (Table 12). Also, 
‘missingness’ was not associated with incidence of CVD. For example, 26% of those 
who experienced at least one cardiovascular event had missing CRP values. On the 
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other hand, 28% of those who did not experience a cardiovascular event had missing 
CRP values.  
 
Measurement of ABI 
Another limitation is that data to adjust for measurement error in ABI were not 
available; again, this probably led to an underestimation of the strength of the 
reported associations. Also, for the ABI change analysis, participants in the 5 and 12 
year follow up examinations were probably healthier at baseline than those who died 
during the follow up period. This might explain the higher baseline ABI (1.07) of 
those 747 subjects who attended all 3 clinical examinations. However, the trend in 
ABI decline during the 12 years between the individual examination attenders and 
the group who attended all 3 clinical examinations was similar and suggests that the 
findings and conclusions are likely to be valid.  
 
Incident disease 
Most studies on PAD have defined the disease according to the presence of 
symptoms of IC only. In the present study the more severe events of CLI and 
surgical interventions were included to increase the generalizability of the findings. 
However, asymptomatic diseased as defined by the ABI was not included because 
this measurement was not available after 17 years of follow up. Therefore the 






The generalization of these results to other ethnic populations and age groups is 
unknown. Furthermore, the analyses were not adjusted for aspirin or statin use at 
baseline; however, at the time of baseline examination (1987/1988), very few of the 
Edinburgh population took such drugs for the prevention of CVD. 
Despite the prospective design of this study, an observational study cannot establish 
causal relations, and residual confounding cannot be ruled out. Therefore, the precise 
pathway through which inflammation and haemostasis influence atherosclerotic 
progression and the directionality of the reported associations remain unknown. 
Similarly, non-significant associations may have resulted if inflammatory/ 
haemostatic markers exerted their effect on the disease outcome via cardiovascular 
risk factors like diabetes or BMI. If this was true, these variables should not be used 
as covariates in the model because they were not confounders but intermediary 
factors. 
 
7.3 Progression of peripheral atherosclerosis and 
incident PAD 
In this population cohort study, the progression of peripheral atherosclerosis was 
assessed by the change in ABI between 3 time points over a 12 years follow up 
period. Although the mean changes in the whole population were subtle, the ABI 
decreased significantly over the years. This demonstrates the progression of 
peripheral atherosclerosis over time in the study population and their increasing risk 
of developing CVD since the ABI is a reliable and accurate marker of generalized 
atherosclerosis in populations (Bird et al 1999; Fischer et al 1996).  
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The measurement of ABI as a quantitative measure of disease over time has not been 
thoroughly investigated before. In the San Diego study, the ABI was measured at 
baseline and after 5 years of follow up and a progression was defined by the highest 
tertile of decline which was a -0.30 ABI (Aboyans et al 2006). Approximately 11% 
of the baseline population with valid ABI on both legs had progression of disease 
under this definition. The mean (SD) change in the whole population was -0.06 
(0.15) after 5 years which is a little higher than the -0.04 (0.18) (also at five years) 
observed in our cohort. A decrease of -0.014 per year has been reported in 
claudicants (Aquino et al 2001).   
 
Also, among those with an ABI>0.9 at baseline, 13% and 18% had an ABI  0.9 at 5 
and 12 years, respectively. This incidence of asymptomatic PAD is difficult to 
compare
 
with other studies because of lack of data and differences
 
in the use of 
diagnostic methods to assess asymptomatic disease.  In the Limburg PAOD study, 
the incidence rate of an ABI  0.9 among people with ABI>0.9 at baseline was 9.9/ 
1,000 person years (Hooi et al 2001). This is slightly smaller than the one reported 
here but in the present analysis, contrary to the Limburg analysis, people who 
developed IC during the follow up were excluded. Moreover, the Edinburgh Artery 
Study population is relatively older than that of the Limburg cohort so that an 
increased incidence of disease might be expected.  
 
Over a longer time period of 17 years, approximately 14% of the study population 
(with no symptomatic PAD at baseline) developed clinical PAD (82 per 10,000 
population per year). In general, our results are higher than annual rates reported 
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from the Framingham Heart Study (61 per 10,000 men and 54 per 10,000 women per 
year aged 64-74) (Kannel et al 1970) or the Quebec Cardiovascular Study (41 per 
10,000 population per year) (Dagenais et al 1991). However, these studies only 
included IC in the definition of PAD and not rest pain, ulceration, gangrene and 
surgical intervention which were recorded in the Edinburgh Artery Study. Therefore, 
it would be expected that the incidence of clinical PAD in this cohort would be 
higher than in the aforementioned studies. 
   
7.4 Cardiovascular risk factors and PAD 
Risk factors for progression of subclinical PAD were older age,
 
male sex, smoking, 
hypertension, total/ HDL cholesterol ratio and history of CVD. Only one other study, 
the Cardiovascular Health Study, has evaluated risk factors
 
for decline in ABI in the 
general population (Kennedy et al 2005). Progression of asymptomatic PAD was 
defined as a decline of a participant’s
 
ABI of more than 0.15 and to 0.9 or less and 
the predictors
 
of ABI decline were age, current cigarette use, hypertension, diabetes, 
higher LDL
 
cholesterol level and lipid-lowering
 
drug use. These results are in 
accordance with those reported here with the exception of diabetes which failed to 
show significant associations with ABI decline in the present study.  
 
Risk factors for subclinical PAD were similar
 
to those for clinical PAD. Age, male 
sex, smoking, total/HDL cholesterol, hypertension and pre-existing CVD were strong 
independent predictors of PAD development, as previously described (Murabito et al 
1997, Fowkes et al 1992). Despite the higher prevalence of diabetes in the group of 
people who developed PAD compared to those who did not develop PAD, the 
 305 
difference did not reach statistical significance. The absence of significant 
associations between diabetes with the progression of peripheral atherosclerosis and 
with incident PAD is surprising because diabetes is considered an important risk 
factor for PAD. The non-significance of the reported associations might thus be due 
to low statistical power and does not necessarily mean that presence of diabetes is 
not important for the progression and incidence of PAD. 
 
Physical activity has not been extensively investigated in relation to PAD 
development. Here there was not any clear association between decreased physical 
activity and PAD development. BMI also showed no evidence for associations with 
incident PAD. Interestingly it showed borderline significant associations with ABI 
decline after 12 years of follow up but in the opposite direction. Given that high BMI 
and obesity are risk factors for CVD this result is probably a statistical artifact 
especially since it was only significant in the multivariable and not the univariable 
analysis.   
 
7.5 C-reactive protein 
7.5.1 C-reactive protein and subclinical disease 
The main aim of this analysis was to examine the association of inflammatory 
markers with the progression of atherosclerosis. CRP is probably the most 
extensively studied inflammatory marker in relation to CVD (Koenig 2005). The 
present analysis showed that CRP was also associated with progressive 
atherosclerosis measured by the ABI decline after 5 and after 12 years of follow up. 
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Most importantly, these associations changed little after adjustment for conventional 
risk factors and the presence of clinical CVD at baseline. This result shows that CRP 
is associated with atherosclerotic development and that this association is at least not 
entirely due to interrelations between CRP, cardiovascular risk factors and CVD. 
Associations between CRP and the extent of atherosclerotic disease have shown 
conflicting results in previous studies. In general, there is little information on CRP 
and ABI and most research has focused on other markers of subclinical disease such 
as the IMT. Only two other prospective studies exist in the literature. In the 
Rotterdam study, subclinical atherosclerosis was assessed at various sites of the 
arterial tree at 2 points in time, with a mean duration between measurements of 6.5 
years (van der Meer et al 2002b). Data from this analysis showed that CRP levels 
increased with the total number of sites showing progression of atherosclerosis. The
 
odd ratio for generalized progression of atherosclerosis as indicated
 
by the composite 
progression score was 4.5 (95% CI, 2.3 to 8.5) which was as high as those associated
 





Moreover, in relation to progressive carotid atherosclerosis measured by IMT 
change, Hashimoto et al, demonstrated that CRP concentration was an independent
 
predictor of the development of early atherosclerosis and that it was associated with 
the
 
rate of plaque development (Hashimoto et al 2004). However, the latter study was 
conducted among hypertensive patients being managed by
 
drug therapy or lifestyle 
modification and had a short term follow up of 35 months. Interestingly, CRP was an 
equivalent
 
or better independent predictor of the progression of carotid
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atherosclerosis than the pulse pressure or systolic blood pressure (Hashimoto et al 
2004). 
 
Results from two cross-sectional population studies, the Dallas Heart Study and the 
Framingham Heart Study, agreed that measured CRP levels were associated with a 
modest increase in the prevalence of subclinical coronary atherosclerosis as 
measured by electron
 
beam computerized tomography for coronary calcium (Khera 
et al 2006;Wang et al 2002). However, the reported associations were not 
independent of traditional cardiovascular risk factors. In support, CRP was not 
associated with ABI in the multivariable analysis among participants without a 
history of CVD in another cohort (McDermott et al 2003). Also, modestly increased 
CRP levels were observed
 
in male subjects with aortic plaque in the Dallas Heart 
Study; although this relationship
 
was no longer evident after adjustment for other risk 
factors (Khera et al 2006). Similarly, data from the Health ABC study showed that 
CRP was not significantly associated with overall subclinical CVD defined as 
positive findings on the WHO questionnaire for angina or claudication, ABI<0.9, or 
electrocardiographic abnormalities (Cesari et al 2003). In a Danish cohort, CRP was 
associated with IMT levels but not with the number of carotid plaques (De Maat et al 
2003).  
 
CRP was also strongly associated with ABI decline in subjects with elevated risk 
factors at baseline (cholesterol, smoking) in the present study. On the other hand, in 
the absence of these factors, the associations between CRP and ABI decline were 
modest. Similar findings were observed when CRP was associated with incident 
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CVD; the effect of CRP on incident CVD among subjects with low cholesterol levels 
was attenuated. Several studies have observed that among ‘low’ risk individuals 
(according to a combination of conventional cardiovascular risk factors) high CRP 
levels do not indicate high CVD event rates (Koenig et al 2004;Ridker et al 2002;van 
der Meer et al 2003). Therefore, results of the present and past studies reinforce 
evidence for a potential limited clinical value of CRP in individuals at high risk on 
the basis of traditional risk factors. It should be stressed however, that given that 
CRP was associated (even weakly) with progression of atherosclerosis and incident 
CVD among non-smoker subjects or among subjects with low cholesterol, it is more 
likely to have a causal role in disease development and progression.   
 
7.5.2 C-reactive protein, PAD and CVD 
CRP levels were also associated with incident PAD. However, this association was 
attenuated after adjustment for cardiovascular risk factors and eventually lost 
statistical significance when history of CVD was accounted for. When CRP was 
adjusted for each risk factor individually, smoking and history of CVD were the two 
variables that had the most pronounced effect on the association between CRP and 
incident PAD. The importance of smoking as a confounder is not surprising given 
that it is the most important risk factor for PAD and at the same time is highly 
correlated with CRP.  
 
Despite the extensive data on CRP and incident CVD from several population 
studies, its role in peripheral atheroma is not well established. CRP has only been 
associated with incident PAD in the Physicians Health study which showed that CRP 
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along with total/HDL cholesterol ratio were the strongest predictors of PAD among 
several biomarkers assessed in healthy males (Ridker et al 1998c). In comparison to 
our study, the crude risk ratio of CRP (2.2 top vs. bottom quartile) for incident PAD 
was little reduced (2.1) in the adjusted analysis. However, this was a nested case 
control study in which cases and controls were matched for age and smoking and 
only males were included. Therefore, the adjustment for other risk factors would be 
expected to have a relatively smaller effect on the estimated risk ratios than in this 
analysis. Moreover, cross-sectional data have shown that CRP levels are higher in 
patients with symptomatic PAD (IC or CLI) compared to healthy controls (Cassar et 
al 2005). 
  
In this study, CRP was also associated with incident CVD (defined as MI or stroke) 
with a hazard ratio of 2.2 which was very close to the 2-fold relative risk for CHD 
(top vs. bottom tertile) estimated by the recent meta-analysis of studies on CRP and 
incident CHD (Danesh et al 2004). Also, the hazard ratio for CVD was slightly 
higher than the hazard ratio of 2.0 observed between CRP and PAD. Contrary to the 
PAD analysis, CRP was also significantly associated with incident CVD when 
cardiovascular risk factors and history of CVD were accounted for. This difference in 
the effect of CRP on incident PAD and incident CVD (MI or stroke) does not 
necessarily support a different effect of CRP on different manifestations of the 
disease. PAD events were considerably fewer than CVD events and this would have 
itself somewhat influenced the precision of estimated effect sizes and the significant 
levels. In addition, it should be noted that CRP (and IL-6) were measured in fewer 
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individuals than the other markers examined in this thesis and this might have also 
contributed to the precision of the estimated effect sizes and the significant levels.  
 
The causality of the association between CRP and CVD is open to debate given the 
strong correlation of CRP with traditional cardiovascular risk factors and 
symptomatic and asymptomatic arterial disease, and the possibility of ‘reverse 
causality’ (Lowe et al 2005). Interestingly, in this study, CRP was associated with 
incident CVD even after adjustment for subclinical atherosclerosis measured by the 
ABI; a result which was also demonstrated by the Cardiovascular Health Study 
(Cushman et al 2005). This is an important finding which weakness the hypothesis of 
reverse causality and provides further evidence of a causative role of CRP in 
atherosclerotic disease. However, adjusting our analysis for multiple measures of 
subclinical disease in addition to the ABI would add to the validity of this result. 
Unfortunately other measures of subclinical disease were not available at the baseline 
examination of the Edinburgh Artery Study and therefore this analysis was not 
performed.  
 
CRP also showed relative importance as a risk factor for stroke, a finding in support 
of a meta-analysis of studies with long follow up (>8 years) that showed that the risk 
for stroke in healthy individuals with the highest quartile of CRP concentrations 
increased nearly 70% compared to those with the lowest quartile (Kuo et al 2005). 
However, despite the fact that the association of CRP with stroke has been 
previously observed by others (Ford et al 2000;Gussekloo et al 2000;Ridker et al 
2000a;Ridker et al 1997;Rost et al 2001), its relative importance compared to MI is 
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controversial. In the 543 healthy males participating
 
in the Physicians' Health Study, 
CRP was a stronger predictor for MI than for stroke (Ridker et al 1997). In contrast, 
data from the Honolulu Heart Programme showed that CRP levels had comparable 
associations with MI and stroke (Curb et al 2003). Above all, the association between 
increased inflammatory markers and future stroke is of particular interest because it 
might provide an explanation for the beneficial role of statins in cerebrovascular 
disease despite the fact that LDL cholesterol
 
is not a strong risk factor for stroke 
(Ridker 2002). 
 
7.5.3 Role of C-reactive protein in atherosclerosis 
The
 
present findings emphasize the tight linkage of CRP to
 
the atherosclerotic 
processes and may support a hypothesis that
 
CRP directly interacts with 
atherosclerotic vessels to promote atherosclerotic development and progression. 
There are many pathways through which CRP may be causally related to 
atherosclerosis (Armani et al 2005b). For example, CRP has been shown to interact 
with modified LDL, a fact that may contribute to the regulation of LDL metabolism 
and foam cell formation in the arterial wall (Rattazzi et al 2003). In addition, CRP 
could promote the activation of monocytes and induce the expression of adhesion 
molecules, IL-6 and PAI-1 by endothelial cells further contributing to atherosclerotic 
development (Pasceri et al 2001). Moreover, CRP can stimulate tissue factor 
production and activate the complement (Li et al 2004). As stated before, tissue 
factor is the main stimulus for initiating the coagulation cascade, which may further 
promote atherosclerosis.  
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On the other hand, CRP directly affects endothelial function by altering NO 
bioavailability. NO is a vasodilator synthesized by the endothelial nitric oxide 
synthase enzyme. In fact, endothelial cells incubated with CRP showed decreased 
endothelial nitric oxide synthase expression and NO release (Venugopal et al 
2002;Verma et al 2002). Two other studies suggested that CRP could also promote 
activation, proliferation and migration of the smooth muscle cells (Hattori et al 
2003;Wang et al 2003).  
 
Further evidence comes from studies that have attempted to localize CRP in the 
atherosclerotic plaques. An early study confirmed the presence of CRP in human 
aortic lesion immunohistochemically (Reynolds et al 1987). Since then, studies have 
replicated this result and have reported the production of CRP from coronary 
plaques, aneurismal aortas, failed venous coronary bypasses and in femoral 
atherosclerotic plaques (Vainas et al 2005).  
 
7.6 Interleukin-6 
7.6.1 Interleukin-6 and subclinical disease 
IL-6 is a pro-inflammatory cytokine which has shown substantial evidence for 
associations with CHD. This is the first study to examine the predictive value of IL-6 
in relation to progression of peripheral atherosclerosis. A significant association 
between IL-6 and ABI at baseline, ABI change at 5 years, and ABI change at 12 
years of follow up in analyses adjusted for conventional risk factors was found. 
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These results were also confirmed by longitudinal analysis with the use of ABI as a 
repeated measurement over 3 time points. 
 
Therefore, a strong relationship between IL-6 and progression of atherosclerosis in a 
series of analyses was reported. Cross-sectional analysis from the Health ABC study 
(Cesari et al 2003) also showed that for those with IL-6 levels in the highest 
compared to the lowest tertile, the odds ratio for subclinical CVD (defined by the 
Angina or IC WHO questionnaire or by ABI<0.9 or by ECG) was 1.58 (95% CI 1.26 
to 1.97). On the contrary, in a subsample of
 
the Rotterdam Study (van der Meer et al 
2002a), IL-6 levels were not found to be associated
 
with another measure of 
subclinical atherosclerosis, carotid IMT. This negative result was replicated in a 
healthy population of 1,111 men and women in the Australian National
 
Heart 
Foundation Survey (Chapman et al 2004). 
 
IL-6 was also an independent predictor of ABI change at 5 years and at 12 years, 
when both risk factors and inflammatory markers (CRP, ICAM-1, VCAM-1, and 
E-selectin) were simultaneously entered as covariates into the model. The 
independence of IL-6 associations with atherosclerotic disease after adjustments for 
inflammatory variables was also observed in relation to incident CVD in this thesis 
and it has been examined in relation to CHD by other investigators. Ridker et al 
reported that IL-6 remained significantly associated with IHD risk after adjustment 
for CRP (Ridker et al 2000a). Also, the Quebec Cardiovascular Study replicated this 
result and showed that IL-6 was associated with long term risk of IHD after 
adjustment for lipid and non-lipid factors as well as for CRP and fibrinogen. The 
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authors claimed that the advantage of IL-6 over CRP might be due to the lower 
biological variability of IL-6, as previously shown (Browning et al 2004). However, 
since IL-6 is a primary stimulant for acute phase response proteins and also 
up-regulates adhesion molecules, the present data might explain why acute phase 
reactants (CRP, fibrinogen) or adhesion molecules have been associated with 
cardiovascular risk.  
 
IL-6 also showed a greater independent effect on ABI compared to haemostatic 
markers. Some evidence for an additive effect between IL-6 and the fibrinolytic 
marker D-dimer was also found. When IL-6 and haemostatic markers were examined 
in the same model, D-dimer, added to the R
2
 value of the model with IL-6 when 
predicting ABI change. Similarly, subjects with high levels of both D-dimer and IL-6 
had a worse disease outcome (greater ABI decline) than those who had one or none 
of these factors at high levels. This additive effect of D-dimer and IL-6 was also 
observed in relation to incidence CVD but not to incident PAD. Evidence for an 
additive effect between these two markers and CHD has been previously reported 
(Lowe et al 2004b). 
 
IL-6 was the only inflammatory marker that predicted ABI decline after 5 and 12 
years of follow up independently of baseline risk factors in subjects without PAD at 
baseline. Moreover, when the baseline population was divided according to 
cholesterol levels (above/ below median) or smoking status (current/ex and never 
smokers), IL-6 was associated with ABI decline with the same magnitude among 
high or low risk individuals. The same was not true for CRP which had considerably 
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lower predictive ability when cholesterol levels were decreased. IL-6 has previously 
shown high correlations with prevalent PAD and CVD and cardiovascular risk 
factors. The latter subgroup analysis confirmed the original analysis and stressed the 
fact that IL-6 associations with atherosclerotic progression were not only a 
consequence of elevated cardiovascular risk factors or prevalent CVD and thus are 
more likely to be causal. 
 
7.6.2 Interleukin-6, PAD and CVD 
In relation to incident PAD, IL-6 was independently associated with clinical PAD 
events in analysis adjusted for CVD risk factors. However, as with CRP, IL-6 lost 
significance when the history of CVD at baseline was accounted for, probably due to 
the high correlation between IL-6 and prevalent CVD. On the other hand, IL-6 was 
associated with incident CVD (MI or stroke) independently of conventional risk 
factors and of baseline CVD. In fact, IL-6 showed the greatest hazard ratio (top vs. 
bottom tertile) for CVD (1.8) compared to other markers studied here and was 
considerably higher than that estimated for incident PAD (1.5). 
 
Data on IL-6 and PAD are very limited. Several cross-sectional studies have shown 
that IL-6 is elevated in patients with PAD compared to healthy controls (Brevetti et 
al 2003;DePalma et al 2003;Erren et al 1999;McDermott et al 2005a;Signorelli et al 
2003;Silvestro et al 2003;Yu et al 2004). This is the first study to assess the role of 
IL-6 in relation to PAD prospectively and the results need cautious interpretation. 
They may reflect a modest effect of IL-6 on PAD and therefore a possible difference 
in its predictive ability across diverse disease manifestations. Also, as with CRP, 
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PAD events were fewer than combined CVD events and this might have itself 
somewhat influenced the precision of the estimated effect sizes and the significance 
levels. 
 
The reported associations between IL-6 and CVD are in agreement with previous 
published studies. In fact, the hazard ratio of IL-6 in analysis adjusted for 
cardiovascular risk factors was the highest of all other inflammatory markers under 
study and remained significant after adjustments for other inflammatory markers. IL-
6 has been found before to be a stronger predictor of incident CVD compared to 
other inflammatory markers including CRP or fibrinogen (Luc et al 2003b; Cesari et 
al 2003). Finally, IL-6 was also associated with incident stroke; a result that has only 
been reported by the Heath ABC Study (Cesari et al 2003).  
 
In the previous analysis IL-6 was strongly associated with subclinical atherosclerosis 
and its progression. Notably, here, the associations of IL-6 with incident CVD were 
independent of subclinical disease measured by the ABI. Therefore, the association 
between IL-6 and incident CVD is less likely to simply reflect an inflammatory 
response to early atherosclerotic development and thus more likely to play a causal 
role in atherosclerotic disease.  
 
Composite score: IL-6, fibrinogen and t-PA 
Finally, IL-6 along with fibrinogen and t-PA had the highest hazard ratios for 
incident CVD. A composite score for elevated concentrations of these markers was 
calculated. Interestingly, an incremental risk between people with 1, 2 or 3 markers 
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in the top tertile was found. One possible explanation of this effect could be that 
these markers might promote atherosclerosis through distinct pathways. Composite 
scores have previously been reported to add to the ability to assess cardiovascular 
risk for other biomarkers. Data from the Quebec Cardiovascular Study indicated that 
an inflammatory score defined as a combination of high IL-6 and fibrinogen levels, 
in combination with a series of traditional risk factors, may better discriminate 
incident IHD cases from IHD-free individuals (St-Pierre et al 2005). In addition, in 
the Health ABC Study a composite summary indicator of inflammation including 
CRP, TNF- and IL-6 showed a strong association with cardiovascular events. It 
must be stressed however that the use of a score based on increased levels of 
biomarkers needs careful consideration from a clinical viewpoint in terms of cost and 
time effectiveness. 
 
7.6.3 Role of interleukin-6 in atherosclerosis 
Findings of this thesis support a strong association between IL-6 and atherosclerotic 
progression which is independent of major cardiovascular risk factors and other 
inflammatory and haemostatic markers. IL-6 is a pro-inflammatory and 
pro-coagulant cytokine which might have important implications on the 
atherosclerotic development and progression. In fact, IL-6 induces the production of 
several inflammatory and haemostatic molecules that have been in turn associated 
with atherosclerosis and thrombotic complications. Firstly, IL-6 up-regulates the 
expression of CRP, fibrinogen and other acute phase reactants by the liver. Also, 
IL-6 increases basal glucose intake, alters insulin sensitivity and induces the 
expression of adhesion molecules and the secretion of other cytokines by endothelial 
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cells (Yudkin et al 2000). In addition, it has important pro-coagulant properties 
promoting platelet production, stimulating coagulants and inhibiting anti-coagulants 
which might further induce IL-6 production (Kerr et al 2001). Finally, IL-6 may also 
be associated with plaque stability through its role in extracellular matrix deposition 
and reorganization (Galis et al 1994;Grote et al 2003;Schieffer et al 2004;Solis-
Herruzo et al 1999). 
 
IL-6 was also found within human atherosclerotic plaques in different vascular beds 
by several investigators further suggesting a vital and potentially causative role of 
this molecule in atherosclerotic disease (Kaneko et al 1997;Rus et al 1996;Salomon 
et al 1992;Seino et al 1994). Scheiffer showed that IL-6 is expressed particularly at 
the shoulder of the atherosclerotic plaque (Schieffer et al 2000). In a later report, 
Scheiffer (Schieffer et al 2004) showed a direct link between IL-6 and plaque 
decomposition in mice models. In this study, a deficiency in IL-6 enhanced 
atherosclerotic plaque development and was associated with increased lipids levels 
(Schieffer et al 2004).  
 
7.7 Adhesion molecules 
7.7.1 Adhesion molecules and subclinical disease 
The relationship between adhesion molecules and the extent of atherosclerosis is 
very little studied whereas existing reports have shown conflicting results. In the 
present analysis, ICAM-1 showed significant associations with progressive 
peripheral atherosclerosis after 5 and after 12 years of follow up. Also, the 
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associations at 12 years were independent of cardiovascular risk factors and baseline 
CVD. Additionally, ICAM-1 was a significant predictor of ABI change at 5 and 12 
years of follow up in subjects without PAD at baseline (baseline ABI and age 
adjusted analyses). Results on ICAM-1 and progression of atherosclerosis were also 
confirmed by repeated measures analysis. VCAM-1 and E-selectin showed no 
significant associations with ABI change in any analysis and indeed they were not 
even associated with baseline ABI.    
 
Previous evidence showed that ICAM-1 and VCAM-1 were independently 
associated with ABI among 88 subjects (Iwashima et al 2005) Also, strong 
correlations between carotid
 
IMT and plasma ICAM-1 and VCAM-1 have also been  
reported (Rohde et al 1998). In addition, ICAM-1 was independently associated with 
the risk of having at least one carotid plaque and with the risk of having at least one 
femoral plaque but not with IMT in another study (Bongard et al 2002). Moreover, 
the present study supports previous evidence for a different role between ICAM-1 
and VCAM-1 according to the stage of the disease. In fact, studies have shown that 
VCAM-1 is associated with PAD progression in subjects with pre-existing disease, 
but ICAM-1 predicts disease development in healthy populations as found in this 
cohort. Finally, our null data for E-selectin is in accordance with previous studies, 
which did not find any association between E-selectin levels and PAD severity or 
PAD location (De Caterina et al 1997;Blann et al 1997;Blann et al 2000). 
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7.7.2 Adhesion molecules, PAD and CVD 
Plasma levels of ICAM-1, but not of VCAM-1, were strongly associated with 
incident PAD and retained statistical significance after adjustment for traditional risk 
factors. This is in accordance with one prospective study which had examined the 
association between ICAM-1 and VCAM-1 with symptomatic PAD (Pradhan et al 
2002a). The authors concluded that ICAM-1, and not VCAM-1, was associated with 
more than a 3 fold increase in the risk of developing symptomatic PAD in analysis 
adjusted for cardiovascular risk factors (top vs. bottom quartile) (Pradhan et al 
2002a). In addition, in the present analysis the hazard ratio of ICAM-1 in the 
adjusted analysis was 1.8 (top vs. bottom tertile) which was little changed when 
analysis was further adjusted for levels of other inflammatory markers. No evidence 
was found for an association of E-selectin and PAD development which is in 
agreement with previously published negative results for the presence and 
progression of peripheral atherosclerosis (Blann et al 1998;De Caterina et al 
1997;Peter et al 1997). 
 
In contrast to PAD analysis, ICAM-1 showed significant associations with incident 
CVD only when adjusted for age and sex and lost significance in the multivariable 
analysis. Other studies have also failed to show significant associations between 
ICAM-1 and incident CVD in the multivariable analysis (Ridker et al 2000a; Jenny 
et al 2006). Moreover, the combine meta-analysis of 5 studies on ICAM-1 and CHD 
has yielded a modest odds ratio of 1.4 (top vs. bottom tertile) (Malik et al 2001). A 
potentially favorable role of ICAM-1 in peripheral rather than coronary or 
cerebrovascular atherosclerosis could be argued from results reported here. ICAM-1 
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showed strong associations with ABI decline and with incident PAD but not with 
incident CVD defined as MI or stroke. However, since there is no biological 
mechanism that could explain this importance of ICAM-1 in the peripheral vascular 
bed, its relative value needs replication from future studies.  
 
Data on VCAM-1 and E-selectin are generally negative for associations with incident 
CVD and therefore they are in line with results reported here (Malik et al 2001). 
Interestingly, E-selectin had a significant hazard ratio when incident stroke was 
examined separately and retained significant associations in the multivariable 
analysis. Since there are no other published data on E-selectin and stroke, a 
preferential effect of E-selectin on stroke events only needs cautious consideration 
and validation from future studies. 
 
7.7.3 Role of adhesion molecules in atherosclerosis 
The aforementioned analysis showed a strong association between ICAM-1 and the 
progression and incidence of peripheral atherosclerosis and provided further support 
for a role of adhesion molecules in atherosclerotic development. In fact, adhesion 
molecules are thought to contribute to the earliest stage of atherosclerotic disease by 
facilitating leukocyte adhesion to the endothelium and their migration to the intima. 
E-selectin is thought to play a pivotal role in rolling and tethering of the leukocytes 
in the arterial wall whereas ICAM-1 and VCAM-1 are thought to participate in the 
later stages of firm adhesion and transmigration of leukocytes across the endothelium 
(Hope 2003).  
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In addition, expression of adhesion molecules has been found in atherosclerotic 
plaques (Huo et al 2001). E-selectin expression by endothelial cells was shown on 
the surface of fibrous and lipid containing plaques (Davies et al 1993). However, the 
expression of E-selectin was not found in atherosclerotic plaques of rabbits or mice 
(Iiyama et al 1999). Increased expression of ICAM-1 was also observed on the 
surface of human atherosclerotic plaques and on the surface of lesion-prone areas in 
rabbits or mice (Iiyama et al 1999;Poston et al 1992). Finally, VCAM-1 was 
expressed on the endothelial cells in fibrous and lipid containing plaques (Davies et 
al 1993;Iiyama et al 1999). 
 
7.8 Fibrinogen 
7.8.1 Fibrinogen and subclinical disease 
Fibrinogen is the most extensively studied haemostatic marker as a risk factor for 
CVD. In this analysis, fibrinogen was associated with progression of peripheral 
atherosclerosis as evaluated by changes of ABI after 12 years. This association was 
independent of cardiovascular risk factors and also of other haemostatic factors 
studied here. At 5 years, no significant associations were found between fibrinogen 
levels and ABI reduction probably due to small power of this analysis since the ABI 
change after 5 years was much smaller compared to that over 12 years.  
 
The association between elevated fibrinogen and subclinical atherosclerotic disease 
has been previously examined in cross-sectional studies only. In the Cardiovascular 
Health Study, fibrinogen was associated with subclinical atherosclerosis measured by 
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a variety of methods including electrocardiography, echocardiography, carotid 
ultrasound and the ABI (Tracy et al 1995).  Other studies have confirmed the 
association between fibrinogen and asymptomatic atherosclerosis measured by the 
ABI (McDermott et al 2003;Philipp et al 1997). In 693 hypercholesterolemic men, 
fibrinogen was also associated with the presence of carotid, femoral and aortic 
plaque (Levenson et al 1997). Moreover, fibrinogen has been associated with carotid 
IMT and with carotid plaque formation independently of cardiovascular risk factors 
(Chapman et al 2004; De Maat et al 2003; Martinez-Vila et al 2003). The ARIC 
study has also evaluated the relationship between plasma fibrinogen and progression 
of carotid atherosclerosis measured by IMT change. A significant relationship 
between fibrinogen and IMT change has only been observed in the univariable 
analysis (Chambless et al 2002).  
 
The present analysis showed a significant association between fibrinogen levels and 
progression of peripheral atherosclerosis over 12 years. This effect of fibrinogen was 
limited in the absence of cardiovascular risk factors cholesterol and smoking. Also, 
the individual effect of fibrinogen on ABI decline was smaller than that estimated for 
CRP or IL-6 whereas adjustments for any of these markers reduced the reported 
associations to non-significance for fibrinogen. These results highlight an important 
role of fibrinogen in atherosclerotic progression but on the same time suggest that 
these associations are to some extent due to interrelationships of fibrinogen with 
cardiovascular risk factors and with other inflammatory markers.  
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Finally, fibrinogen and D-dimer were the only haemostatic markers examined in this 
thesis that showed associations with peripheral atherosclerotic progression. In fact, 
other haemostatic markers were not even associated with baseline ABI. Fibrinogen 
and D-dimer are acute phase reactants and therefore these results might demonstrate 
a primary role of inflammation rather than of haemostasis in atherosclerotic 
development and progression.  
 
7.8.2 Fibrinogen, PAD and CVD 
Fibrinogen was associated with PAD independently of conventional risk factors and 
history of CVD. Its hazard ratio of 2.2 for subjects in the top vs. the bottom tertile of 
fibrinogen at baseline was higher than any of the other markers studied here. 
Fibrinogen was also significantly associated with incident PAD in the absence of 
major PAD risk factors including smoking and cholesterol levels. The association 
between fibrinogen and PAD has been confirmed by many cross-sectional studies 
(Fabsitz et al 1999;McDermott et al 2003;McDermott et al 2005a;Meijer et al 
2000;Selvin et al 2004;Smith et al 1993;Wildman et al 2005;Zheng et al 2005). 
However, evidence from prospective studies is very limited. The prognostic
 
value of 
fibrinogen is illustrated by the 5 year follow up of the Edinburgh Artery Study,
 
in 
which median fibrinogen levels were higher in patients who
 
later went on to develop 
PAD (Smith et al 2000b). These results were confirmed by the Physicians' Health 
Study (Ridker et al 2001). 
 
Apart from PAD, fibrinogen also presented significant associations with incident 
CVD independently of cardiovascular risk factors and incident CVD. This is in 
 325 
accordance with the recent individual participant meta-analysis which found 
moderately strong associations between usual plasma
 
fibrinogen level and the risks 
of CHD, stroke, other vascular
 
mortality, and nonvascular mortality in a wide range 
of circumstances
 
in healthy middle-aged adults (Danesh et al 2005). In the present 
analysis, fibrinogen also had significant hazard ratios for both MI and stroke and 
retained significant associations after adjusting for subclinical atherosclerosis. The 
latter has also been observed for CRP and IL-6 and is of particular importance 
because it implies that elevated fibrinogen levels are more likely to be causally 
associated with CVD than to simply reflect the result of CVD risk factors and 
subclinical or clinical atherosclerotic disease. 
 
7.8.3 Role of fibrinogen in atherosclerosis 
This thesis has provided evidence that fibrinogen might not only be a marker but also 
might have a role in the pathophysiology of atherosclerotic disease. In fact, several 
roles of fibrinogen in atherosclerotic development and progression have been 
proposed. For example, fibrinogen binds to ICAM-1 on endothelial cells which may 
lead to the release of vasoactive mediators, enhanced monocyte- endothelial cell 
interaction and increased platelet adhesiveness (Hicks et al 1996;Kamath et al 2003). 
The binding of fibrinogen on ICAM-1 also up-regulates its gene expression, which 
further promotes the adhesion of leukocytes, platelets, and macrophages to 
endothelial cells (Kamath et al 2003). 
 
Also, fibrinogen has been shown to promote smooth muscle cell proliferation and 
migration (Kamath et al 2003). Fibrinogen may also play a role in foam cell 
 326 
formation by facilitating the transfer of cholesterol molecules from platelets to 
macrophages (Koenig 2003). It may also contribute to platelet aggregation and 
thrombus formation by binding to GPIIb/IIIa receptor and it also affects thrombus 
size, structure and deformability (Koenig 2003). In addition, fibrinogen is a major 
determinant of plasma viscosity and erythrocyte aggregation and, therefore, affects 
blood viscosity which has in turn shown associations with CVD (Koenig et al 1992). 
Finally, fibrinogen has been shown to accumulate inside atherosclerotic plaques 
(Bini et al 1989).  
 
7.9 D-dimer and tissue plasminogen activator 
7.9.1 D-dimer, tissue plasminogen activator and 
subclinical disease 
The aforementioned analysis showed significant associations of D-dimer with 
atherosclerotic progression, independently of other haemostatic factors and 
conventional risk factors. However, D-dimer failed to retain significant associations 
with ABI change when results were adjusted for IL-6 levels. D-dimer has shown an 
additive effect with IL-6 levels as was already discussed in the IL-6 section. In 
addition, t-PA showed no significant associations with ABI decline even in the 
univariable analysis and was only weakly associated with baseline ABI. 
 
D-dimer and t-PA have been extensively studied in relation to CHD but 
epidemiological research on asymptomatic atherosclerotic disease is scarce. In 
accord with our results, D-dimer, but not t-PA, has been independently associated 
with ABI in two cross-sectional studies (Cushman et al 1996;McDermott et al 2003). 
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Moreover, neither of them has shown evidence for associations with IMT in three 
other studies (De Maat et al 2003;Lee et al 1998;Salomaa et al 1995). Also, in 
patients with symptomatic PAD, D-dimer was associated with the occurrence of 
myocardial infarction but not with progression of atherosclerosis assessed by 
changes in ABI or carotid duplex scanning progression (Musicant et al 2006).  
 
7.9.2 D-dimer, tissue plasminogen activator, PAD and CVD 
As in previous analysis, D-dimer but not t-PA was significantly associated with 
incident PAD independently of cardiovascular risk factors and history of CVD 
disease. In addition, D-dimer showed a dose response relationship with disease 
severity. The relationship between these fibrinolytic markers and PAD is 
undetermined. In previous analysis of the Edinburgh Artery Study, t-PA and D-dimer 
were not associated with incident PAD after 5 years of follow up. However, both 
plasma markers have shown higher levels with the presence and increasing severity 
of PAD in cross-sectional analyses (Cassar et al 2005;Killewich et al 1998;Smith et 
al 1995;Unlu et al 2006). 
 
Both these markers were associated with incident CVD independently of CVD risk 
factors, history of CVD and subclinical disease and their estimated hazard ratios are 
in agreement with those yielded from meta-analysis of prospective studies on CHD 
(Danesh et al 2001; Lowe et al 2004a). However, the association of D-dimer was 
marginal and much weaker than that observed for fibrinogen, CRP or IL-6. On the 
other hand, t-PA had a relatively high association with incident CVD in the 
multivariable model but this was considerably decreased when individuals with 
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history of CVD were excluded from the analysis. Therefore, t-PA might be 
especially important in people with pre-existing disease as previous studies on 
patients with angina pectoris have shown (Held et al 1997; Juhan-Vague et al 1996; 
Smith et al 2000a). Finally, results showing associations of t-PA with incident MI 
and stroke but not with the presence and progression of asymptomatic atherosclerosis 
might reflect an importance of this molecule in later disease stages (e.g. plaque 
rupture) rather than in the early (asymptomatic) disease stage.  
 
7.9.3 Role of D-dimer and tissue plasminogen activator in 
atherosclerosis 
Results from the aforementioned analysis showed a modest effect of D-dimer and 
t-PA in atherosclerotic progression and its complications. In particular, D-dimer was 
associated with several manifestations of atherosclerosis (ABI decline, PAD and 
CVD) whereas t-PA showed no evidence for associations with asymptomatic and 
progressive atherosclerosis but was associated with incident CVD defined as MI or 
stroke. Levels of t-PA and D-dimer reflect plasmin and fibrin formation, 
respectively. Von Rokitansky, in 1852, first suggested that the persistence of fibrin 
deposits at the site of injury may promote the formation of an atherosclerotic lesion 
(Robbie et al 2001). According to this hypothesis these molecules might reflect the 
contribution of intravascular fibrin to atherogenesis as well as to thrombogenesis 
(Lowe et al 1999). There is also evidence that D-dimer within the evolving plaque 
influences atherogenesis through several other mechanisms including modulation of 
endothelial cell permeability, and stimulation of migration and proliferation of 
smooth muscle cells (Rabbani et al 1994). D-dimer is also chemotactic for 
 329 
monocytes and provides a surface for the accumulation of LDL cholesterol 
(Thompson et al 1989).  
 
The role of the fibrinolytic system in the development of the atherosclerotic plaque 
was further supported with reports demonstrating the deposition of fibrin and its 
degradation products in atherosclerotic arterial walls. In one study (Raghunath et al 
1995) on human coronary arteries, t-PA tended to be more abundant
 
in the intima of 
atherosclerotic arteries, with the intima/media
 
ratio of t-PA being significantly higher 
in these atherosclerotic arteries. Similarly, smooth muscle cells located in the media 
showed a strong
 
staining for t-PA mRNA and antigen, suggesting a constant t-PA
 
production (Lupu et al 1995). Moreover, the main inhibitor of fibrinolysis PAI-1 is 
also more abundantly expressed in tissues of patients with atherosclerosis (Spronk et 
al 2004). D-dimer has also shown increased concentrations in atherosclerotic plaques 
and has also shown increased levels with increasing severity of atherosclerotic 
plaques (Bini et al 1989).  
 
7.10 Other haemostatic markers  
There was very little evidence from results presented in this thesis for associations 
between vWF, factor VII, F1+2 or FpA and PAD. In fact, none of these markers was 
associated with the progression of peripheral atherosclerosis and incident PAD 
whereas only vWF was associated, albeit weakly, with incident CVD.  
 
The literature review on the introduction of this thesis showed that factor VII, F1+2 
and FpA have received little attention in the literature as potential risk factors for 
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CVD and that existing evidence for associations is very weak. vWF has been more 
extensively studied and a recent meta-analysis shows that relative risks of CHD 
associated with increased vWF were relatively modest (Whincup at el 2002). In 
relation to PAD, in support with findings presented here, previous investigators 
(Folsom et al 1993; McDermott et al 1993; McDermott et al 2003; Philipp et al 1997; 
Tracy et al 1995), as well as previous reports of the Edinburgh Artery Study (Lee et 
al 1998; Lowe et al 1993; Smith et al 2000b), have also failed to find independent 
associations between these markers and ABI, PAD development or measures of 
asymptomatic disease such as the IMT.  
 
These negative results however need cautious interpretation. The lack of associations 
presented here and in other reports does not necessarily mean that these molecules 
are not involved in atherosclerotic disease and its progression. On the other hand, 
lack of associations might be due to the pre-analytical and analytical properties of 
these markers which may not be adequate for their measurement in epidemiological 
studies or clinical routine. For example, FpA was highly variable (range 1.0-50.2 
ng/ml) and its assay had limited sensitivity because 38% of the population had levels 
<1ng/ml.  
 
7.11 Inflammation, haemostasis and atherosclerotic 
disease 
The primary aim of this analysis was to examine associations between a number of 
markers and the progression of atherosclerotic disease in order to identify possible 
mechanisms involved in the aetiology, development and progression of disease. 
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Results have confirmed an association between the activation of these two 
mechanisms and atherosclerosis. CRP, IL-6 and fibrinogen have shown associations 
with peripheral atherosclerotic progression and incident PAD, MI and stroke. To a 
lesser extent, the same was true for D-dimer and ICAM-1.  
 
Several of these markers may be used as a tool to better identify individuals at high 
risk of developing a cardiovascular event. However, the usefulness of these markers 
in risk prediction models and clinical practice was beyond the scope of this thesis 
and therefore was not examined. The clinical value of each marker should be judged 
both upon its incremental value above conventional risk factors and its assay/ 
measurement features.  
 
Results reported here are in favour of a fundamental role of coagulation, fibrinolysis, 
and inflammation in the atherosclerotic process. Biological markers reflecting the 
activation of these mechanisms were associated with several phases of the 
atherosclerotic process, from lesion initiation through to progression and, ultimately, 
the thrombotic complications of atherosclerosis. For many of these markers, 
associations between their levels and an increased risk of cardiovascular events have 
been repeatedly examined before. However, this is the first time that associations 
between their levels and the progression of atheroma have been examined 
prospectively in the general population. Our findings showing that CRP, IL-6, 
fibrinogen and to a lesser extent D-dimer and ICAM-1 are associated with the 
progression of atherosclerotic disease have important implications. In fact, these 
findings are highlighting a role of these molecules in the early atherosclerotic process 
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and not only in vulnerable atherosclerotic plaques, as it has often been hypothesised. 
Moreover, these markers maybe useful in assessing the progression of asymptomatic 
disease in individuals who are seemingly healthy but are at high risk of developing a 
cardiovascular event.  
 
Also, the associations reported here were independent of conventional risk factors, 
which supports a possible causal role of inflammation and haemostasis in 
atherosclerotic disease. The same conclusions can be drawn from the fact that the 
same markers were associated with incident CVD independently of asymptomatic 
atherosclerosis at baseline.  
 
Moreover, this thesis has examined the relative value of several biomarkers in the 
same cohort and has thus had the ability to compare their effects and their 
associations with cardiovascular disease. Most importantly, some of these markers 
have shown evidence for an additive effect on disease progression. It is important to 
note that the biological pathways of inflammation and haemostasis are not 
independent but rather they are interconnected (Esmon 2004). This is also reflected 
by the high correlation coefficients found between various markers. It is therefore 
essential to focus not just on the individual pathways but also on the ways that these 
molecules interact. This will then enable the design of new therapeutic and 
preventive strategies that interrupt pathologic activities, such as the initiation and 
progression of atheroma, without affecting homologous physiologic
 
activities, such 
as the acute phase response or wound repair, which often involve
 





8 Conclusions and Recommendations 
In this chapter, the principal conclusions are summarized and the recommendations 
for further research are listed.  
 
8.1 Conclusions 
1. Atherosclerotic progression was measured by the change in ABI after 5 and after 
12 years of follow up. The mean ABI change was -0.04 and -0.06 at 5 and 12 
years respectively. This decline was statistically significant and reflected a 
progression of atherosclerotic disease in our population over the years.  
2. Risk factors for progression of subclinical PAD were similar to those for clinical 
PAD and included age, male sex, smoking, total/HDL cholesterol, hypertension 
and pre-existing CVD. Prevalence of diabetes was higher among those who 
developed PAD or whose ABI declined but it failed to reach statistical 
significance.  
3. CRP, IL-6 and ICAM-1 were associated with ABI decline independently of 
conventional risk factors and baseline CVD. These findings suggest that these 
molecules are molecular markers associated with atherosclerosis and its 
progression. IL-6 showed more consistent results and stronger independent 
predictive value than other inflammatory markers. 
4. Fibrinogen and D-dimer, but no other haemostatic markers, were associated with 
ABI decline independently of conventional risk factors and baseline CVD. Since 
D-dimer and fibrinogen are acute phase reactants, these data support the 
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hypothesis that inflammation is more related to atherosclerosis than is 
hypercoagulation. Moreover, associations between fibrinogen or D-dimer and 
ABI change were no longer significant when analyses were adjusted for either 
CRP or IL-6. There was also some evidence for an additive role of interleukin-6 
and D-dimer in progressive atherosclerosis. 
5. IL-6 showed the greatest independent effect of all markers studied here and had 
significant associations with ABI change event after adjustments for 
inflammatory and for haemostatic markers. Elevated levels of IL-6 might reflect 
the extensive interaction between inflammation and coagulation which, after 
repeated cycles, leads to atherosclerotic progression. 
6. CRP and IL-6 showed modest associations with incident symptomatic PAD 
which were no longer statistically significant in the multivariable analysis. These 
results may reflect a modest effect of these markers on PAD and therefore a 
possible difference in their predictive ability across diverse disease 
manifestations. On the other hand, these findings might be in support of recent 
evidence from other studies that have also demonstrated a modest effect of CRP 
on CVD prediction (Danesh et al 2004; Lawlor et al 2005). Finally, CRP and IL-
6 were measured in fewer individuals at baseline than other markers studied here 
and this might have influenced the effect sizes and the significant levels. 
7. ICAM-1 showed strong associations with incident PAD and retained statistical 
significance after adjustment for traditional risk factors. ICAM-1 has also been 
associated with progression of asymptomatic PAD and therefore might be an 
important marker for peripheral atherosclerosis.  
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8. Levels of CRP, IL-6, fibrinogen, D-dimer and t-PA had significant and 
independent hazard ratios associated with incident CVD even when analysis was 
adjusted for subclinical disease at baseline (measured by the ABI). These 
markers, with the exception of t-PA, have also been associated with 
asymptomatic atherosclerotic disease which may further induce their production. 
These results show that their association with future CVD was independent of 
asymptomatic atherosclerosis and thus they are less likely to simply reflect an 
inflammatory or haemostatic response to early atherosclerotic development 
(‘reverse causality’). 
9. IL-6, fibrinogen and t-PA had the strongest independent effect on development of 
CVD compared to other factors in this study, with hazard ratios between their top 
and bottom tertiles greater than 1.8. An incremental risk between people with 1, 2 
or 3 markers in the top tertile was found. One possible explanation of this effect 
could be that these markers might promote atherothrombosis through distinct 
pathways. 
10. CRP and E-selectin showed a relatively stronger associations with stroke than 
with MI. Increased inflammatory markers associated with future stroke might 
reflect a larger role of inflammation in stroke rather than in MI, and might 
provide an explanation for the beneficial role of statins in cerebrovascular disease 
despite the fact that LDL cholesterol
 
is not a strong risk factor for stroke. 
11. Other markers investigated in this thesis including VCAM-1, factor VII, FpA, 
F1+2 showed no evidence for associations with ABI decline, incident PAD or 
CVD. E-selectin was associated with incident stroke only, whereas vWF showed 
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modest associations with incident CVD. These results suggest that these 
molecules are not good markers of atherosclerotic disease.  
 
8.2 Recommendations 
1. The ABI change was used to assess asymptomatic atherosclerotic disease in the 
study population over 5 and 12 years of follow up. The progression of 
asymptomatic disease prospectively is very little studied in the literature and 
further studies are needed to investigate the progression of disease over time. 
Other markers of subclinical disease such as the IMT need to be examined as 
well. Most importantly, the simultaneous study of several non-invasive tests 
would be very informative on the progression of systemic atherosclerosis.  
2. In this thesis, levels of inflammatory and haemostatic markers have been 
associated with ABI decline prospectively. Associations between these markers 
and other measures of asymptomatic disease need to be examined in order to 
validate conclusions drawn here.  
3. In the Edinburgh Artery Study, inflammatory and haemostatic markers were 
measured at baseline examination. Further studies should investigate longitudinal 
measurements of these markers and the effect of the changes of their levels on 
atherosclerotic progression and cardiovascular risk.  
4. Further studies are required to determine whether the relationships between CRP, 
IL-6, fibrinogen, D-dimer and ICAM-1 with the development of PAD and 
progression of peripheral atherosclerosis are likely to be causal. Randomized 
control trials are needed to test this hypothesis by assessing the effects of agents 
which lower markers’ levels on the risk of CVD, PAD or on the progression of 
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atherosclerosis. To be informative the agents need to be specific and to lower 
only the markers under investigation. 
5. Also, genetic epidemiology and Mendelian randomization studies would be very 
informative. In this design, genetic variants serve as unconfounded markers of 
exposures and better allow the test of causality. Current studies on inflammatory/ 
haemostatic genotypes are inconclusive and larger cohorts are needed to draw 
definitive conclusions using this approach (Smith et al 2006). 
6. Moreover, the interaction between the inflammatory and haemostatic markers 
needs further investigation in order to understand the complex association 
between inflammation and haemostasis and thus design relevant pharmaceutical 
agents for cardiovascular risk prevention. Some evidence for an additive effect 
between different markers was shown here. The use of a predictive ‘score’ 
according to the number of elevated inflammatory/ haemostatic markers needs 
further investigation. 
7. The laboratory measurement of these markers requires further research so that the 
tests might be more relevant to epidemiological research and clinical practice. 
Low analytical variability is fundamental. At the same time, the assays need to be 
standardized, inexpensive and with high sensitivity and specificity.  
8. The utility of novel risk markers for screening and risk prediction should be 
judged upon their incremental value over and above conventional cardiovascular 
risk factors. Prospective studies should examine potential additional utility
 
in the 
context of existing risk factors by the calibration of models with the 
inflammatory/ haemostatic marker and by comparing
 




(AUCs) or c-statistics for risk scores calculated 
with and
 
without the inflammatory/ haemostatic marker.  
9. Until the value of these potential risk factors in atherosclerotic disease is 
evaluated, attention in clinical practice should be given to modifying 
conventional cardiovascular risk factors associated with PAD and its progression, 
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WHO Angina/ IC questionnaire 
 
1. Chest Pain  
                                                                                                              Yes          No  
 
    (a) Do you ever get pain discomfort in your chest? 
 
 
IF NO, PROCEED TO QUESTION 2 
 
   (b) Do you get pain discomfort when you walk uphill or hurry?  
 
 
IF NO, PROCEED TO QUESTION 2 
 
   (c) Do you get pain discomfort when you walk at an ordinary pace  
        on the level?  
 
 
   (d) When you get any pain or discomfort in your chest what you do? 








Continue at same pace 
 
                                                                                                              Yes          No  
 
   (e) Does it go away when you stand still or sit down?  
 
   (f) How soon? 
                                                                                                             Tick one 
10 minutes or less 
 








                                                                                                               
                                                                                                               Yes           No 
2. (a) Have you ever had a severe pain across the front of your  
chest lasting for half an hour?  
 
    (b) What was the cause? 
    …………………………………………………………………. 
 
 
FOR OFFICE USE ONLY A:                        GRADE:                               MI: 
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2. Leg Pain  
                                                                                                                       Yes         No 
 
(a) Do you get a pain in either leg on walking? 
  
IF NO, GO TO QUESTION 2 
 
(b) Does this pain ever begin when you are standing still or sitting? 
 
(c) Do you get this pain in your calf (or calves)? 
 
(d) Do you get it when you walk uphill or hurry? 
 
(e) Do you get it when you walk at an ordinary pace on the level? 
 
(f) Does the pain ever disappear when you are still walking? 
 
(g) What do you do if you get it when you are walking? 
                                                                                                                 Tick one 
a. Stop 
 
b. Slow down 
 
c. Continue at same pace 
 
(h) What happens to it if you stand still? 
                                                                                                                 Tick one 
a. Usually continuous for more than 10 minutes 
 
b. Usually disappears in more than 10 minutes 
 
(i) Have you ever had surgery on the arteries of your legs other            Yes          No  
than varicose veins?                                                                                             
Please specify:………………………………………. 
 
(j) Have you evr had surgery to remove 
a. Toes 
 
b. Leg below the knee 
 
c. Leg above the knee 
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EDINBURGH ARTERY STUDY 
2005 QUESTIONNAIRE 
Please complete and return in the prepaid envelope 
                                                                                               PLEASE TICK 
     Yes          No 
 
1. Have you changed your address in the last year?     
 If yes - New address :  
 ……………………………………………………………… 
2. Have you changed your GP in the last year?       
If yes - New GP name : ……………………………… 
Address:………………………………………………… 
     
3. Have you experienced any of the following for the first time in the last year?    
                                                                                                                           Yes         No    Not Sure 
(i) Severe pain in your chest?   
(excluding any pain which was treated as an infection) 
 
(ii) Heart attack? 
 
(iii) Angina?          
 
(iv) Stroke?  
 
(v) Pain in either leg below the knee when walking? 
(excluding any pain due to varicose veins or arthritis)    
 
   (vi)       Blood clot or hardening of the arteries in either leg?     
                     
 
4. Have you attended your GP with any of the above?   
 
5. Have you attended hospital as an outpatient with any of the above? 
     
 If yes, which hospital?
 …………………………………………………………………………… 
 
 Date of attendance?
 ……………………………………………………………………………… 
 
6. Have you been admitted to hospital with any of the of above?  
 
If yes, which hospital?
 ……………………………………………………………….………… 
 
Date of admission? 
 ………………………………………………..…………………….……….
       
6. Do you take aspirin daily?   
MANY THANKS FOR ANSWERING THESE QUESTIONS 
